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ABSTRACT 
RADIOIMMUNOTHERAPY W I T H YTTRIUM MACROCYCLES 
Timothy John Norman (September 1994) 
Monoclonal antibody fragments (Fab') which recognise tumour-associated 
antigens provide an ingenious means of selectively targeting a therapeutic 
radionuclide to a tumour for radioimmunotherapy. The radionuclide yttrium-90, a 
long range p ' emitter, was chosen to deliver a sterilising dose of radiation to the 
tumour. 
A selection of novel functionalised macrocyclic ligands based on a 1,4,7,10-
tetraazacyclododecane skeleton have been synthesised, and the stabilities of their 
yttrium (HI) and gadolinium (III) complexes studied in vitro through association and 
dissociation measurements, and in vivo through animal biodistribution studies. The 
radiolabelled complexes do not dissociate in vivo. 
Maleimides are compounds which are capable of selectively reacting with a 
thiol of an antibody fragment. Selective functionalisation of one of the yttrium 
binding macrocyclic ligands with either one or three maleimides has been carried out, 
and the resulting compounds conjugated to tumour seeking humanised antibody 
fragments. Subsequent radiolabelling with ^^Y, gave the desired tumour targeting 
drug for use in radioimmunodierapy. 
Acridines are a class of intercalating agents which are capable of reversibly 
binding to DNA. A maleimide functionalised ligand derivatised with acridine was 
formed. Conjugation of this compound to antibody fragments capable of entering a 
tumour cell, may permit drug binding to tumour cell DNA, and thus enhance the 
targeting efficacy of the radiolabelled conjugate. 
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Chapter 1 
Introduction 
1.1 I N T R O D U C T I O N 
The work described herein could be described as a fusion of both clinical 
oncology and synthetic chemistry, and it is this multidisciplinary approach which 
leads us to draw on the resources not only of a chemistry department, but also on the 
expertise of the Medical Research Council's Radiobiology Unit at Harwell, and on the 
biological skills of my sponsors Celltech Ltd.. It is this blurring of the so often too 
rigid boundaries of science which may in the future lead to both novel and improved 
approaches to medicine, and science in general. 
Effective methods for the radioimmunotherapy of cancer have been explored 
with a view to employing the cytotoxic properties of particulate radiation in the 
selective irradiation of cancerous tissues. The term 'radioimmunotherapy' is self 
explanatory in that the term 'radio' refers to the use of radiation, and 'immuno' refers 
to the use of some form of immunological approach, in our case the exploitation of 
the selective and precise nature of antibody-antigen recognition of the human immune 
system, and finally 'therapy' infers the therapeutic benefit of this approach. 
1.2 C A N C E R 
"Cancer, created by life itself, 
exists within life, 
Yet in the end makes life untenable." ^ 
Cancer can be thought of as a departure from the constraints of normal cell 
growth control.^'2 The extent and rate to which healthy cells grow is normally 
controlled. Cancerous cells however, do not appear to respond to normal growth 
control mechanisms, and spread chaotically with no apparent consideration for their 
immediate environment. This often leads to a swelling called a tumour. 
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There are two distinct forms of tumours; benign, which do not spread, but 
merely confine themselves within a capsule, and the more dangerous malignant 
tumour. Malignant tumours shed cells into the blood and lymphatic streams which 
subsequently localise in other organs leading to the formation of secondary 
(metastatic) tumours. 
Cancer is caused initially by the damage / mutation of a cell's DNA. This 
damage can be attributed to a number of factors such as exposure to radiation, certain 
chemicals, and specific viruses, but it may be many years until these dormant cells 
become active and develop into a tumour. 
1.3 THE PREVALENCE OF CANCER 
Cancer is a very common disease being the cause of death for a high 
proportion of people, and is classified according to the organ from which it originates. 
The incidence rates of cancers are highly age and sex specific. For instance, there is 
a logarithmic increase with age for the incidence of cancer of the lung and colon, 
whereas the number of cases of cancer of the testes peaks in men of 32 years old.2 
Many cancers such as lung, stomach and liver cancer are also more common in men, 
although many of these different rates can be attributed to working environments, and 
social habits such as smoking, eating and drinking. 
1.4 THE TREATMENT OF CANCER 
1.4.1 Surgery 
There are two principal options for the treatment of cancer: surgery and 
therapy. Surgery is the front line approach to cancer, being however only effective 
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and practical in the removal of large easily accessible tumours, usually of a benign 
nature. More inaccessible and dispersed malignant tumours (metastases) require a 
different approach. 
OEEASES 
OSEASES 
ofoe*TH 
Figure 1.1: The incidence of cancer in the USA in 1975} 
1.4.2 Ch^niQth^rapyl-2'4.5 
It is in the treatment of metastatic tumours where chemotherapeutic drugs 
come into their own. As yet, chemotherapy is crude with little or no distinction 
between its action on cells of a specific tumour, and normal cells of the rest of the 
body. The potency of most conventional chemotherapeutic drugs can be attributed to 
their action on the DNA of rapidly dividing cells. It is at the point of division that 
4 -
cells are at their most vulnerable. Unfortunately, tumour cells are not necessarily 
dividing faster than all those in healthy tissues, and thus cells such as the bone 
marrow and the mucosa of the gastro-intestinal tract are also vulnerable, leading to 
undesirable toxic side effects. It is this current problem of selectivity which needs to 
be surmounted, 
0 
A. 
CI 
H 
R 
/ \ 
-N .N 
X ^ \ O^^^H^ HaN' "NH3 
• 0 ^ 0 CI ^ 
Cyclophosphamide 5-Fluorouracil Cisplatin 
Figure 1.2 : Examples of some chemotherapeutic drugs currently in use. 
The mode of action of chemotherapeutics varies. Cyclophosphamide, a DNA 
alkylating agent causes intermolecular cross linking in DNA hence inhibiting 
replication, 5-FIuorouracil fraudulently incorporates into DNA halting further 
synthesis, and the drug Cisplatin has had remarkable success with testicular cancer 
owing to its guanine binding ability. 
1 1.4.3 RaHiotherapv 
An alternative approach to the cytotoxic effects of cheraotherapeutics is the 
effect of radiation. Again cells are more sensitive to radiation damage when they are 
dividing, or when immature. The magnitude and nature of damage caused to a cell 
wil l depend on the amount of energy absorbed, and the nature of the absorbing tissue. 
Irradiation of a cell can damage its membrane, or cytoplasm, but more importantly its 
nuclear DNA which contains the biological coding for replication. Damage can be 
observed as a swelling of the cell as the damaged membrane allows extra fluid in, by 
a cloudiness of the cytoplasm indicating damage to its components 
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(e.g. mitochondria), and by fragmentation of the chromosomes. Although other 
forms of damage will also lead to immediate cell death, it is this muldple cleavage of 
the chromosomal DNA which is most important, as a toxic dose of radiation which 
acts direcdy on the DNA must affect the whole cell since it is the DNA which 
regulates the cell's life. 
Cell membrane 
Cytoplasm 
iNucleus 
Mitochondria 
Figure 1.3 : The structure of a human cell. 
Conventional radiotherapy relies on the use of external radiation sources such 
as a linear accelerator (which produces therapeutic X-rays or p ' particles), the more 
powerful betatron (produces P' particles), or radioactive cobalt (produces y rays). For 
the treatment of a deep tumour, e.g. cancer of the lung (approx. 10-15 cm deep), a 
radiation energy of 4 Mega Volts could be required because, as Figure 1.4 shows, the 
percentage of administered radiation reaching a tumour may be small, as the majority 
of die radiation is absorbed by the intervening healthy dssue. 
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100 kV 
Skin 
100% 
10% 
80% 50% 
I I I I 
1 3 cm 5 7 
Figure 1.4 : A depth-dose profile for a 100 kV source, showing the relationship 
between the depth of radiation penetration and the fraction of the 
total dose received. (Source : ref 1) 
The use of lead blocks and templates is necessary to localise the radiation dose 
to a small area, but clearly the inherent problem with this approach is that in order to 
reach a deep seated cancer, the radiation must first pass through, and damage healthy 
tissues. In fact, irradiation of a tumour can later lead to the onset of another different 
tumour, caused ironically by the very radiation which was supposed to cure the 
patient. Again, as with chemotherapy, what is required is some degree of tissue 
specificity. 
1.5 ANTIBODIES AND ANTIGENS 
1.5.1 Cell Surface Antigens 
The surface of a cell contains a mosaic of different glycoproteins and 
glycolipids.2.6 Some of these molecules are shared by many types of cells, and 
others are more specific, in some cases being limited to one particular type of cell. I f 
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these molecules elicit a response from the human immune system, i.e. if they 
stimiulate the production of antibodies they are classed as antigens. 
Tumour cells, although similar in many ways to normal cells, do exhibit some 
crucial differences. When a cell becomes malignant it may express a tumour-specific 
antigen on its surface. Being able to make use of this important difference between 
healthy and cancerous cells may enable us to target tumours. 
al tered carbohydrate mutant protein 
prol i ferat ion-l inked / C A N C E R \ , v i ra l ly -coded 
determinant ^ C E L L / " protein 
oncofoetal antigen normal t issue antigen 
Figure 1.5 : Possible antigenic targets on the surface of a cancer cell. 
(Source: ref. 2) 
Each particular antigen on the cell surface will have its own complement 
antibody to which it will bind to in a "lock and key" manner. 
1.5.2 Anribodies 2 A 6 
An antibody (or Immunoglobulin) is a protein synthesised by the immune 
system in response to a foreign material (antigen). The most common type of 
antibody found in the blood stream is Immunoglobulin G (IgG). This antibody has 
an overall mass of 150,000 Daltons with a complex folded three-dimensional 
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structure, approximated to a 'Y' shape in two dimensions. The antibody comprises of 
four polypeptide chains: two identical heavy chains (H) (50,000 Da) held together by 
a disulphide bond in the hinge region, and two identical light chains (L) (25,000 Da) 
each joined by a disulphide bond to one of the heavy chains. 
Variable 
domain 
Constant 
domain 
Light 
Chain (L) 
Heavy 
Chain (H) 
Fab' arm 
Hypervariable 
regions 
Figure 1.6 : The structure of a typical IgG antibody. 
In the variable domains of each of the four chains exist hypervariable regions 
which form an antigen binding site (seven amino acid sequence) at the end of each 
Fab' arm. It is this site ("key") which is responsible for binding to the hapten ("lock") 
on the antigen (Figure 1.7). 
Antibody binding 
site "key" 
\ 
Antigen 
Antibody 
CELL SURFACE 
Hapten "lock" 
Figure 1.7 : The specificity of antibody-antigen binding. 
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1.6 ANTIBODIES FOR TUMOUR TARGETING 
1.6.1 RadipimmMnQtherapy 
Tumour targeting may be achieved through the judicious use of an antibody 
specifically designed to bind only to a tumour associated antigen. It was as long ago 
as 1957 that Pressman 7 conceived this idea of a "magic bullet" approach to the 
treatment of cancer utilising the property of an antigen-antibody interaction, but it 
was not until Kohler's and Milstein's discovery of hybridoma technology in 1975 ^  
that antibodies of a sufficiently high tumour specificity became available to test 
Pressman's theories. 
This is the basis of my work, the intention being to inject into a patient's 
bloodstream a radiation source (radionuclide) bound to a tumour specific antibody 
which will in turn bind only to the tumour. In this way we hope to localise radiation 
damage solely to the target tumour, and hence negate the need for high doses of 
deeply penetrating external radiation. This use of antibodies in conjunction with a 
therapeutic radionuclide is known as "radioimmunotherapy". 
In its simplest form, something of the nature shown below is a synthetic 
target. 
• = Radionuclide 
= Radiation 
Tumour 
Figure 1.8 : The principle of radioimmunotherapy. 
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1.6.2 Polyclonal Antibodies 
Unfortunately, tumour cells have many differing antigens on their surfaces, 
some found on many tissues, and others found only on tumours. In response to the 
presence of these antigens the immune system will produce a variety of antibodies 
("polyclonal"), each specific for an individual antigen on the tumour cell's surface. 
For radioimmunotherapy we are interested only in tumour specific antibodies, and as 
it is not possible to separate these from the rest of the polyclonal mixture, an 
alternative approach to obtaining pure "monoclonal", tumour-specific antibodies is 
required. 
1.6.3 Monoclonal Antibodies^ 
In 1975 Kohler and Milstein discovered ^ that if they fused a mouse myeloma 
cell (a malignant mouse lymphocyte with the capacity for continuous proliferation) 
with a healthy lymphocyte from the spleen of a mouse immunised against a specific 
antigen (which will therefore produce antibodies specific to that antigen), the 
resulting hybrid species retained the abilities of its parents in that it continuously 
produced large quantities of an identical "monoclonal" murine antibody. Using this 
technique, any antibody can be produced for any given antigen, e.g. those found only 
on a tumour cell. Kohler and Milstein's technique for monoclonal antibody 
production is shown in Figure 1.9. 
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a 
ANTIGEN 
u—u ^ C ANTIGENIC 
OETEBMINANT 
LYMPHOCYTES MYELOMA CEUS 
HYBRID-
MYELOMA 
LYMPHOCYTES 
/ I w 
/ 
ANT18C0Y 
ANTIGEN 
^ ^ ^ 
CLONE 1 
ANTISERUM 
t 
MIXED ANTIBODIES MONOCLONAL ANTIBODIES 
Figure 1.9 : Monoclonal antibody production. (Source : ref. 9) 
1.6.4 Chimeric Antibodies 
There is a fundamental flaw in the use of monoclonal mouse antibodies in 
humans in that they are themselves immunogenic, invoking an immune response 
(a HAMA response = Human Anti Murine Antibody) which will seriously damage 
the efficacy of immunotherapy, and can produce allergic side effects.^ '^^ ^ 
Unfortunately, production of a monoclonal human antibody in an analogous manner 
proved both experimentally difficult and ethically unsound, as the only source of 
1 2 
these antibodies is from the spleen of cancer victims. An alternative approach had to 
be found. 
Chimeric antibodies appear to be one solution to the problem.12.13 Using 
modern genetic engineering techniques it is now possible to introduce the human 
coding for the constant region of an antibody (it had been shown that it was the 
constant region of the murine antibodies which was the most immunogenic) into a 
mouse myeloma cell, and obtain large quantities of a monoclonal antibody with a 
human constant region and a mouse variable region, retaining the original antigen 
binding specificity, but being substantially less immunogenic.^ "^ More recently 
geneticists have gone one step further to the goal of a human monoclonal antibody in 
the production of a "humanised" antibody. This antibody has both human constant 
and variable regions, but the binding sites of the hypervariable regions remain murine 
in their nature, and has been shown to elicit a minimal immune response. 15.16 
1.6.5 Antibody Fragments^ 
For radioiramunotherapy, as well as not invoking an immune response, 
antibodies must satisfy certain criteria with regards to their rate and ability to 
penetrate tissues, and their rate of clearance from non-target tissues. These processes 
are essentially size and shape dependent, the smaller die antibody or fragment thereof, 
the faster its distribution around the body. 
The antigen binding sites of an antibody are found in the hypervariable 
regions of the two Fab' arms. Thus, from the point of view of radioimmunotherapy, 
the constant region of an antibody becomes superfluous. Using the protease enzyme 
papain, an antibody can be selectively cleaved in the hinge region, yielding two Fab' 
fragments (and also an Fc fragment) (Figure 1.10), which have been shown to retain 
their binding affinity, and as a bonus show less of an immune response than the intact, 
parent antibodies. 
13 
Variable 
domain 
Constant 
domain 
Fab' arm 
> Fc portion 
Papain 
Digestion 
+ Fc 
Fab' 
Figure 1.10 : Papain site-selective digestion of IgG. 
As a result of their diminished size, Fab' fragments are able to localise more 
quickly, penetrate more deeply (thus improving access to more hindered regions of a 
tumour), and significantly reduce the time for unbound antibody to clear from 
non-target tissues thereby reducing irradiation of healthy t i s s u e s . A s a 
consequence, it would appear that the future of radioimmunotherapy lies in the use of 
either chimeric or humanised monoclonal antibody fragments. 
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1.7 CHOICE OF RADIONUCLIDE FOR RADIOIMMUNOTHERAPY 
There are a number of radioinuclides available for therapy, the choice of 
which depends on the tumour morphology and the radionuclide's properties. 
1.7.1 Tumour Morphology ^  8 
Densely packed tumours are often poorly vascularised resulting in a 
complicated pattern of diffusion gradients guiding radiolabelled antibodies through 
the tumour. As a consequence of this, and the lack of uniformity of antigen 
expression on tumours ('cold spots' occur where no antigens are found), some tumour 
cells will remain unbound by radiolabelled antibodies, and hence require efficient 
cross-fire from neighbouring cells to receive a sterilising dose of radiation. This 
necessitates the use of a long range P~ emitter (see Figure 1.11). 
Antigen deficient 
area "cold spot" Tumour 
Antigen 
rich area 
Radiolabelled antibody Long range P' emission 
Figure 1.11 : The importance of long range p- emission in the treatment 
of a tumour with non-uniform antigen expression. 
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If however the target is single circulating cancer cells such as those found in 
leukaemia, then a short range (0.1 mm) p~ emitter or an a emitter is required as long 
range emission could damage surrounding healdiy cells. The need for short rather 
than long range emission can be seen in Figure 1.12. 
Blood vessel 
wall 
Healthy 
ceU 
Radiolabelled antibody 
— ^ Short range a emission o 
Long range P' emission 
Circulating leukaemia cell 
Figure 1.12 : A short range emitter is required to minimize irradiation of 
healthy cells when treating circulating leukaemia cells. 
1.7.2 Radionuclide's Properties 
The aim of radioimmunotherapy is to deliver to the target as great a dose of 
sterilising radiation over as short a time as possible, so as to effect efficient DNA 
double strand cleavage. Suitable radioisotopes are either a and P" emitters with little 
or no Y component. To be useful, die radioisotope must comply to some exacting 
criteria. Firstly, it must be cheap, readily available, of a high chemical purity, and 
free from "cold" isotopes. It must be amenable to attachment to an antibody and 
decay to a stable daughter. 
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Also of prime importance is the half life (ti/2). This should be in the region 
of 1 0 to 2 0 0 hours; sufficiently long to allow transport to the target, yet not so long as 
to deliver its radiation dose over too long a period. A list of possible radionuclides 
along with their properties is given below in Table 1 . 1 . 
RudionucHde 11/2 rtiours) ji'max (MeV) % 
Mean range 
9 0 Y 6 4 2 . 2 5 ( 1 0 0 % ) 3 . 9 
67Cu 6 2 
0 . 4 0 ( 4 5 % ) 
0 . 4 8 ( 3 % ) 
0 . 5 8 ( 2 0 % ) 
0 . 2 
l86Re 9 0 1 . 0 7 ( 7 4 % ) 
0 . 9 3 ( 2 1 % ) 
1 . 1 
l88Re 1 7 1 . 9 6 ( 1 8 % ) 
2 . 1 2 ( 8 0 % ) 
3 . 3 
1 9 3 0 . 6 1 ( 9 0 % ) 0 . 4 
l l lAg 1 7 9 1 . 0 4 ( 9 3 % ) 
0 . 6 9 ( 6 % ) 
1 . 1 
16lTb 1 6 6 
0 . 4 5 ( 2 6 % ) 
0 . 5 7 ( 6 4 % ) 
0 . 5 8 ( 1 0 % ) 
0 . 3 
1 9 9 A U 7 5 0 . 2 5 ( 2 2 % ) 
0 . 3 0 ( 7 2 % ) 
0 . 1 
212Bi 1 . 0 1 7 . 2 ^ 0 . 1 
211 At 7 . 2 1 6 . 8 ^ 0 . 1 
a) The a particle energy. 
b) 0 . 1 mm is approximately equal to 1 0 cell diameters. 
Table 1.1: Possible candidates for use in radioimmunotherapy. 
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The following conclusions can be drawn. Copper-67 with its low P" energy 
may be suitable for the treatment of leukaemia and small metastases,^  9 but is 
expensive and difficult to obtain carrier-free. The two isotopes of rhenium 
(186 and 188) require a complex prelabelling protocol, whilst the relative ease of 
dehalogenation of iodine-131 in vivo poses practical problems for its use. A stable 
complex of silver-Ill is as yet to be found,20 terbium-161 is difficult to obtain 
carrier-free, whilst complex stability rules out the use of gold-199. 
Of the a emitters, only ^^^At and 212gj r^e plausible candidates,21'22.23 but 
the ease of dehalogenation of the former, and the shortness of the half life of die latter 
may rule these out. 
1.7.3 Yttriuni-90 for Radioimmunotherapy 
Of the original candidates proposed for radioimmunotherapy only ^ ^ Y 
remains. It can be produced cheaply and in high chemical and radiochemical purity 
from a ^^Sr generator and decays (ti/2 64 hours) with a single high energy p~ 
emission to a stable zirconium daughter. 
90 P 90 „ 
Y Zr 
39 40 
It is the long path length (4mm) of this p~ emission which makes ideally 
suited for the treatment of densely packed tumours. The combination of all these 
points makes the obvious choice for radioimmunotherapy, although it must be 
noted that because of a similar coordination chemistry to Ca^ "*", free ^ O Y 3 + 
preferentially localise in the bones, the radiotoxic effect of which has potentially fatal 
repercussions (myelosuppression, a reduction of the body's immune system due to 
damage of the bone marrow will result). 
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1.8 BIFUNCTIONAL COMPLEXING AGENTS FOR YTTRIUM 
1.8.1 Requirements 
Being a metal, yttrium cannot be directly attached to an antibody, but must 
first be bound by a metal complexing agent which has been functionalised in such a 
way as to enable it to be covalently bound to an antibody. This type of moiety is 
referred to as a "bifunctional complexing agent" because of its dual role in binding 
both the desired radionuclide and the antibody. Initial attempts to synthesise 
bifunctional complexing agents for yttrium centred around the use of functionalised 
E D T A 2 4 . 2 5 and DTP A. 26.27 
The earliest documented example of a bifunctional complexing agent 
however, was in 1968 when Benisek and Richards bound transition metals to hen egg 
white lysozyme using picolinimidate (Figure 1.13).28 
N — Lysozyme 
N — H 
Figure 1.13 
As a result of the toxicity of yttrium-90 in vivo, any proposed bifunctional 
complexing agent for 90Y3+ ^ust satisfy two important criteria. Firstiy the metal 
complex formed must be kinetically stable with respect to acid and cation catalysed 
dissociation in vivo (there are regions of pH as low as 2 in the stomach and liver, and 
cation concentrations in serum are high [Ca2+] = 1.25 mM, [Zn2+] = 0.01 mM). 
Secondly radiolabelling of the complexing agent must be efficient (in excess of 90% 
in < 30 min.) under conditions compatible with antibody integrity (pH 4-7.5,4-40°C), 
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and under concentrations mirroring those to be found in an antibody conjugate 
(5 to 10 |IM). 
Although a group three element, the coordination chemistry of yttrium 
resembles that of the lanthanides. This can be attributed to its possessing a similar 
charge density and ionic radius (1.07 A for a coordination of 9) because of the 
"Lanthanide Contraction".29 The variation of the ionic size with coordination 
number for yttrium and the lanthanides highlights this similarity, and is shown below 
in Figure 1.14. 
IONIC 
RADIUS 
0 
A 
8 9 10 
COORDINATION _ 
NUMBER 
Figure 1.14 : Effective Ionic Radii vs Coordination Number 
for yttrium and the lanthanides. 
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Yttrium shows a preference for ligands containing hard nitrogen or oxygen 
donors which form 8 or 9 coordinate complexes (Figure 1.15). 
(a) (b) 
(d) 
Figure 1.15 : 8 coordinate (a) square antiprismatic and(b) dodecahedral 
and 9 coordinate (c) monocapped square antiprism and 
(d) tricapped trigonal prism geometries of yttrium 
Considering initially only die metal coraplexing part of a suitable bifunctional 
linker (the mode of linkage to the antibody will be discussed later in Section 1.9), 
there are two principal types of ligands available: acyclic, and macrocyclic. 
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1.8.2 Acyclic Complexing Agents 
The most commonly used acyclic complexing agents are derivatives of EDTA 
(I) 25,30 and DTPA ((H), (HI), and (IV)).27,31 E D T A (I) being only hexadentate 
(yttrium requires octadentate coordination) was found to form yttrium complexes that 
were too unstable for use in vivo (log K ^ L = 18.1). DTPA (Illa) however is ideally 
suited to bind Y^"^ in that it provides eight donor atoms (3 nitrogens and 5 oxygens) 
and was shown to form a very thermodynamically stable complex with yttrium 
(log KjviL = 22.1).^2 xhis high stability can be accounted for by virtue of the "chelate 
effect" 33 whereby there is a favourable entropy term in the displacement of nine 
water molecules surrounding the yttrium cation by one chelating ligand. 
D T P A ^ - + Y{H20)s^* " Y . D T P A ^ - + 9 H 2 O 
Although the thermodynamic stability of the complex was found to be 
reasonably high in serum studies, with 8% dissociation over 24 hours,^ ^ this did not 
take into account regions of low pH and high cation concentration in vivo. As tiie 
primary route for DTPA metal complex dissociation is acid catalysed (complex is 
sufficientiy flexible to permit protonation of one of die binding nitrogen atoms), the 
in vivo stability was accordingly found to be appreciably lower than that found in 
serum studies. 
/ C O 2 H •CONHR 
/ — N 
^ HO2C / ^ C O a H 
( I ) ( H ) 
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In the first attempts to use functionalised DTPA, the so called DTPA 
anhydride product (II) showed stability results poorer than DTPA owing to the 
replacement of one carboxylate donor by an amide. A study in human serum 
(37°C, pH 7.4) highlighted this point when backbone functionalised DTPA (mb) was 
shown to dissociate 45 times more slowly than (n).35 DTPA derivatives (Ulb) also 
showed slighdy enhanced in vivo stability compared to DTPA (Ilia) due to the extra 
complex rigidity imparted by the side chains. Further backbone functionalisation as 
in (IV) sterically hinders the breakage of metal chelate rings and improves the 
orientation of the chelating groups,^ ^ further increasing complex stability.23 
R 1 ^ C O S H / \ /—CO2H 
( V - C G ^ H W ^ C O a H 
HO^C^ ( ^ C O a H HO2C / / _ C 0 2 H 
R2 \ _ c O 2 H ^ C O a H 
(III) «V) 
(a)R^ = R' = H R = Hor H 2 C - Q - X 
(b) R^ = HorMe 
R ' = H 2 C - ^ X 
X = NO2 or N C S 
Unfortunately, these derivatives were still not of sufficient stability for safe in 
vivo use, thus ruling out DTPA based radioimmunotherapy, as significant quantities 
of yttrium would build up in die bone. 
Other related acyclic chelating agents include (V) BOPTA, developed by 
Bracco of Italy for use with gadolinium in magnetic resonance imaging (MRI), and 
EGTA (VI) and TTHA (VII) 37 also considered for use in MRI. Aldiough (V) forms 
a relatively stable Gd complex (log K J ^ L = ^2.5), the corresponding yttrium complex 
23-
(like those of EGTA (VI) and TTHA (VII)) is not sufficiently stable with respect to 
acid-catalysed dissociation to allow safe in vivo use. 
Ph-
HO2C 
0-
-CO2H 
•N 
^ C 0 2 H 
-N 
/ ^ C O s H 
(V) 
/ \ / - C O 2 H H 0 2 C - \ CO2H 
(VI) (Vli) 
Although backbone functionalised DTPA derivatives do go some way to 
improving kinetic stability, a further enhancement is still needed to warrant use with 
90Y3+, 
1.8.3 Macrocyclic Complexing Agents 
Although acyclic yttrium complexes, specifically those based on DTPA, have 
been shown to exhibit high thermodynamic stability, their use in therapy is 
compromised by their inherent lack of kinetic stability. Macrocyclic complexing 
agents however have been shown to display both the required thermodynamic and 
more importantly, kinetic stability. 
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C-Func. DOT A 
* C-Func. DTP A 
o DTPA amide 
Time, days 
Figure 1.16 : Loss of yttrium from acyclic and macrocyclic chelates in 
serum (37°C, pH 7.4), showing the enhanced stability of 
a macrocyclic complex. (Source : ref. 34). 
As mentioned earlier, yttrium requires an octadentate ligand containing hard 
nitrogen or oxygen donors. Yttrium also shows a preference for ligands which will 
form complexes of a square antiprismatic or dodecahedral geometry. With this in 
mind, a number of tetra-aza cycles of varying ring size and varying functionality have 
been synthesised, the most important being 12-membered 1,4,7,10-tetra 
azacyclododecane-l,4,7,10-tetraacetic acid (DOTA) ( V i l l a ) and its 
derivatives,^^-'^^ 13-merabered 1,4,7,10-tetraazacyclotridecane-1,4,7,10-tetraacetic 
acid (TRITA) (IXa) and its derivatives,^! and 14-membered 1,4,8,1 l-tetra 
azacyclotetradecane-1,4,8,11-tetraacetic acid (TETA) (Xa)'^^ its derivatives. 
Stability constants {298K, I = 0.1 [NMe4N03]} for the formation of 1:1 
complexes of yttrium with DOTA (Vil la) , TRITA (IXa) and TETA (Xa) were 
shown to be [Y.DOTA]" = 24.9, [Y.TRITA]- = 19.6 and [Y.TETA]" = 16.3. The rate 
of dissociation of yttrium from preformed complexes of DOTA and TRITA was also 
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compared (pH 3.6, OAc" buffer), and showed that whilst no dissociation was 
observed for [Y.DOTA]", the half life of [Y.TRITA]" was only 5 minutes.43 
HO2C 
HOgC-
.N N 
~N N' 
R 
)—C02H 
•CO2H 
HOgC-
HOsC-
,N N 
N 
CO2H 
R 
CO2H 
(VIII) 
(a) R ' = = H 
(b) R 2 = H , R ^ = C H 2 ^ X 
or R ' = H , R ^ = C H 2 ^ - X 
X = NO2, NCS 
(IX) 
(a) R = H 
(b) R = C H 2 ^ - X 
(c) R = C H 2 - N 
H02C-
H02C-
•N N 
•N N 
(X) 
CO2H 
R 
CO2H 
(a) R = H 
(b) R = C H 2 - ^ - X 
(c) R = CH2 N 
-CO2H 
X = NQ2, NCS 
Unlike crown ethers,'*'* the variation in the thermodynamic stabilities of 
yttrium complexes of DOTA, TRITA and TETA complexes is not ring size 
dependent. Indeed the cavity formed in the plane of the four ring nitrogen donors is 
too small (DOTA radius 0.56 A ^5) to accomodate the yttrium (III) cation (radius 
1.07 A coordination 9). A metal ion wil l essentially sit above the N4 ring plane 
whilst the four pendent ligating arms encapsulate the cation from above forming a 
nearly spherical cage-like structure.'*^ This has been shown to be the case in the 
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solid state for both europium and yttrium complexes of DOTA, both being nine 
coordinate (8 coordinate DOTA + 1 water molecule) with a mono-capped square 
antiprism structure."^^ 
C l l O l O - O C O l 
'I'CIZl ICIIGI 
012-1 '"^ 0 i 7 ^ > : ^ ^ 018-1 
Figure 1.17 : The molecular structure of Na[Y.DOTA.H20].4H20. 
The relative thermodynamic stability of the 12, 13, and 14 ring metal 
complexes may then be related to the degree of steric crowding and torsional strain of 
the five and six membered chelate rings of the complexes. The six membered 
propylenediamine chelates found in complexes of TRITA and TETA possess 
unfavourable eclipsing interactions between C H 2 groups compared to the five 
membered chelates in DOTA complexes. These five membered chelates of DOTA 
are also better suited (have a better chelate "bite") to the ionic radius of yttrium as a 
five ring chelate favours binding to larger metal ions in higher coordination. Six ring 
chelates on die other hand favour smaller low coordination cations.'*^ It is for these 
reasons that of the three ligands, DOTA forms the most diermodynamically stable 
yttrium complex. 
As the primary route for yttrium dissociation is acid catalysed, it would be 
reasonable to expect from an electrostatic point of view that complexes with overall 
charge neutrality would be less susceptible to acid catalysed dissociation. Taking 
this into consideration, three neutral complexes of l-oxa-4,7,10-triaza cyclododecane-
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4,7,10-triacetic acid (ODOTRA) (XI), 4-(N-benzyl-N-methylcarboxamidomethyl)-
4,7,10-tetraazacyclo dodecane-l,4,7-triacetic acid (DOTA-BMA) (XII) and 1,7-
dioxa-4,10,13-triazacyclopentadecane-4,10,13-triacetic acid (DTCTA) ( X n i ) were 
synthesised."*^ 
HO2C-
,N N 
-CO2H HO2C-
O 
H 0 2 C - ^ \ / 
N N 
Me 
N 
O 
Ph 
H 0 2 C - ^ \ / ^ C 0 2 H 
(XI) 
CO2H 
O 0 
oai) 
HOgC- -CO2H 
(XIII) 
Both [Y .(XI)] and [Y . (XIII)] were found to be unstable with respect to 
trans-complexation by DTPA (pH 5.5, 500 fold excess of DTPA), undergoing 
complete dissociation in 48 hours, whilst the yttrium complex of DOTA-BMA (XII) 
was stable. 
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For a ligand to be suitable, it must complex yttrium efficiently. The rate of 
yttrium complexation for ligands (VIII) to (XIII ) was examined and the results 
shown in Table 1.2. 
[LigandJ Dgand 
/ lO^moldra '3 X I x m 
5 84 48 
10 98 81 0 
100 99 0 94 10 
500 >99.5 13 0 31 - 72 
1000 >99.5 52 0 82 98 86 
Table 1.2 : Labelling efficiencies for ^^Y^'*' complexation 
(30 mm., pH 5.5, 0.1 mol dm'^ NH4OAC, 310K). 50 
The poor labelling efficiency and complex kinetic instability of TRITA (IXa), 
and the obvious lack of labelling and poor complex thermodynamic stability of TETA 
(Xa) essentially rules them out. ODOTRA (XI) labels poorly, whilst the yttrium 
complex of DTCTA (XIII ) was found to be kinetically unstable. Only DOTA 
(Vnia) and the amide DOTA-BMA (XII ) appear to label sufficiendy well and 
exhibit adequate complex stability for use in radioimmunotherapy. 
The poor labelling of TRITA (IXa) by yttrium has led one group to 
investigate the use of TRITA attached to a flexible pendent carboxylic acid donor 
(IXc),^l which it was postulated would loosely capture Y^ "*" ions, and consequendy 
increase the metal ion concentration in die immediate vicinity of the ligand binding 
site, thereby increasing the complexation rate. Although this approach has proven 
successful, apparently without further loss of complex stability, it must be noted that 
Cox et al showed [Y.TRITA]" to be essentially too kinetically unstable to warrant its 
use.'*^ Similarly, in an attempt to obtain complexation rates closer to those oberved 
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for acyclic complexing agents such as DTPA (Ilia), one group synthesised the larger 
more flexible ligands PEPA (XIV) and HEHA (XV).32 
^002H H 0 2 C ^ / \ ^ C O g H 
^ N—^ 
"N 
H O g C ^ N N ^ C 0 2 H 
H O ^ - ^ ^ C O g H H 0 2 C ^ ^ C 0 2 H 
(XIV) (XV) 
Yttriuim labelling of PEPA (XIV) and HEHA (XV) was shown to be 100 
times faster than for DOTA (Villa), and only 10 times slower than for DTPA (Ilia). 
The thermodynamic stabilities of the corresponding yttrium complexes {298K, 
1 = 0.20 [NaN03]} were found to be log K j ^ = 16.07 and 24.04 respectively. 
Although HEHA shows a 100-fold increase in complexation rate, and an yttrium 
complex thermodynamic stability comparable to that of [Y.DOTA]', the more crucial 
kinetic stability has as yet not been published. It would seem plausible however, that 
such a flexible and anionic metal complex would suffer from the same inherent lack 
of kinetic stability as observed for acyclic ligands such as DTPA. 
It would seem therefore that the choice of ligand for a bifunctional 
complexing agent lies in the use of DOTA and perhaps other 12-membered 
macrocyclic tetra-aza ligands with four pendent ligating arms (e.g. DOTA-BMA). 
1.9 Y T T R I U M COMPLEX CONIUGATION TO AN ANTIBODY 
Once the metal complexing part of a bifunctional complexing agent has been 
chosen, it must then be joined to an antibody. Introduction of a reactive functional 
group onto the complexing agent allows conjugation to the antibody. 
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Reactive functional groups which can be introduced onto the ligand are 
generally of two types; those which wil l react with the e-amino groups of lysine 
residues on the antibody, and those which are able to react with free thiol groups on 
the antibody. Macrocycles functionalised with examples of these reactive functional 
groups can be seen below. 
Linl^ggg to Lyging Residygg 
Q C H 2 ^ Q - N = C = S 
isothioq^anate 
O 
a-bromoacetamide 
O 
active ester 
H2N- / = \ H 
H ° 
Q ( C H 2 ) n N y O ^ N . 
Linkage to Thiol Groups 
a-bromoacetamide 
Q(CH2)n 
vinyl pyridine 
H K 
O 
maleimide 
HS-
Q(CH2)n 
Q{CH2)n N •N 
O O 
Figure 1.18 : Antibody conjugation via an amino or thiol residue. 
3 1 -
An example of the use of a bifunctional complexing agent can be seen below 
where DTPA, backbone functionalised with an isothiocyanate moiety, is conjugated 
to an antibody via a e-amino lysine residue, and subsequently radiolabelled. 
COgH 
N'^OpH 
CO2H 
s r ^ ° ' " 
L 
^COgH 
= Radionuclide 
CO2H 
CO2H 
Figure 1.19 : The use of a bifunctional complexing agent to radiolabel an antibody. 
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1.10 T A R G E T I N G M E T A L COMPLEXES IN VIVO • AN O V E R V I E W 
The use of antibodies for targeting, although very specific, is only applicable 
for cells and tissues expressing a unique surface antigen. For this reason, and also for 
reasons of simplicity, other techniques are being pursued for the targeting of tissues 
and tumours for both imaging and therapy. 
1.10.1 Tissue Targeted Complexes 
In general, the biodistribudon of a given metal complex is determined both by 
blood perfusion and by the size, charge, lipophilicity, redox properties, and specific 
binding interactions of the metal complex. 
Solely on the basis of size, ^^""Tc (ti/2 6 hours, Ey) particulates are used to 
assess disease state and blood perfusion throughout the body. These technetium 
particulates consist of a range of large molecules, colloids or microspheres whose size 
determines their biological fate. Particles of size >15 f i M (but < 100 |iM) are trapped 
purely by a mechanical process in the lung capillaries allowing evaluation of 
pulmonary perfusion (^^""Tc-MAA (macroaggregated albumin) is marketed for this 
purpose), whilst particles below 1-10 ^iM in size (^^""Tc-albumin colloid) are taken 
up by the liver, spleen, and bone marrow. 
TcO(HM-PAO) and TcO(L,L-ECD) ^1 are both used as a cerebral perfusion 
agents for brain imaging. These charge neutral metal complexes are able to cross die 
blood-brain barrier (BBB) where TcO(HM-PAO) is transformed, perhaps by 
intracellular glutathione, to a more hydrophilic species which is unable to diffuse 
back across die lipophilic BBB,52 whilst one of die two esters of TcO(L,L-ECD) is 
enzymatically hydrolysed to give die monoanionic carboxylate complex which is also 
unable to diffuse back across the BBB. Thus, dirough die use of lipophilicity and 
charge, brain localisation can be achieved permitting successful imaging. 
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'''••r^^^^?U^^ E t 0 2 C ^ N ^ 0 ^ N H ,.C02Et 
Tc To 
6^ .0 
TcO(HM-PAO) TcO(L,L-ECD) 
Cu(PTSM) is a heart and brain imaging agent 3^ which utilises the redox 
property of Cu(n). The neutral lipophilic complex is taken up by the heart and brain, 
where intracellular glutathione reduces the neutral copper (U) complex to the unstable 
anionic copper (I) complex which then deposits its "^ ^Cu radiolabel (ti/2 9.7 min., P^) 
in the cell. 
NHCHo 
Cu 
ks. / \ 
N S 
N = < 
NHCH3 
Cu(PTSM) 
Nitroimidazoles tend to localise in oxygen-deficient regions such as those 
found in tumours and damaged heart tissue where they are substrates for reductase 
enzymes. The reduced product is then less able to diffuse out of the cell and 
therefore builds up there. TcO(PnAO)-l-(2-nitroimidazole) is a nitroimidazole-
technetium complex conjugate which has shown promise for imaging of diseased 
heart tissue.54 
Technetium phosphonate complexes are used as bone and myocardial infarct 
imaging agents. A diphosphonate ligand, such as HMDP, complexes 99m forming 
a 1:1 oligomer in which each technetium atom is bound by two diphosphonate 
ligands, and each phosphonate is coordinated to two technetium centres.55 The 
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complex wi l l localise in bone due to the tridentate binding of the coordinated 
diphosphonate ligand to calcium in actively growing bone.^^ Similarly, the metal 
complex will target infarcted heart muscle due to calcium deposits in the muscle. 
\ n ^ HO H 
I I T 
NO 
HO OH 
TcO(PnAO)-l-(2-nitroimidazole) HMDP 
Muscarinic acetylcholine receptors (mAChR) in the brain can also be targeted 
using TcO(N2S2)-quinuclidinol, a technetium radiolabelled portion of a high affmity 
ligand for mAChR. Unfortunately, a three fold decrease in affmity for the receptors 
is observed as compared to the intact ligand from which it was derived. 
H 
Tc 
TcOCN2S2)-quii^"clidinol 
It can be shown therefore, that a number of different properties can be utilised 
to effect specific tissue targeting. Technetium particulates localise due to their size, 
TcO(HM-PAO) and TcO(LJL-ECD) localise because of their lipophilicity and charge, 
Cu(PTSM) and TcO(PnAO)-l-(2-nitroimidazole) show selectivity because of their 
redox properties, whilst technetium phosphonates and TcO(N2S2)-quinuclidinol, 
selectively target because of their ability to bind to their respective targets. 
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1.10.2 Tumour Targeted Complexes 
Non-antibody based tumour targeting compounds have been investigated 
because their small size permits rapid biodistribution and tumour localisation without 
significant liver localisation. 
The anti-cancer drug Bleomycin for example has the unusual property of 
accumulating in some types of cancer cells. For this reason, Meares and Wensel 
attached to it an ^^^In-EDTA complex for the purpose of tumour imaging.57 
^^^Re labelled progestin (llp-ReO(N2S2)-progestin) is another diagnostic 
imaging agent, designed to bind to steroid positive tumours. 58 it was shown to have 
enhanced binding to the tumour compared to progestin itself, but non-specific binding 
was too high for the complex to be of significant use. 
llp-ReO(N2S2)-progestin 
It has been postulated that instead of an intact antibody or a fragment thereof, 
only the amino acid sequence concerned with receptor binding may be required for 
tumour localisation. ^^^In-DTPA-octreotide is a somatostatin receptor binding 
radiopharmaceutical with less than 10% non-specific binding.59 This has allowed 
^^ I^n based imaging of somatostatin-positive tumours using only an eight amino acid 
sequence. 
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COg 
N-
N In^" 
CO2 
- N - ^ O 
NH 
\ 
D-Phe Thr 
Cys—S-S—Cys 
I i 
Phe Thr 
\ / 
D-Trp Lys 
In-DTPA-D-Phe-octieotide 
Similarly, the same octreotide amino acid sequence has been conjugated to 
^^Y radiolabelled DOTA and TRITA for tumour therapy, and to backbone 
functionalised ^^^In-DTPA for tumour imaging.^O 
1.10.3 Antibody Based Tumour Targeting 
The forerunners of radiolabelled antibodies were radiolabelled proteins. 
I n d i u m - I l l labelled DTPA and EDTA were conjugated in an similar way as for 
antibodies, to proteins such as human serum albumin, and fibrinogen for use as 
biological probes.^O-^l 
Since then, antibodies such as those specific for colorectal carcinoma, the 
human interleukin 2 receptor, or antibody Fab' fragments to canine cardiac myosin 
(for myocardial infarction location) have been successfuly conjugated to EDTA and 
DTPA giving site-specific imaging or therapy when labelled with ind ium-I l l 
62,63,64,65 or bismudi-212 21 respectively. Macrocyclic metal complexes have also 
been conjugated to antibodies, showing promising results wiUi indium-lU labelled 
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NOTA ,66 copper-67 and 64 labelled tetraaza cycles, '^^ ''^ ^ and yttrium-90 labelled 
DOTA.69 
Other interesting approaches to the radiolabelling of antibodies include a first 
attempt to attach a radiolabelled carborane ligand; a so called Venus Flytrap Cluster 
(VFC), to a tumour localising antibody,'^ ^ and the 99mj(, labelling of antibodies using 
an imaginative thiolactone based bifunctional complexing agent." l^ The novel VFC 
showed excellent in vivo stability and tumour localisation, and although only labelled 
with ^^Co, there is scope for alteration to allow the synthesis of '^ ^Cu labelled clusters 
for use in radioimmunotherpy provided the forward rate of copper complexation is 
sufficiently fast under ambient conditions. The ^^Co cluster is shown below in 
Figure 1.20. 
Figure 1.20 : The VFC to which an antibody can be conjugated. 
In the technetium labelled antibody, the thiolactone on reaction with a e-amino 
lysine residue of an antibody liberates a diamino-dithiol technetium binding ligand 
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which on addition of ^^^Tc glucoheptanonate yields a stable radiolabelled product 
which has shown good in vivo stability. 
Me 
Me' 
Me 
V 
Me 
(i) aq. DMF, pH 8 
(ii) ®^'^TcO(gIucoheptanoate)2 
^IN. ^ I N - V 
Tc 
» » ' - / - S ' I I ^ S ^ " " M 
Me 
-N. .N 
Figure 1.21: The use of a thiolactone bifunctional complexing 
agent to label an antibody with ^^"^Tc. 
L l l SCOPE OF THIS WORK 
The majority of this thesis is concerned with the synthesis of a number of 
ligands for yttrium and gadolinium, and with the testing of their suitability for safe 
in vivo use. The rate of both ytti"ium complexation and decomplexation wil l be 
examined, along with a detailed biodistribution study of the metal complexes to 
determine of in vivo stability, and the rate and mode of clearance from the body. 
Once chosen, a suitable ligand will dien be functionalised to permit its conjugation to 
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one or more antibody fragments, or to a tumour localising moiety such as a 
nitroimidazole. 
The functionalised ligands once conjugated to antibodies wil l then be tested to 
determine antibody immunoreactivity, and most importantly tumour localising ability. 
Finally, the use of DNA binding intercalators will be discussed with a view to their 
incorporation into antibody conjugates to bring the complexed radionuclide into 
closer proximity to its target, the chromosomal DNA of tumour stem cells. 
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Chapter 2 
Ligand Design 
and 
Synthesis 
2.1 TNTRODDCTION 
Chapter 1 (Section 1.8) discussed die need for high complex stability when 
using yttrium-90 complexes conjugated to antibody fragments for radio 
immunotherapy. At the outset of this work, and of the ligands discussed so far, 
DOTA (V i l l a ) and also the mono-amide functionalised DOTA-BMA (XU) 
(Section 1.8.3), both based on the 1,4,7,10-tetraazacyclododecane (I2N4) skeleton 
showed the greatest promise for radioimmunotherapy, forming very stable yttrium 
complexes with little indication of decomplexation of the highly toxic free 90Y3+ 
cation. 
Me 
N-
HO2C-V / — \ ^ C O g H H 0 2 C - ^ /—\ y—I Ph 
N N N b 
H02C—^ \ / \—CO2H H O g C ^ \ / ^ C O g H 
DOTA DOTA-BMA 
2.2 C O M P L E X NEUTRALITY 
Although radioimmunotherapy was the primary objective of the research, an 
additional goal was to covalently attach to an yttrium-90 complex, tumour localising 
moieties such as 2-nitroimidazoles. 
f = \ . 
- R 
NO2 
A 2-Nitroimidazole 
These have been shown to localise in oxygen deficient cells such as those 
found in the dead core of solid tumours, or in ischaemic heart tissue. It was hoped 
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that conjugation of such a molecule to an yttrium-90 complex would facilitate uptake 
of the metal complex into the tumour (see also Chapter 3, Section 3.8). 
To be most effective, 2-nitroimidazole must first be internalised into the 
tumour cell by diffusing through the cell wall (Section 1.10.1). Unless an active 
uptake mechanism operates, only a charge neutral compound is able to do this. For 
this reason, and to reduce acid or cation promoted metal dissociation, conjugation to a 
charge neutral yttrium complex such as [Y.DOTA-BMA] is essential. 
With this in mind it should be noted that, because of the so called "lanthanide 
contraction", many of the I 2 N 4 functionalised ligands that form neutral complexes 
with Gd-^ "*", and have been studied as paramagnetic contrast agents for Magnetic 
Resonance Imaging (MRI) (see Section 2.13), may also be potentially useful as 
ligands for yttrium. The thermodynamic stability of [Gd.DOTA]" (log K ^ L = 25.8) 
is almost identical to that of [Y.DOTA]- (log K M L = 24.9 1). 
Complex Overall Charge 
rGd.D03A] 21.1 2.4 0 
rGd.D03MA] 25.3 0.162 0 
rGd.HP-D03A] 23.8 31 X 10-3 0 
[Gd.DOTA-PA] 20.1 _ 0 
[Gd.A] 25.9 _ 0 
[Gd.B] 26.4 - 0 
[Gd.DOTA]- 25.8 0.84 X 10-3 -1 
[Gd.DTPA]2- 22.5 >5 -2 
rGd.EDTA]- 17.3 - -1 
Data taken from references 2, 3,4, 5,6,7,8,9 and 10. 
Table 2.1: Stability constants (I = 0.1 [NMe4Cl or A^Afe^ A^OjiA and relative 
rates of acid catalysed dissociation (pH 1.0) at 298 K. 
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A number of the neutral gadolinium complexes that have been synthesised as 
contrast agents for MRI incorporate a pendent amide and are shown in 
Figure 2.1 & Table 2.1 (anionic [Gd.DOTA]", [Gd.DTPA]^- and [Gd.EDTA]" are 
given for comparison). 
HOgC^ / - ^ H 
D 0 3 A 
Me 
H02C-(. r-^ H 
Me-( VMe 
CO2H CO2H 
D 0 3 M A 
H02C-
HO2C-
.OH 
Me 
•CO2H 
H P D 0 3 A 
OH OH 
O 
\ , N H 
H 0 2 C ^ w ^ C 0 2 H 
HO2C 
HO2C-
Me OH OH n / ^ H a 
^ O ^ OH OH HOsC-Nj^/-^/ ' 
^ O g H 
"N N' 
HO^C-^ w V-C02H 
DOTA-PA 
Figure 2.1: Examples of ligands for gadolinium MRI. 
Whilst all the neutral gadolinium complexes shown have a high 
thermodynamic stability, it should be noted that the two seven coordinate complexes 
[Gd.D03A] and [Gd.D03MA] are the least kinetically stable with respect to acid 
catalysed dissociation, whilst the eight coordinate complex [Gd.HP-D03A] shows 
better kinetic stability. 
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2.3 T JGAND FUNCTTONALTSATION 
2.3.1 Amide Functionalised Ligands 
The amide carbonyl oxygen is an effective ligand for cations of high charge 
density such as Li"*" and Ca^ "*" (Gd and Y^ "*" also have a high charge density). This 
is due to its appreciable ground state dipole moment (HC0NMe2 has a dipole 
moment of 3.82 debye) which allows it to act as a good a' donor.^ ^ Bearing in mind 
the kinetic stability of neutral gadolinium complexes (Table 2.1), and the related 
yttrium complex [Y.DOTA-BMA] (Section 1.8.3), it would appear that for in vivo 
use, any neutral complex of yttrium should be eight coordinate with an amide 
(or perhaps an alcohol) ligating group. 
This rationale, coupled with the fact that further functionalisation of the 
macrocycle (e.g. introduction of a reactive group to permit antibody conjugation) 
could easily be effected at the nitrogen of the amide donor (e.g. as for B, Figure 2.1), 
led to the decision that one amide should be introduced into the target ligand for 
yttrium. 
2.3.2 Phosphonic Acid Functionalised Ligands 
Although all die ligands proposed so far for yttrium contain pendent ligating 
carboxylate arms to satisfy the positive charge of the metal centre, there are 
alternatives. 
OH HO 
H O - P — \ / — \ ^ P ' O ^ 
O N 6 
HO OH 
H O - P - ^ V_y \-^-0H 
I I I I 
o o 
Figure 2.2: DOTP 
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Currently under investigation for use with lanthanides is DOTP, a phosphonic 
acid derivative of DOTA.12,l3,14 Despite ^H NMR suggesting that lanthanide DOTP 
complexes are non-fluxional, and hence have an increased complex rigidity compared 
to DOTA, DOTP was found to have a greatly increased rate of complexation, 
although its complex stabilities have been shown to be smaller. ^ 5 There is also a 
pronounced tendency for this ligand, with its two basic sites per phosphorus, to form 
protonated metal complexes of diminished stability, thereby facilitating acid mediated 
metal decomplexation. Because of this, and the anionic nature of an yttrium complex 
incorporating four methylphosphonic acid arms, phosphonic acids are an 
inappropriate alternative to carboxylic acids. 
2.3.3 Phosphinic Acid Functionalised Ligands 
The second alternative, and one which has been exploited in the work of 
others,l6,17 jg the use of phosphinic acids (-PRO(OH)) rather than carboxylic acids 
(-CO(OH)). There are two basic differences in the chemistry of these two systems 
that are of particular importance. Firsdy, the phosphinate moiety is more difficult to 
protonate on the oxygen than is the carboxylate, i.e. it possesses a lower pK^ which 
may mean that enhanced complex kinetic stability with respect to acid catalysed 
dissociation will result. This can be seen in the pKg of Uie raonoanionic complexes 
of [Y.DOTA]', and its mediylphosphinate analogue [Y.12N4P4Me4]'.^8 This is 
obviously of prime importance when dealing with the radionuclide ^^Y in vivo. 
Me Me 
O O O O 
Me Me 
0 0 0 
pKa=3.07 pKa=1.28 
Figure 2.3 : pK^s oflY.DOTA]' and [Y.12N4P4Me4r 
0 
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The second important difference is the pentavalency of phosphorus which, by 
varying the nature of the alkyl or aryl P-substituent, permits control over complex 
lipophilicity, and provides the opportunity for a site of further functionalisation, 
including perhaps conjugation to an antibody. 
2.4 LTGAND CON.TTIGATTON TO AN ANTIBODY 
The purpose of forming these stable yttrium complexes is to allow 
radiolabelling of an antibody for radioimmunotherapy. This means diat additional 
functionalisation of the ligand is necessary to permit conjugation to an antibody. 
A ligand can essentially be functionalised in four places. Functionalisation 
can take place at the phosphorus atom of the phosphinic acid, although this requires 
extensive preparation of an initial phosphinate ester. ^  7 xhe arm of the carboxylic 
acid donor can be functionalised, or a more time consuming and tedious synthesis 
requiring a cyclisation step wil l permit the introduction of functionality into the 
carbon backbone of the I2N4 ring.^^ 
The fourth, and perhaps the most direct approach to functionalising the ligand 
is through a pendent amide. A suitable functional group can be readily incorporated 
through selective choice of the R' or R" moieties on the nitrogen of the amide 
(See Figure 2.4). Because of the simplicity of this approach, this was the technique 
employed. 
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2.5 r H O T C E OF LIGAND 
In summary, to achieve complex neutrality and subsequent further 
derivatisation, it would appear that a likely target ligand for yttrium is a mono-amide 
tri-phosphinic or tri-carboxylic acid derivative of I 2 N 4 , such as those depicted below. 
R' R' 
N—R" R N—R" 
HO-c-^ H o - p - \ / - c 
" - ^' O O b 
R 
H O - C - - ^ \ / ^ C - O H H O - P - ^ N / ^ P - O H 
6 0 6 0 
R, R", R" = alkyl, aryl 
Figure 2.4 : Proposed ligands for yttrium 
There are two principal approaches to the formation of a mono-amide 
tri-phosphinic or carboxylic acid derivatised ligand; initial tri-substitution of the ring 
by acid functionalities, followed by reaction at the fourth site by an amide 
(Scheme 2.1 (a) & (b)), or initial selective mono-substitution of the cycle by an amide 
followed by addition of three acid groups (Scheme 2.1 (c) & (d)). 
Synthetic routes (a) and (c) do not take advantage of any protection 
procedures, relying simply on the addition of the correct ratio of reagents followed by 
careful separation of the various mono, di, tri, or tetra substituted products. Although 
effective, yields are low and purification can be laborious. 20 
Alternatively, a higher yielding protection scheme can be employed, 
selectively and precisely protecting either one (route (b)) or three (route (d)) of the 
four ring nitrogens. A particularly interesting and useful example of the 
mono-protection of the tetra aza ring (route (b)), is in the formation of the previously 
unknown 1-formyl-1,4,7,10-tetraazacyclododecane 21 by the partial hydrolysis of the 
known l,4,7,10-tetraazactricyclo[5.5.1.0] tridecane.22 This ingenious protection 
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scheme permits the addition of acid functionalities to the remaining three ring 
nitrogens, followed by a simple acid hydrolysis to remove the formyl protecting 
group (Scheme 2.2) . 
Similarly, a metal complex of I 2 N 4 can be formed which incorporates three of 
the four ring nitrogens, leaving the fourth site free for functionalisation (route (d)).23 
H I—V P Acid / — V P 
Protection 
(b) 
H ^ H Acid ^ Acid 
H. ^ H 
(a) 
H' ^ 'H 
H^ .H 
>J N 
H' ^ "H 
(0 
(d) 
Protection 
Acid 
Arr\ide 
Deprotection 
Acid ^ .H 
-N Amide 
Acid' ^ VVcid 
Acid^ I—V Amide 
^ N 
Acid ^ Acid 
H I—^ Amide 
-
H' ^ 'H 
Acid 
Ps ^ .H Ps ^ .Amide 
N>. Amide^ 
p ' w p P' ^ P 
Deprotection 
Scheme 2.1: Selective fiinctionalisation of the cycle. 
P = Protecting group. Amide = CH2C0NR'R", Acid = CH2CO2H or CH2PRO2H. 
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H ^ H H / — \ H ^ H 
S I ^ I ^ N " ^ N-^ 
H' w ^ H' ^ "CHO 
111 
t-BuOpC-^ / — V ^ C 0 2 - t B u H O o C - x /-^ / — C O 2 H 7 1 iv r 
t-BuOsC-^ ^ "CHO HOgC-^ ^ H 
Scheme 2.2 : Formyl ring protection. Reagents: (i) (CH^)2NCH(OCHj)2^ 
cyclohexane; (ii) H2O; (Hi) BrCH2C02-tBu, Toluene, 
NaOH,H20; (iv) H2SO4. 
Synthesis and testing of both carboxylic and phosphinic acid functionalised 
ligands wi l l enable us to compare the relative merits of the two ligand systems 
showing i f indeed an enhanced complex kinetic stability can be observed for the 
phosphinic derivatives. 
2.6 f TGANn SYNTHESIS 
2.6.1 Macrocycle Synthesis 
A modified version of Stetter and Frank's general synthesis of 
tetraazamacrocycles^"* was employed to synthesise the twelve-membered ring 
1,4,7,10-tetraazacyclododecane (12N4). 
In place of sodium ethoxide employed by Stetter and Frank in the cyclisation 
step (ii), potassium carbonate was used as it was found to give a cleaner reaction by 
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reducing the major side reaction; oligomerisation.20 Potassium carbonate, although 
not a strong base, is able to deprotonate both of the tosylamides of (1) (in DMF the 
potassium cation is highly solvated, leaving C03^" to act as a strong base) which then 
undergo 8^2 displacement reactions with TsO(CH2)20Ts yielding the tetratosylated 
cycle (2). Subsequent detosylation of (2) with concentrated sulphuric acid followed 
by acid-base work up yielded the tetraamine (3) as its free amine white powder 
(Scheme 2.3). 
> NH2 ; NHTs .. < n N, 
^6% NHTs 61% : N 79% X i^ ^ 
W T s ' ^ Ts H' W 
(1) (2) (3) 
Scheme 2.3 : Synthesis ofl2N4 Reagents: (i) TsCl, K2CO3, H2O; 
(ii) TsO(CH2)20Ts, K2CO3, DMF; (Hi) C.H2SO4. 
2.6.2 Amide Functionalisation of the Macrocycle 
Choice of the pendent amide side arm to functionalise the cycle was dictated 
by the need for further functionalisation at a site on one of the amide nitrogens 
substituents. For reasons of simplicity, and because of its ease of further 
derivatisation, it was decided that one of these substituents would possess a primary 
amine which would permit reaction with molecules exhibiting such functionalities as 
acid chlorides, active esters or a-haloamides. 
Two different amides (5) and (6) were used. The bifunctional amide (5) 
possesses a primary amine group protected as its sulphonamide. Once attached to the 
macrocycle, deprotection could be undertaken to allow further functionalisation of the 
free amine group. Because of its enhanced sensitivity to acid deprotection 
(HBr, AcOH),25 p-methoxy benzenesulphonamide was used in preference to 
-56-
tosylamide for primary amine protection of (5), negating the need for the forcing 
conditions of concentrated sulphuric acid, and its associated amide hydrolysis. 
Monoprotection of 1,4-diaminobutane by its use in large excess yielded the 
amine (4), which subsequently underwent a low temperature Schotten-Baumann 
acylation (the low temperature reduced competitive amine alkylation) to give (5) as a 
white powder. Similarly, a low temperature Schotten-Baumann acylation of 
diisobutylamine with bromoacetylbromide gave the a-bromoamide (6) to serve as a 
comparison to (5). 
OMe OMe 
I 
H2N' 
88% 36% ^ 
O 0=S=0 
NH 
(5) 
'iBu -72% '^ "^  
(6) 
Scheme 2.4: Synthesis of a-bromoamide side arms. 
Reagents: (i) p-MeOC6H4S02Cl, CH2CI2; (ii) BrCH2C0Br, C2H4CI2, 
NaOH, H2O; (Hi) BrCH2C0Br, C2H4CI2, NaOH, H2O. 
Following the discovery that chromium hexacarbonyl would form metal 
complexes with a selection of cyclic and acyclic tetraamines,23 the reaction of 
molybdenum hexacarbonyl and I2N4 (3) in dibutyl ether analogously formed the air 
sensitive, yet relatively stable (under argon) [Mo(CO)3l2N4] complex, (7), 
(Scheme 2.5). 
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H 
H. H 
N N 
H' ^-J 'H 
>95% 
O C ' ' I ' ' 'CO 
C O 
(3) (7) 
Scheme 2.5 : Synthesis of the [Mo(CO)jl2N4J complex. 
(7) 
o c ^ l ' t o 
C O 
87% 111 
H 
(8) 
^ B u 
(9) 
Scheme 2.6 : Monoalkylation ofl2N4 with pendent amides (5) and (6). 
Reagents: (i) (5), K2CO3, DMF; (ii) (6), K2CO3, DMF; (Hi) 10% HCl. air. 
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Owing to its unusual ring nitrogen protection scheme, whereby three of the 
four ring nitrogens are protected, selective monoalkylation of (7) at the remaining 
fourth uncoordinated site was possible using (5) or (6) and potassium carbonate as a 
strong base in DMF (Scheme 2.6). 
Subsequent molybdenum deprotection of the resulting mono-alkylated 
protected cycles merely required their 10 % HCl solutions to be stirred overnight in 
contact with air, to give after acid / base work up, the free amines (8) and (9) in high 
yield. 
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2.6.3 Carboxvlate Functionalisation of the Macrocvcle 
Unlike the synthesis of the tetracarboxylic acid substituted cycle DOTA,26 
chloroacetic acid was not used to alkylate the three ring nitrogens of (8) and (9). 
Instead, for ease of purification, conversion of these monoalkylated species to their 
respective tricarboxylic acid derivatives proceeded through the intermediacy of the 
tricarboxylate esters (10) and (12) (Scheme 2.7). After extensive column 
chromatography, reasonable yields (60%) of these pure esters were obtained, which 
after subsequent base (KOH) or acid (HBr, glacial acetic acid, phenol) ester 
hydrolysis yielded the carboxylic acids (11) and (13). In the acid hydrolysis of (10), 
the reaction proceeded with concomitant deprotection of the primary amine of the 
amide side chain (NB. Sulphuric acid was not used for ester hydrolysis or 
deprotection because amide hydrolysis may also occur). 
2.6.4 Phosphinate Functionalisation of the Macrocvcle 
As in the carboxylic acid functionalisation of the I2N4 ligands, diere are two 
different routes for the synthesis of phosphinic acid functionalised ligands. Either 
direct reaction of the monosubstituted ligand with a suitable alkylphosphinic acid in 
the presence of aqueous formaldehyde under acidic conditions, or as in the preferred 
synthesis of carboxylic acids functionalised ligands (Section 2.6.3), via the 
intermediacy of a phosphinate ester. Choice of the direct route, although yielding the 
product in one step, results in contamination by H O C H 2 R P O 2 H . For this reason the 
two step synthesis via the ester was chosen, whereby condensation of the monoamide 
substituted ligands (8) or (9) with paraformaldehyde in anhydrous THF yielded an 
intermediate iminium ion which was trapped by a dialkoxyphosphine (RP(0Et)2) to 
give the corresponding monoamide-trimethylenephosphinate ester functionalised 
ligands (14) and (17) (Scheme 2.8). Exclusion of water through the use of anhydrous 
reagents and molecular sieves was found to be essential to prevent the formation of 
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hydroxymethylphosphinate esters HOCH2PR02Et. Attempts to increase the yield of 
the reaction by deliberately promoting the Arbusov reaction by the addition of 
anhydrous tetrapentylammonium chloride or bromide failed to produce any noticeable 
improvements in the reaction products. 
Direct base (KOH) or acid (HBr, AcOH, PhOH) hydrolysis of the 
phosphinate esters (14) and (17) yielded the phosphinic acids (15), (16), and (18). 
Again deprotection of the tosylamide was observed as (14) underwent acid hydrolysis 
to (15). 
(8) 
57% 
EtOgC 
(10) 
60% 
(11) 
iBu 
(9) 
68% 
iBu 
EtOgC 
EtOaC--^  \ / ^-COzB. 
(12) 
43% or 58% 
HO2C 
11 or 111 
(13) 
Scheme 2.7 : Synthesis ofmonoamide tricarboxylic acid ligands. 
Reagents : (i) BrCH2C02Et, K2CO3. EtOH; (ii) HBr, AcOH, PhOH; (Hi) KOH, H2O. 
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.OMe 
(8) 
E t O a R P - / \ / " W R O g E t 
^ s y D M e 
(a) R = Me 
(b) R = Bu 
(c) R = Bz 
H02RP' 
(14) 
H02RP- ^ROgH 
(15) 
(a) R = Me 
(b) R = Bu 
(c) R = Bz 
IV 
H O a P M e - p ^ ^ 
HOaPMe-/ V _ / M e^POgH 
(16) 
IBu 
EtOgMeP 
HOaMeP 
HOaMeP 
•^Bu 
EtOgMeP-^  \ / V45Me02Et 
(17) 
u or IV 
iBu 
Sbu 
Me02H 
(18) 
Scheme 2.8 : Synthesis ofmonoamide triphosphinic acid ligands. 
(i) RP(0Et)2, (CHOH)^ THE; (ii) HBr, AcOH, PhOH; 
(Hi) MeP(0Et)2, (CHOH)n, THE; (iv) KOH, H2O. 
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2.7 rOMPT.EX SYNTHESIS 
Yttrium complexes of ligands (13) and (16) and a gadolinium complex of 
(15a) were formed by dissolving either Y 2 O 3 or Gd203 in water at pH = 1.5, and 
heating at reflux overnight to effectively dissolve the metal oxide. Subsequent 
raising of the solution pH to 6, and continuation of heating, permitted complexation to 
occur. An indium complex of (16) was also formed at room temperature in 
pH 5.5 acetate buffer. Although no crystal structures of these amide complexes were 
obtained, its is expected that like [Y.DOTA]'P and the DOTA-monoamide complex 
[Gd.A], 6 (Figure 2.1) the complex structures wi l l adopt a distorted square 
antiprismatic structure capped widi a water molecule (Figure 2.5). 
= Metal O = Water 
Figure 2.5 : Distorted square antiprismatic complex structure showing four ring 
nitrogens, three acidic donors, an amide oxygen donor, and one coordinating water. 
For these monoamide triphosphinic acid complexes, there are 32 possible 
stereoisomers. For each complex three stereogenic centres exist giving eight possible 
stereoisomers, RRR, SSS, RRS, RSS, RSR, SRS, SRR and SSR. Through a 
combination of ring inversion, and phosphinate arm rotation, each of these eight 
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stereoisomers can exist in four structural arrangements, giving a total of 32 possible 
stereoisomers (Unpublished work from S. Aime and M . Botta (Turin)). 
2.8 r O M P I . E X CHARACTERISATIGN 
On complexation, a number of different changes in the properties of the ligand 
can be observed by I.R. and NMR. In I.R., both die acid and amide carbonyl 
stretching frequencies are reduced as their overall bond order decreases due to 
donation to the metal centre. This effect was observed for all of the complexes made, 
and can be taken as an indication of coraplexation. For instance in the case of 
[Y.(16)], there is an amide carbonyl shift of 53 cm"^ from 1679 cm'^ for the free 
ligand to 1626 cm'^ for the complex. Similar shifts ranging from 18 cm'^ to 49 cm'^ 
were observed for [Y.(13)], [In.(16)], and [Gd.(15a)]+. 
Similarly, observation of the acid and amide carbonyl shifts using -^^ C NMR 
gives information on the nature and extent of complexation. Generally, there was an 
8 - 9 ppm shift to higher frequency of the carbonyl resonance on complexation. This 
was seen with [Y.(16)] for example where the amide carbonyl shifted from 175.6 ppra 
for the free ligand to 183.9 ppm for the corresponding yttrium complex. 
Both ^^P and ^^Y have a nuclear spin of 1/2, and therefore should exhibit 
coupling. The complex [Y.(16)] did indeed show yttrium-phosphorus coupling in its 
^^P NMR spectrum. The free ligand exhibited two resonances at 38.68 ppm and 
39.23 ppm in the ratio 2:1 corresponding to the two slightly different environments of 
the phosphorus atoms of the ligand. Following complexation, the two resonances 
were split by coupling to yttrium with a coupling constant Jy-p of 5 Hz. (Figure 2.6). 
This compares well with the reported value of 5.1 Hz for [Y{S2P(OEt)2}4]'.^ 
A l l of this spectral data is consistent with simultaneous metal coordination of 
both the acid groups and the amide carbonyl oxygen. 
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2.9 Y T T R I U M COMPT EX N.M.R. 
Despite being hampered by the long relaxation time required between pulses 
(30 seconds), ^^Y NMR spectra were acquired for [Y.(13)], [Y.(16)], and other 
related yttrium complexes (see Figure 2.7 for ligand structures, and Table 2.2 for 
chemical shift data). 
HO. 
HOgMeP-^ W ^ M e O a H HOgRP-' W ^PROaH 
NHMe 
N N HOgRP^ W ^ R O j H 
P3Me3NBu2 - R = Bu 
PjMeaNBzj - R = Bz 
P4Me4 - R = Me 
P4Bu4 - R = Bu 
P4PI14 - R = Ph 
P4BZ4 - R = Bz 
PaMejNHMe - R = Me 
PaBusNHMe - R = Bu 
Synthesised by K. Pulukkody & C. J. Broan 
Figure 2.7 
In the case of [Y(16)], the low concentration of the solution meant no 
coupling information could be seen, (although a doublet of triplets was expected). 
However, for the two tetraphosphinic acid complexes [Y.P4BZ4]' and [Y.P4Me4]", a 
quintet of lines was observed with Jyp of 5 Hz. This was the predicted splitting 
pattern with yttrium being split four times by the four equivalent phosphorus atoms. 
Complex 
[Y.DOTA] -Hlll.8 
[Y.P4BZ4]- -hl52.8 
[Y.P4Me4]- -t-156.8 
[Y.P^Me3NBu2] -(-168.3 
[Y.EDTA]- -1-123.5 
rY.DTPA]2- +S1.6 
[Y.(13)] +111.3 
[Y.(16)] -^152.0 
Table 2.2: ^^Y Chemical shift data 
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Although the ligands thus far are presumed to be eight coordinate in solution, 
yttrium is capable of assuming a nine-coordinate geometry, with the ninth 
coordination site being taken up by the solvent, a water molecule. Indeed X-ray 
crystallography has shown both [Eu.DOTA]",29 and [Y.DOTA]" 27 to have a ninth 
coordinating water molecule. It was therefore quite possible that on going from H 2 O 
to D 2 O , [Y.DOTA]- would exhibit a solvent isotope effect in its ^^Y NMR . I f 
indeed this were the case, it was suggested that the extent of the effect would be a 
reflection of the ability of the ligand to shield bound yttrium from the solvent. It was 
hoped therefore that [Y.DOTA]' having one coordinating water molecule would show 
a considerable effect, whilst the analogous phosphinic acid functionalised complexes 
would not, due to the shielding of yttrium by the alkyl or aryl groups on phosphorus 
(a tetrabenzylphosphinic acid functionalised yttrium complex was shown 
crystallographically to have no coordinating water). 
Although small, there is a precedent for a solvent isotope effect of this nature; 
the solvent isotope effect for the Y^ "*" aquo-ion is 4.3 ppm.^ S Unfortunately, no 
solvent isotope effect was observed for [Y.DOTA]', or even for [Y.EDTA]^', thus 
precluding any conclusions being made concerning the solvation state of complexed 
yttrium. 
2.10 KINETICS OF ASSOCTATION 
Suitable complexing agents for use in radioimmunotherapy must label rapidly 
under conditions mirroring those required for conjugation to an antibody 
(Section 1.8.1). The forward rate of ^^Y uptake by a number of ligands was 
assessed, comparing (15a) and (11) to four other ligands prepared independently 
(see Figure 2.7 for structures). 
Each ligand to be tested was incubated with the highest purity yttrium-90 
possible, samples were removed at set time intervals, and any unbound yttrium 
-67-
scavenged by a large excess of DTPA at pH 5.5. Anion exchange chromatography 
permitted separation of [Y.DTPA]^", and the neutral or monoanionic yttrium 
complexes, allowing the extent of yttrium association to be determined (Table 2.3). 
The choice of solution pH and temperature was found to be a crucial factor in 
determining the extent of yttrium association as the extent of radiolabelling was 
dramatically reduced on changing from a solution of pH 6.5 to pH 5.5 or by a 
temperature change from 37°C to 20°C. 
LIGAND 
t/mia DOTA P4Me4 (15a) ( I t ) 
1 54.4 8.8 2.0 5.9 17.4 3.4 
2 80.5 18.3 4.1 12.0 36.2 8.9 
5 98.5 55.2 12.6 35.2 78.5 23.6 
ID 99.7 85.3 24.7 61.1 90.2 42.8 
15 - 35.8 78.7 97.4 59.9 
20 92.6 45.4 86.8 67.6 
30 93.4 58.4 90.2 81.3 
60 79.8 91.8 
Tests performed at the MRC Radiobiology Unit. 
Table 2.3 : Percentage uptake by charged and uncharged ligands. 
[Ligand] = 5 ^ mol dm'^, pH 6.5, 37 °C, 0.2 mol drn^ NH4OAC. 
With the exception of P3Me3NHMe all the ligands tested gave a radiolabelling 
yield in excess of 90% within 60 minutes, with DOTA, the tetraphosphinic acid 
P4Me4, and the monoamide phosphinate (15a) looking very promising. 
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2.11 K I N E T I C S OF DTSSOCTATION 
It is now generally accepted that the relative rate of complex dissociation at 
low pH (kinetic stability) rather than the 1:1 ML thermodynamic stability constant is 
a more accurate guide to complex stability in vivo. With a view to use in 
radioimmunotherapy or magnetic resonance imaging, the rate of dissociation of a 
number of yttrium and gadolinium complexes (Figure 2.7) was determined over the 
pH range 1-2 (Table 2.4). 
Complex 
^8 Haif life {hi 
1 5 2 0 I.O \ 13 2.0 
[Gd.DOTA]- 3.2 0.9 0.05 60 214 3929 
[Y.DOTA]- 15.0 1.9 0.3 13 102 583 
[Gd.P4Me4]- 10.4 4.6 1.1 19 42 171 
[Y.P4Me4]- 21.0 9.6 3.1 9 20 62 
[Gd.P3Me3NBu2] 1.3 0.5 0.2 153 389 943 
[Y.P3Me3NBu2] 1.9 0.7 0.3 102 276 721 
[Gd.P3Me3NBz2] 4.3 1.6 1.0 45 118 192 
[Y.P3Me3NBz2] 4.3 1.6 1.0 145 380 989 
[Gd.P3Bu3NHMe] 4.1 1.5 0.45 47 127 427 
[Gd.P4Bu4]- 36.9 20.1 7.08 5.2 9.6 27.2 
[Gd.P4Ph4]- 77.7 36.4 14.7 2.5 5.3 13.1 
[Gd.P4Bz4]- 23.9 9.1 2.8 8.1 21.1 69.0 
Tests performed at the MRC Radiobiology Unit. 
Table 2.4 : Kinetics of dissociation of ^^Y and ^^^Gd complexes at 31 OK. 
It is evident from these results that the tetraphosphinic acid ligands P4R4 do 
not form complexes with yttrium or gadolinium which are quite as stable as those of 
DOTA. It must be noted however, that the kinetic stability of these tetraphosphinic 
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acid complexes shows a less steep dependence on pH, perhaps associated with their 
reduced tendency to protonate compared to that of a carboxylic acid. Generally it 
was found that gadolinium complexes were less sensitive to acid-catalysed 
dissociation than their yttrium analogues. 
The use of monoamide triphosphinic acid ligands which form neutral 
complexes with yttrium and gadolinium was vindicated by these studies. Markedly 
increased kinetic stability over the anionic tetra phosphinic acid complexes was 
observed, with a less steep pH dependence. Such kinetic stability was predicted to 
arise owing to the reduced tendency of neutral complexes to protonate, giving more 
labile protonated species. 
The neutral complexes tested showed promising kinetic stability, and in 
accordance with these results it was hoped that the complexes formed by (15), (16) 
and (18) would also exhibit an acceptable stability in vivo, as well as an efficient 
radiolabelling when used in radioimmunotherapy. 
2.12 C O M P L E X BTODTSTRIBUTION 
As well as satisfying the preliminary requirements for radioimmunutherapy, 
the ligands thus far mentioned also have considerable potential in MRI, with 
gadolinium complexes of related ligands being used as paramagnetic conurast agents 
in MRI. Current MRI agents in clinical use, e.g. [Gd.DTPA]^", and [Gd.DOTA]" are 
excreted predominantly through the kidneys. Consequently, neither is suitable for 
targeting specific organs such as the liver. 
The biodistribution of gadolinium complexes of (11), (13), (15 a, b, c) and 
(18) as well as others synthesised by K. Pulukkody in Durham, were tested in mice to 
define the structural and charge properties which determine the mode of clearance of 
a complex from the body, to perhaps give an insight into the design of more tissue 
-70-
specific complexes. A selection of the results is shown in Table 2.5, and represented 
graphically in Figures 2.8 and 2.9. 
% Dase ^^^Gd in Whole Tissue 
Gd Complex 
Blood Kidneys Uver 
Call 
BlacWcr Smmacft 
Small 
^ IntesUnc 
Large 
Intestine 
[Gd.DOTA]- 13.8 6.7 1.8 0.09 0.33 1.4 0.63 
[Gd.P4Bz4]- 3.7 2.3 14.3 3.10 1.40 45.3 0.37 
[Gd.(13)] 17.5 7.5 3.2 0.03 0.42 1.8 1.00 
[Gd.(18)] 15.9 5.7 1.7 0.13 0.41 2.1 0.91 
[Gd.(ll)]+ 17.3 8.4 1.7 0.03 0.44 1.7 0.90 
[Gd.(15a)]+ 17.0 9.0 2.0 0.02 0.45 1.8 1.10 
[Gd.(15b)]+ 17.3 12.5 2.5 0.02 0.47 2.0 0.89 
[Gd.(15c)]+ 20.6 12.5 2.7 0.03 0.39 2.2 1.0 
Tests performed at the MRC Radiobiology Unit. 
Table 2.5 : 5 minute biodistribution of^^^Gd radiolabelled complexes in mice. 
There are two principal excretion routes from the body for the complexes: via 
the kidneys (renal clearance), or via the liver and the gut (hepatobiliary clearance). 
The excretion route taken by a specific complex is indicated by a larger dose of ^^^Gd 
found in that organ. Thus, renally cleared complexes show a higher dose of radiation 
in the kidneys (see Table 2.5), whilst hepatobiliary cleared complexes show high 
doses in the liver, gall bladder and at later time intervals, in both the small and large 
intestines (also in the stomach due to reflux back from the intestine). Looking at 
Figures 2.8 and 2.9 plotted from Table 2.5, it is obvious that only [Gd.P4Bz4]' 
exhibits significant hepatobiliary clearance. "Total gut" (from Figures 2.8 & 2.9) 
refers to the combined value for the stomach, and the small and large intestines. 
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It should be noted also, that the blood radiation level for [Gd.P4Bz4]' is 
substantially lower than the others. The reason for this is that at the low dose of 
complex given, the liver is capable of removing complexes from the blood stream 
faster than the kidneys. At higher concentrations of complex however, the receptor 
sites in the liver becomes saturated, and more of the complex is excreted by the 
kidneys. 
Very generally, it was expected that hydrophilic complexes would pass 
through the kidneys, whilst more lipophilic complexes would be excreted by the liver. 
From the results given in Table 2.5, along with other information not shown here, but 
reported elsewherc^O it was found that both complex charge and lipophilicity played 
important roles in determining complex biodistribution. Cationic complexes 
(e.g. [Gd.(ll)]+ and [Gd.(15 a, b, c)]+) and neutral complexes (e.g. [Gd.(13)] and 
[Gd.(18)]) were found to show predominantly renal clearance, although some more 
lipophilic neutral complexes did show a small degree of hepatobiliary clearance. 
Hydrophilic anionic complexes such as [Gd.DOTA]' also exhibited renal clearance, 
but lipophilic anionic complexes such as [Gd.P4Bz4]' exhibited hepatobiliary 
clearance. 
The link between complex lipophilicity and the extent of hepatobiliary 
clearance can be explained in terms of plasma protein binding. Hydrophilic 
complexes which do not bind to plasma proteins are non-specifically filtered out in 
the kidneys. As complex lipophilicity increases, plasma protein binding increases 
reducing the free fraction available for renal filtration thus increasing the amount of 
complex which can be taken up by liver cells and excreted into the bile 
(hepatobiliary excretion). 
It should be noted that the anionic nature of a complex also plays a crucial role 
in determining hepatobiliary excretion. It is thought that anionic complexes are 
taken up by the same carrier system that transports bilirubin IXa, (the dicarboxylic 
acid breakdown product of heme), and various anionic dyes such as 
bromosulfophthalein to the liver. ^ 1 This carrier system involves membrane proteins, 
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and thus in addition to being anionic, the complex must also exhibit some degree of 
lipophilicity so as to bind to these proteins. This would explain why the anionic 
lipophilic complex [Gd.P4Bz4]" exhibits hepatobiliary clearance whilst the anionic 
hydrophilic complex, [Gd.DOTA]', does not. 
With the exception of [Gd.ClSb)]"^, all complexes in Table 2.5 were shown to 
be stable with respect to gadolinium dissociation in vivo, in that they met the standard 
set by [Gd.DOTA]" of < 0.15 % of the injected dose in the liver, and < 0.1 % in the 
skeleton after 24 hours 30 (data not shown). The deposition of gadolinium by 
[Gd-ClSb)]"*" may be simply due to a lack of kinetic stability, or may possibly be 
explained by the very low concentrations of complex used in these studies. At such 
low concentrations, there is a comparatively high concentration of cations with which 
to catalyse complex dissociation. However, at the high concentrations of complex 
required for MRI, the extent of dissociation would be limited by the concentration of 
cations in the plasma. This has indeed been found to be the case for [Gd.DTPA]^' 
which shows much greater complex dissociation at low complex concentration.^O 
From these results, it seems evident that all of the ligands synthesised, with 
the exception of (15b), are suitable for use in vivo, and we have come a step closer to 
designing more specific complexes. 
2.13 GADOLINIUM MAGNETIC RESONANCE IMAGING 
As previously stated, the ligands designed for yttrium-90 based 
radioimmunotherapy may also find use as their gadolinium complexes, as contrast 
agents in magnetic resonance imaging. 
Magnetic resonance imaging (MRI) is a diagnostic imaging technique which 
relies on the detection of NMR signals of water protons in the body. A gradient 
magnetic field (rather than a static field used in laboratory based NMR) is applied 
across the body which causes water protons to resonate at slightly differing 
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frequencies depending on their position in the gradient field, thus allowing spatial 
information about the subject to be obtained. 
Paramagnetic compounds such as gadolinium (S = /^2) catalyse proton 
relaxation in aqueous solutions as the water oxygen atom is coordinated to die metal 
ion (Gd-^ "*"). This causes a perturbation in signal intensity which can be utilised to 
increase the signal intensity and obtain a more intense image. Free gadolinium ions 
are however highly undesirable in the body because of a poor acute tolerance 
(LD50 ca 0.1 mmol kg'^). Gadolinium therefore must be administered as a stable 
complex. This is where the ligands synthesised earlier are useful. The 
biodistribution experiments (section 2.12) have shown the ligands to form gadolinium 
complexes which are stable in vivo, and thus to be possible candidates for MRI. 
In general there are two distinct mechanisms for the relaxation of water 
protons in the presence of the paramagnetic ion Gd^ "*": inner sphere and outer sphere 
relaxation. The inner sphere contribution to the relaxation arises from the dipolar 
interactions between Gd-'"'' and the proton nuclei of the water molecule directly 
coordinated to the metal ion. The number of water molecules coordinated to the 
metal ion is denoted q. These dipolar interactions are modulated by the molecular 
reorientation ( X R ) , electron spin relaxation ( 1 3 ) and chemical exchange ( X M ) times. 
The latter chemical exchange process, which is a measure of the mean residence 
lifetime of the water molecule at the coordinating site of the metal, is sufficiently fast 
for Gd^ "*" to provide a means of transferring the relaxation effect to the bulk water. 
The outer sphere relaxation process involves the electron-nuclear magnetic dipolar 
coupling which occurs when solvent water molecules approach the metal complex 
during their translational diffusion. 
The large quantity of structural and dynamic information on the solvent 
relaxation rates of Gd(III) complexes can only be obtained through a magnetic field 
dependent study. Experimentally this can be done with a field-cycling relaxometer 
developed by S. H. Koenig and R. D. Brown 01,32 which allows the relaxation rate to 
be determined in a range of magnetic fields corresponding to Larmor frequencies 
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0 . 0 1 to 5 0 MHz. What is obtained is a Nuclear Magnetic Relaxation Dispersion 
(NMRD) profile. 
An NMRD study was carried out on the gadolinium complex of (15a) at 5 , 2 5 , 
and 3 5 °C (Figure 2 . 1 0 & Table 2 . 6 ) and its profile compared to the theoretical one 
for no water coordination (solid lines in Figure 2 . 1 1 represent q = 0 , i.e. only outer 
sphere contribution). The results were also compared to those obtained for the 
tetrabenzylphosphinic acid complex [Gd.P4Bz4]- which has been shown 
crystallographically and by NMRD studies to be a complex with q = 0 (Figure 2 . 1 1 ) . 
Parameter 
Temperdture/'X: 
5 2 5 3 5 
x s o / 1 0 - 1 1 s 9 . 5 0 8 . 0 3 8 . 4 7 
Xyl 1 0 - 1 1 S 2 . 5 4 1 . 4 1 1 . 5 4 
X M / 1 0 - ^ s 1 8 . 0 1 0 . 0 7 . 0 6 
X R / 1 0 - 1 1 s 1 5 . 5 9 . 2 6 . 8 0 
q 1 . 0 0 1 . 0 0 1 . 0 0 
r / A 3 . 4 7 3 . 4 7 3 . 4 7 
a / A 4 . 0 0 4 . 0 0 4 . 0 0 
D / 1 0 - 5 1 . 0 0 2 . 2 0 3 . 0 0 
Unpublished data from S. Aime, and M. Botta (Turin). 
Table 2.6: NMRD parameters for [Gd.(15a)}+ 
Xso ~ electron spin relaxation time at zero field, Xy = correlation time 
characterising the time dependence of the interaction responsible for the relaxation 
process, x ^ = the chemical exchange time of the water molecules, X R = molecular 
reorientation time proportional to molecular size, q = number of coordinating water 
molecules, r = distance between the water protons and the unpaired electron spin, 
a = the molecular radius, and D = the diffusion coefficient of the complex. 
It was found for [Gd.(15a)]'^ that q = 1, i.e. that there was one bound water 
molecule in the complex. This is in contrast to the tetrabenzylphosphinic acid 
- 7 6 -
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complex [Gd.P4Bz4]' which had q = 0, presumably because the four bulky benzyl 
groups totally shield the gadolinium ion from the water. 
The complex Gd.DOTA-PA (see Figure 2.1) is very similar to [Gd.(15a)]''', in 
that they both possess a pendent amide, and three acidic groups; phosphinic acids in 
the case of (15a), and carboxylic acids in the case of DOTA-PA. NMRD profiles 
have been reported for both [Gd.DOTA-PA] and [Gd.DOTA]-.10 Like [Gd.(15a)]+, 
both showed the presence of just one inner sphere water molecule, suggesting that an 
amide functional group, like a carboxylate or a phosphinate does, as predicted, 
occupy a site in the gadolinium coordination sphere, thereby preventing an increase in 
inner-sphere water molecules. 
2.14 rONCLUSTONS 
A number of ligands suitable for the complexation of yttrium and gadolinium 
have been synthesised with a view to producing neutral yttrium complex conjugates 
for radioimmunotherapy, and perhaps for use in MRI . The use of pendent 
phosphinic acids on the ligands has been shown to produce complexes which are 
kinetically slighdy less stable than their carboxylic acid analogues, alUiough the 
complexes are still of sufficient stability for use in vivo. The monoamide 
triphosphinic acid ligands which were designed specifically to form neutral 
complexes have however shown excellent stability, whilst I.R. and NMR studies 
(including an NMRD profile) have all shown that the pendent amide takes part in 
binding to the complexed cation. Ligand (15a) appears particularly promising, with 
further ligand functionalisation being possible at the pendent NH3'*" site to give a 
desired bifunctional complexing agent. Chapter 3 wi l l concentrate on the 
functionalisation of ligand (15a) (to form a bifunctional complexing agent), 
specifically dealing with the attachment of functional groups with which to bind to 
antibody fragments. 
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Chapter 3 
Bifunctional 
Complexing 
Agents 
3.1 TNTROniJCTION 
This chapter is primarily concerned with the synthesis of bifunctional 
complexing agents with which to radiolabel antibody fragments, (see Section 1.6.5) 
with yttrium-90. Ligand (15a) (Scheme 2.8) satisfied the criteria laid out in Chapter 1 
(Section 1.8.1) for the metal complexing component of a bifunctional complexing 
agent, and was accordingly chosen as the foundation of any proposed synthesis. 
H O a M e P - ^ ^ 
N 
HOaMeP-^ ^PMeOgH 
(15a) 
3.2 LTGAND CONTTIGATION TO AN ANTIBODY 
3.2.1 Reactive Antibody Sites 
There are only two practical sites for linkage of a ligand to the polypeptide 
chains of an antibody fragment; at the e-amino sites of lysine residues, of which there 
are up to ninety in a typical monoclonal antibody, or at the site of a free thiol 
(Section 1.9). 
Although readily accessible, the inherent problem with effecting Fab' 
conjugation via e-amino sites of lysine residues lies in the fact that some of them may 
be found close to, or at the antigen binding site of the Fab". Hence attachment of a 
metal complex at one of these sites will severely impair the specificity of antigen 
binding, resulting in a diminution of the 'immunoreactivity' of the Fab'. Using 
recombinant antibody methods however, a free cysteine thiol residue can be 
introduced into the C ^ l domain of an antibody (Figure 1.10),1 effectively negating 
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the problems experienced with lysine, and permitting site specific derivatisation of 
the antibody fragment away from its andgen binding site. It should also be noted that 
unlike the functionalisation of a Fab' at its e-amino sites, the use of die cysteine thiol 
dictates the introduction of one metal complex only. For this reason, it was decided 
to attach a ligand at a free thiol introduced into the C H I domain. 
3.2.2 Thiol Selective Agents 
There are really only two possible candidates widi which to target a free diiol 
in the presence of e-amino lysine residues; vinylpyridines, and maleimides 
(Figure 3.1). 
•N' 
R - N 
Y 
(a) (b) (c) 
Figure 3.1: Thiol selective agents (a) 2-vinylpyridine, 
(b) 4-vinylpyridine, and(c) maleimide. 
Although their use is compromised by a slow rate of reaction with thiol 
groups, previous work in the pH range 5-9 has shown vinylpyridines to be 
substantially more reactive towards the thiol group of cysteine than towards primary 
amines which showed less than 3 % reaction over a period of two hours.^ 
A 
O 
H2O 
N - R 
pH>7 
Scheme 3.1 : Maleimide hydrolysis to a maleamic acid. 
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Maleimides on the other hand exhibit a comparatively greater rate of reaction 
with thiols, but show only moderate selectivity for thiols over primary amines, and 
tend to undergo slow hydrolysis to maleamic acids at a pH in excess of 7 
(Scheme 3.1). 
3.3 BIFUNCTIONAL COMPLEXING AGENT DESIGN 
Both 2-vinylpyridines 2.3,4 ^nd maleimides -^'^ -^  have been used with some 
success in the conjugation of antibodies to ligands. However, because of their speed 
of reaction with thiols, and ease of synthesis, maleiraides were chosen for this work to 
form part of a bifunctional complexing agent with which to bind a Fab'. 
I f we can furnish ligand (15a) with a pendent maleimide, it should be possible 
to attach it to an anfibody fragment via the free thiol of the cysteine residue 
(Scheme 3.2). 
Bifunctional Complexing Agent Cystein free 
thiol residue 
Scheme 3.2 : A bifunctional complexing agent incorporating a maleimide to 
bind to the cysteine residue in the C^l domain of a Fab'. 
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As radiolabelling of the ligand is usually done after it has been attached to the 
antibody fragment, the metal binding site should ideally remain easily accessible for 
complexation. I f the ligand is direcdy attached to the antibody fragment with little 
distance between the two, the ligand can become engulfed within the comparatively 
large three dimensional structure of die Fab', sterically hindering the approach path of 
an aquo yttrium-90 species, and reducing overall labelling efficiency. To reduce this 
effect, a spacer group should be incorporated into the bifunctional complexing agent 
between the ligand (15a) and die maleimide funcdonality. 
As intended, any functionalisation of ligand (15a) wil l occur at the primary 
amine site of the aminoalkyl chain of the amide. Thus, incorporation of a maleimide 
onto this primary amine site requires a maleimide reagent which possesses a 
functional group capable of reacting with die primary amine. 
A range of maleimides are commercially available, coming in one of two 
forms; either with an attached carboxylic acid functional group (maleimido 
carboxylate) or as an active ester of the carboxylic acid form (see Figure 3.2). 
0 
A 
M 
0 
IN, 
0 0 
R = alkyl or aryl 
Figure 3.2 : (a) Maleimido carboxylates, and (b) N-hydroxysuccinimide active esters 
The carboxylic acid derivative of the maleimide can be converted into its 
reactive acid chloride, or coupled to the amine of (15a) using a coupling agent such as 
dicyclohexylcarbodiimide (DCC), whilst the active ester form can be used directiy to 
react with the pendent amine of (15a). 
The use of maleimide active esters for the coupling of biomolecules such as 
antibody fragments is not without precedent. Indeed, as far back as 1976 Kitagawa 
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and Aikawa used the raaleimide active ester meta-maleimidobenzoyl 
N-hydroxysuccinimide to couple insulin via a primary amine to the enzyme 
P-D-galactosidase through a free thiol group.^ Since then, a variety of maleimide 
active esters have been used to couple a range of biomolecules for use in the 
preparation of sensitive enzyme immunoassays .^ 'This use of active esters is 
analogous to the proposed coupling of a Fab' to the ligand (15a). In both cases, the 
maleimide reacts with a free thiol group of an antibody fragment, whilst the active 
ester functionality reacts with a primary amine (Scheme 3.3). 
H 
HOjMeP -
o 
PMeOzH 
(15a) 
o o o 
(i) C^N-o^Sh-N^ 
o o 
(ii) Fab*-SH 
c > 
HOaMeP-' \ f P^MeCfeH 
2 K 
g.Fab' 
Scheme 3.3 : The coupling of an antibody fragment to ligand (15a) or 
to an enzyme using a maleimide active ester. 
3.4 MAT.FJMTDE SYNTHESIS 
It was previously noted that raaleimides underwent slow ring-opening 
hydrolysis at a pH of 7 or over. The stability of a number of maleimide active esters 
was accordingly tested at 30°C in pH 7 phosphate buffer in order to choose the most 
suitable candidate for use in immunoassays. Nine different active esters were 
tested, showing maleimide hydrolysis ranging between 10 and 93% over a period of 
6 hours. Active esters with R = CH2, (CH2)3, (CH2)5, or CH2Cyclohexyl, 
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(see Figure 3.2) were shown to possess the greatest stability, whilst the use of 
aromatic R groups considerably reduced maleimide stability. 
Unfortunately, commercially available maleimides are very expensive at £80 
and £1000 per gram for the maleimido carboxylates and the active ester derivatives 
respectively. Laboratory scale synthesis of these maleimides however is relatively 
simple, requiring two steps for the synthesis of the maleimido carboxylate from 
maleic anhydride, and an extra step to form the active ester. 
In view of the reported maleimide stabilities, the synthesis of 
maleimidohexanoate, R = (CH2)5 was brought about following the standard literature 
s y n t h e s i s . I n i t i a l ring opening of maleic anhydride by 6-aminohexanoic acid 
yielded the maleamic acid (19) in reasonable yield which, on heating in acetic 
anhydride subsequently underwent ring cyclisation via an anhydride intermediate, to 
give on careful crystallisation the maleimide (20) (Scheme 3.4). In an analogous 
manner, the maleamic acid N-(4-carboxycyclohexylmethyl)-maleamic acid also 
underwent cyclisation to the maleimide N-(4-carboxycyclohexylmethyl)-maleimide 
(21). In both cases, incomplete cyclisation and a mixture of products, resulting in a 
black viscous oil in the case of (20), severely hampered product crystallisation, and 
led in part to the low yields (approx. 15 %) of pure material reported. 
In an investigation into possible primary amine protecting groups for use in 
peptide chemistry, Keller and Rudinger explored the possibility that an amino 
group may be protected as a maleimide in a similar manner to protection as a 
phthalimide. During their studies, it was confirmed that ring opening could be 
effected under mildly basic conditions but, more importantly, they also found that on 
treatment with 1 mol dm'-^ acetic acid at 40°C, the maleamic acid (19) showed 
complete conversion back to 6-aminohexanoic acid. In our cyclisation of the 
maleamic acids to the maleimides (20) and (21), acetic anhydride was used, but was 
later hydrolysed to acetic acid by heating in water at 70°C for 3 hours. This may 
perhaps go some way to explain the mixture of products observed from the 
cyclisation step, particularly as ethylene-1,2-dicarboxylic acid was formed, as much 
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of the unreacted maleamic acid would undergo acid hydrolysis back to the amino acid 
(Scheme 3.4). 
o 
HzN C^OjH CO2H 
fl H 
Acetic Anhydride 
(19) R= -(CH2)5-
Acetic Acid 
Hydrolysis 
II 2 > '^V^' 
(20) R= -(CH2)5-
(21) R= C H 2 - Q -
Scheme 3.4 : Synthesis ofmaleimido carboxylic acids, showing unwanted 
acetic acid hydrolysis of the maleamic acid 
Conversion of the maleimides, 4-maleiraidobutyric acid (R = (€112)3) 
(purchased from Sigma), and 6-maIeimidohexanoic acid (R = (€112)5) (20) to their 
respective succinimidyl active esters (22) and (23) followed the synthesis laid out by 
Keller and Rudinger^^ using DCC to couple N-hydroxysuccinimide to the maleimido 
carboxylic acid in DMF (Scheme 3.5). 
|j N.j^ C^O^ H 
(20) R= (CH2)5 
Q - N - C = N ^ 
N-OH , DMF 
O O 
I L / R ' "o' ^ 1 6 
(22) R= (CH2)3 
(23) R= (CH2)5 
Scheme 3.5 : The synthesis of succinimidyl maleimido carboxylates using DCC 
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Reasonable conversion to the active esters resulted, although purification 
using a silica column still gave products which contained up to 20 % unreacted acid 
(this would not interfere in the next step as it is merely the product of ester 
hydrolysis). 
It should also be noted that, although not attempted, an alternative active ester 
synthesis has been reported. 2^ xhis required initial conversion of the maleimido 
carboxylic acid to its acid chloride, and conversion of N-hydroxysuccinimide to its 
sodium salt. Addition of die two reagents resulted in a 76% yield of the required 
active ester. 
3.5 MONQ-MALEIMIDE - BIFUNCTIONAL COMPLEXING AGENT 
3.5.1 Synthesis 
Incorporation of a maleimide functionality onto the pendent amine of ligand 
(15a) proceeded as proposed upon the addition of excess active ester succinimidyl 
4-maleimidobutyrate (22), to a DMSO solution of the ligand (15a) and 
N-methylmorpholine (ligand was an HBr salt) (Scheme 3.6). 
° o ° 
H0^M6P^^^a^>^NH3- ° (22) ^ ^ ^^O^MeP^^^^^S^^j^A^p] 
H02MeP-^ vJ'--PMe02H DMSO 38% HOzMeP-^ ^W -^PMeOzH 
(15a) (24) 
Scheme 3.6 : Synthesis of a mono-maleimide bifunctional complexing agent 
Because of the relatively slow rate of reaction of the active ester widi (15a), 
competitive ester hydrolysis was a problem. Therefore an excess of the ester was 
required, and the utmost care was taken to ensure the use of anhydrous solvents and 
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reagents. After overnight reaction, analytical HPLC indicated approximately 60% 
conversion of the ligand, and approximately 25% hydrolysis of the active ester to 
4-maleimidobutyric acid. Purification required preparative HPLC, giving the 
product as its tri TFA salt in 38% yield, contaminated with approximately 20% 
4-maleimidobutyric acid which eluted at the same time from the column. Attempts 
to remove excess acid using a diethyl ether wash failed to improve product purity. 
3.5.2 Stability and Biodistribution Resulte 
Because the mono-maleimide (24) was designed for use in vivo as its yttrium 
complex, the kinetic stability of its yttrium complex was tested at pH 1.0, 1.5, and 
2.0, and compared to the yttrium complex of C-functionalised DOTA 
mono-maleimide (Table 3.1). 
Complex 
i.o ! 5 
5s 
23 
Half 
to 1.5 
lars) 
2.0 
[Y.(24)] 6.56 2.11 0.52 29 91 370 
[Y.DOTA 
mono-maleimide]' 
2.72 0.76 0.14 71 254 1368 
Tests performed at the MRC Radiobiology Unit. 
Table 3.1: The rates of dissociation and half lives of two 
mono-maleimides under acidic conditions 
The figures in Table 3.1 are approximate, but do show that the neutral 
complex [Y.(24)], though less inert than [Y.DOTA-mono-maleimide]", is still 
remarkably stable at pH 1.0 (compares well with the results for yttrium complexes 
given in Table 2.4), and at pH 1.5, the half life of the complex, 91 hours, exceeds the 
physical half Ufe of ^^ ^Y (64 hours). 
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Although a very good indicator, kinetic stability measurements need to be 
backed up by actual in vivo testing. The mono-raaleimide (24) was designed not 
only to complex yttrium, but also to couple to an antibody fragment (Fab')- The Fab' 
conjugates of [Y.(24)] and [Y.DOTA-mono-maleimide]", from now on referred to as 
[Y.(24)]-B72.3 and [Y.DOTAJ--B72.3 respectively (B72.3 is the antibody from 
which the specific Fab' used was derived), were accordingly formed, and their 
biodistributions examined in mice after 48 hours. 
In comparing the two Fab' conjugates, it is was found that the % dose per 
gram of blood was higher for [Y.(24)]-B72.3, not because of any stability differences, 
but merely because of the size of the initial injected dose. It was therefore more 
informative to compare ratios of doses, rather than absolute values (i.e. % dose in 
tissue). The ratios of tissue dose to the blood dose for various tissues is given in 
Table 3.2. 
Tissue 
9^Tissue: Blood Ratio 
|Y,DOTAr'B72.3 
Brain 0.024 ±0.004 0.028 ±0.006 
Femur 0.193 ±0.021 0.176 ±0.022 
Kidneys 0.304 ±0.059 0.322 ±0.116 
Liver 0.702 ±0.198 0.740 ± 0.244 
Lungs 0.371 ±0.058 0.348 ± 0.020 
Muscle 0.083 ±0.018 0.072 ±0.016 
Spleen 0.393 ± 0.090 0.374 ± 0.066 
Tests performed at the MRC Radiobiology Unit. 
Table 3.2 : The ratios of the amount ofyttrium-90 found in various tissues compared 
to that in the circulating blood 48 hours post injection into mice. 
-93-
Complex instability is accompanied by a deposition of ^^Y in the bones 
(e.g. the femur). A stable complex will therefore exhibit a low value for the ratio of 
femur to blood (see Tables 3.2 and 3.3), and an unstable complex will give a higher 
value. The raUos of femur to blood for [Y.(24)]-B72.3 and [Y.DOTA]--B72.3 were 
found to be 0.19 and 0.18 respectively indicating high complex stability for both 
complexes. In comparison, [Y.DTPA]-^'-B72.3 gave a ratio of 1.7, showing once 
again the kinetic instability of acyclic complexing agents compared to macrocyclic 
agents. The marrow of the femur is perfused by blood, hence much of the 
radioactivity detected in the femur may not be attributed to ^^Y decomplexation and 
subsequent bone deposition, but merely due to stable complex in the circulating 
blood. For this reason the marrow was removed (leaving the shaft), and new ratios 
calculated. Once again the ratios showed both [Y.(24)]-B72.3 and [Y.DOTAJ--B72.3 
to be very stable in vivo, whilst the DTPA complex was shown to be unstable. The 
results can be seen in Table 3.3. 
fY.(24)1-B72.3 fY.DOTAr^B72J |Y.DTPAl2^-B72.3 
Femur: Blood 0.193 ±0.021 0.176 ±0.022 1.7 
Shaft: Marrow 0.14 0.16 2.17 
Shaft: Blood 0.058 ± 0.016 0.058 ±0.010 -
Tests performed at the MRC Radiobiology Unit. 
Table 3.3 
The biodistribution experiments conducted on the two Fab' conjugates 
indicated high complex stability but no significant difference in stability between the 
two, yet the kinetic stability studies clearly indicated [Y.(24)] to be slightly less stable 
than its DOTA analogue. 
In vivo, the circulating antibody conjugates wi l l be exposed mainly to 
conditions in which the pH is in the range 6 to 7.5. Bearing in mind the half lives 
reported in Table 3.1, after 48 hours a negligible amount of complex wil l have 
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dissociated. Therefore there presumably reaches a point where additional kinetic 
stability at low pH has no beneficial effects on in vivo stability as the amount of 
dissociation wi l l be so small. Both macrocyclic complexes satisfy the kinetic 
stability requirement, but the DTPA complex does not reach this point of minimum 
kinetic stability, and is accordingly found to dissociate at an appreciable rate in vivo. 
These kinetic and in vivo tests clearly show (24) to be a good bifunctional 
complexing agent, forming stable yttrium-90 - Fab' conjugates. 
3.6 TRT.MALEIMIDES 
3.6.1 Reasons for Synthesis 
Compared to an intact antibody (IgG), an antibody fragment wil l penetrate 
more deeply, localise faster, and clear more rapidly from the body. Yttrium 
complexes such as [Y.(24)]-B72.3 bearing one Fab' (see Section 3.5.2), have however 
been shown to clear too rapidly from the body to allow sufficient time for tumour 
localisation, and have therefore resulted in lower than expected tumour to non-tumour 
ratios. Whilst still using antibody fragments, it was predicted that a decrease in the 
clearance rate could be obtained i f the ligand (e.g. (15a)) were functionalised not with 
one Fab' as in [Y.(24)]-B72.3, but with two, three, or perhaps even four antibody 
fragments. This increase in overall size, it was hoped, would as for an intact 
antibody reduce the clearance rate, whilst at the same time increase tumour binding 
avidity as the complex would now bear multiple antigen binding sites rather than just 
the one. 
In an attempt to bear out diese predictions, compounds bearing one, two, 
three, and four maleimides were synthesised by Celltech Ltd., and duly conjugated to 
Fab', to give the mono-Fab', di-Fab', tri-Fab', and the tetra-Fab' moieties respectively. 
Tumour binding studies and in vivo experiments did indeed reveal a progressive 
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improvement in the strength of tumour binding, and in the tumour to non-tumour 
ratios on proceeding from the mono-Fab' through to tri-Fab', although the tetra-Fab' 
showed only a modest improvement over the tri-Fab'. 
As a result of the difficulties associated with tetra-Fab' purification, the 
tri-Fab' was chosen as the most suitable candidate for future research. 
3.6.2 Design and Synthesis 
There are two alternative routes to the synthesis of a ligand bearing three 
maleimides. The first is to produce a ligand exhibiting three pendent primary amine 
sites to permit the addition of three maleimide moieties. The second alternative is to 
produce a tri-maleimide functionalised molecule which could then be attached to a 
ligand. Because of the difficulties associated with producing a tri-functionalised 
ligand, and because the synthesis of ligand (15a) was already established, it was 
decided to synthesise a tri-maleiraide, and attach (15a) to it via the pendent primary 
amine. 
Previous research into the synthesis of nine and twelve merabered 
C-functionalised azacycles '^7 utilised a mono-protected tetraamine (Figure 3.3). 
^ = Protecting group 
Figure 3.3 : The mono-protected tetraamine. Starting 
molecule for tri-maleimide synthesis 
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The addition of maleimide moieties to this tetraamine could take place at the 
three free amine sites perhaps as for the synthesis of (24) from (15a) 
(see section 3.5.1), leaving, after removal of the protecting group, a primary amine 
site free for conjugation to the ligand (15a). The choice of protecting group for the 
fourth amine site is of utmost importance. Maleimides are susceptible to base 
hydrolysis, hence any protecting group should be labile under mild acidic conditions. 
The ideal choice it seemed was a BOC protecting group. This could easily be 
removed in 20 minutes with 90 % trifluoroacetic acid at room temperature. 
The synthesis of the tetraamine was completed following the procedures laid 
out by Cox et al.P (Scheme 3.7). 
11 < 111 
75% H 2 N - < 93% 
(25) (26) (27) 
Scheme 3.7 : Tetraamine synthesis starting from lysine, (i) CHjCOCl, 
MeOH; (ii) H2N(CH2)2NH2; (HijBHyTHF 
After esterification of (+)-(2S)-lysine, the dihydrochloride salt (25), was 
treated with excess neat ethylenediamine, and the resulting amide (26) reduced with 
borane-THF to yield the tetraaraine (27). After protection of the diethylenetriamine 
subunit of (27) as its copper ( I I ) complex, (log K J ^ L of ^^ e analogous 
diethylenetriamine copper complex is 16.1) the e-amino group was selectively BOC 
protected, and the copper protecting group dien removed by bubbling H2S through its 
solution (copper sulfide results) to give the mono-protected tetraamine (28) in 66% 
yield (Scheme 3.8). 
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NH2 N H , 
— ^ H2N . 
Cu^V-'-HN: 
% 
11 
B O C N H 
H2N. 
B O C N H 
C U 2 V / - H N L 
111 
Scheme 3.S: Mono-protection of the tetraamine. (i)Cu^'^; (ii) BOCON; (Hi) H2S 
Conversion of the tetraamine (28) to the tri-maleimide can be brought about 
by functionalisation at the three free amine sites. Attempted syntheses included the 
use of (a) a maleimide active ester (as in the conversion of (15a) to (24) (Scheme 
3.6)), (b) a maleimide acid chloride, (c) the coupling agent DCC to couple (28) to a 
maleimido carboxylate, and (d) a hydroxybenzotriazole (HOBT) maleimide active 
ester formed in situ using the water soluble coupling agent EDC and a 
maleimido carboxylate (Scheme 3.9). 
o o 
(a) dN-o-Cfl/j^ 
° ° X 
N H B O C 
N H B O C 
(b) 
(c) DCC HO 
O 
(d) EDC, HOBT H O ^ A ^ ^ 
(29) R = C H 2 - { > 
(30) R = (CH2)3 
(31) R = (CH2)5 
Scheme 3.9 : Various routes to tri-maleimides 
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A l l attempts to functionalise (28) using an active ester (route (a)) failed. 
Solvents used for the reaction included DMF, acetonitrile, dichloromethane, and a 
pH 6.9 DMSO / phosphate buffer, yet on all occasions the only identifiable products 
were the starting ester, and the products of ester hydrolysis. The slow rate or lack of 
reaction may in part be due to the steric crowding around the amine sites, leading to 
competitive ester hydrolysis. For this reason, a maleiraidocarboxylate was converted 
to the more reactive acid chloride using oxalyl chloride or thionyl chloride, and added 
to (28). Immediate reaction occurred, although HPLC purification resulted in a poor 
yield of the tri-maleimide (approx. 15%), and a large amount of an unidentified 
maleimide associated compound. Two other routes (c) and (d) also resulted in the 
desired product. Route (c) used dicyclohexylcarbodiimide (DCC) to direcdy couple 
the maleimido carboxylate to the amine sites, whilst in the case of route (d), the 
hydroxybenzotriazole maleimide active ester was formed in situ to give on reaction 
wiUi (28), the desired product. 
Because the three maleimides of a tri-maleimide are in close proximity to one 
another, it was suggested that on conjugation, steric crowding may result between 
antibody fragments. This could perhaps lead to incomplete reaction at all the 
maleimide sites giving a mixture of tri, di, and mono Fab' products. In an attempt to 
alter the ratios of products, and determine if indeed steric crowding was a problem, 
tri-maleimides with differing length maleimide side chains were synthesised (29), 
(30), and (31) (Scheme 3.9), and conjugated to antibody fragments (see Chapter 5). 
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3.7 TRI-MALEEVUnE FTJNCTIONAT J S E D LIGANDS 
Two different approaches were attempted to couple the tri-maleimide (31) to 
the ligand (15a). Prior to coupling, TFA removal of the BOC protecting group from 
the fourth amine of the tri-maleimide (31) was monitored by HPLC at 302 nm, clearly 
showing quantitative conversion of (31) ( T R 20.5 min.), to the amine ( T R 15.7 min.) 
(Scheme 3.10). Both the ligand (15a) and the deprotected tri-maleimide exhibit a 
primary amine. To couple the two together, a bifunctional linker molecule (e.g. (32) 
Scheme 3.10) must be inserted. 
NHBOC NHj 
O 
o o ^ ^ ^ ^ ^ ^ ^ r ^ 100% ? o T 
/== U nu DCCTHF ° ' ^ l Q . i _ 0 ^ 
(32) 
Scheme 3.10 : Tri-maleimide deprotection, and the synthesis of a bifunctional linker. 
Two slightly differing syntheses (Schemes 3.11 & 3.12) gave the required 
product (34). Reaction of (15a) with the bis paranitrophenol active ester (32) gave 
the active ester (33), which on addition of the deprotected tri-maleimide gave the 
maleimide functionalised ligand (34). 
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H 0 2 M e P - . ^ / - ^ ^ ^ , ^ ^ ^ ^ . (32) " ° 2 ^ « ' ' > ^ N r i r^>'--^^0T^ 
f • [ J ° o 
•^ N N'^ " " 
HOjMeP-' w ^PMeOjH H02MeP-''W^PMe02H 
(15a) 
NH2 
0 * ^ 0 
O H 
H02MoP-'^w'^^PMe02H 
NO2 
0 ^ 0 0 ^ 
(34) 
Scheme 3.11: Route 1 to the tri-maleimide functionalised ligand 
Alternatively, route 2 required initial reaction of the deprotected tri-raaleimide 
with succinic anhydride. Analytical HPLC clearly showed quantitative conversion of 
this deprotected tri-maleimide ( T R = 13.2 min.) to the carboxylic acid functionalised 
tri-maleimide (35) ( T R = 12.7 min.). Addition of oxalyl chloride to (35) gave the 
acid chloride which after immediate addition of (15a) Uien gave (34). Botii routes 
gave die product in very poor yield after HPLC purification. Subsequent conjugation 
to Fab', and gel electrophoresis, confirmed the existence of (34) (see Chapter 5 ) . 
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0*^0 
NH2« 
0=< ^  0= 0=< ^  0= 
o ^ o o ^ o 
(i) (C0C1)2 
(ii) r > 
(15a) 
0 ^ 0 0 ^ 0 
(35) 
H O H 
N N 
HOaMeP^ v_v ^PMeOgH 
O ^ O O ^ O 
(34) 
Scheme 3.12 : Route 2 to the tri-maleimide functionalised ligand 
3.8 NTTROTMIDAZOLES 
3.8.1 Mode of Action 
As a result of out-growing their blood supply, oxygen deprived ('hypoxic') 
cells develop in the majority of rapidly proliferating solid human tumours. Because 
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cellular oxygen essentially serves to 'fix' radiation-induced free radical damage, 
particularly at the DNA level, viable hypoxic cells are considerably more resistant to 
the lethal effects of ionising radiation, and it is this fact which can influence tumour 
control by radiation. 
Hypoxic cells contain a much higher concentration of reductase enzymes than 
normoxic cells and, as a result, have been shown to selectively retain a class of 
compound called nitroimidazoles which are reduced, and then are unable to diffuse 
out of the cell. 
N O 2 
Figure 3.4 : A nitroimidazole 
Nitroimidazoles have also shown promise in acting as radiosensitizers, in that 
they serve to make a hypoxic cell more susceptible to radiation induced damage by 
acting as an oxygen mimic, l ' * This combination of tumour localisation, and 
radiosensitisation, makes nitroimidazoles a reasonable choice for conjugation to a 
radiolabelled ligand (a technetium labelled nitroimidazole for the imaging of regional 
hypoxia in ischaemic heart disease is discussed in section 1.10.1). 
3.8.2 Conjugation to a Ligand 
The nitroimidazole chosen contained an aminoalkyl side chain and, as before, 
(15a) was the choice of ligand. As for the coupling of (15a) to the BOC deprotected 
trimaleimide (Scheme 3.11), both molecules possess a primary amine through which 
coupling can occur. As before, (15a) was converted to its paranitrophenol active 
ester (33) using the bis active ester (32). Addition of 1-aminopropyl-
2-nitroimidazole to the active ester (33), and subsequent HPLC purification gave in 
73% yield the niti-oimidazole-ligand conjugate (36) which on yttrium complexation 
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wil l form a neutral complex-conjugate which should be able to passively diffuse into 
cells (Scheme 3.13). 
c > 
N N 
H 
NO, 
(33) 
73% NO2 
DMSO 
,NH2 
H 0 2 M e P ^ \ f "^PMe02H 
(36) 
0 H 
H O NO2 
Scheme 3.13 
The biodistribution of [^^^Gd.(36)] - 0.1 ^imol kg'^ was examined in mice, 
both in the absence and presence of a large excess of misonidazole (300 jiraol kg"^). 
Misonidazole (Figure 3.5) is a well established nitroimidazole which has shown 
activity in many different tumour types, especially in rodents, and is accordingly 
added to avoid the premature reduction of the small tracer amounts of ['^ •^Gd.(36)] in 
the blood-stream. 
f = \ f 
NO2 
Figure 3.5: Misonidazole 
In both cases, there did not appear to be any significant accumulation of 
[^^^Gd.(36)] in tissues such as the eyes, oesophagus, liver or salivary glands which 
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are expected to be hypoxic. This may simply be due to the inability of the conjugate 
to selectively accumulate in the target tissues, or it may be due to its premature 
reduction even in the presence of a large excess of misonidazole. The complex 
cleared via the usual renal route, and after 24 hours more dian 99% of the ^^^Gd 
activity had cleared from die body, consistent with the excellent in vivo ^rability of 
the conjugate (36). 
3.9 rONCUJSIONS 
The mono-maleimide (24) has been shown to form stable complexes both 
in vitro, and more importandy in vivo, whilst die tri-maleimide (34), as yet untested, 
is hoped to show the same in vivo stability, whilst exhibiting improved tumour 
binding, and tumour to non-tumour ratios. 
Although the nitroimidazole conjugate (36) was found to show no hypoxic 
cell localisation properties, other groups have had some success with nitroimidazole 
conjugates. 15 It may be that (36) needs to be in a higher concentration, and the use 
of nitroimidazoles cannot be totally discounted for further study. 
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Chapter 4 
DNA Intercalation 
4.1 TNTERCALATORS 
4.1.1 Nature and Mode of Binding 
Intercalators are typically planar fused-ring polyaromatic molecules bearing a 
cationic charge on an aromatic ring, and / or on a pendent group. They are capable of 
binding tightly yet reversibly to double helical DNA, and exhibit many properties 
which make their use in medicine, particularly in the treatment of cancers of prime 
importance. 
O 
Anthraquinone Phenanthroline ACTidine 
Figure 4.1: Some common intercalators 
Intercalators get their name from the Latin 'intercalare' which means to insert. 
Accordingly, binding to DNA is through the insertion of the aromatic plane of an 
intercalating molecule between the aromatic planes of two stacked DNA base pairs. 
For intercalation, the planar part of the molecule must possess a minimum surface 
area of 28 with an optimum of three to four rings. ^  Upon intercalation the 
general structure of the DNA remains intact, but because of the resulting helix 
unwinding, and the increased separation of adjacent base pairs from 3.4 A to 
approximately 7 A (to maintain a spacing of approximately 3.4 A between the 
aromatic planes) required to incorporate the intercalator, a slight lengthening of the 
helix occurs. 
Experimentally determined DNA association constants^ for intercalators are in 
the range 10^-10^ M'^ and can be attributed to a number of factors, including K-K 
stacking of the aromatic rings, hydrogen bonding, and electrostatic forces.^ There 
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are however few studies to indicate the relative importance of these factors, and no 
firm guidelines exist whereby one can confidentiy relate intercalator structure to DNA 
binding strength.^ 
9-Aininoacridine 
Figure 4.2 : Insertion of the intercalator 9-amino acridine into the DNA double helix 
4.1.2 Applications 
The primary use of intercalating compounds is in the treatment of cancer. 
Here, changes in the DNA structure impair replication, or induce strand breaking to 
relieve the torsional strain caused by intercalation. Intercalating agents such as 
andiracyclines can also directiy affect strand breakage through their redox properties,'* 
whilst the cytotoxicity of others can be attributed to their ability to induce 
cross-linking in DNA. Generally, intercalators which are most widely used can be 
put into four main categories; actinomycins, anthracyclines such as Daunomycin and 
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Adriamycin, acridines such as Amsacrine, and anthraquinones such as Mitoxantrone 
(see Figure 4.3). 
Sar _Sar 
L-Pro L-W-MeVal L-Rro L-/V-MeVal 
I ' I A 
o-Val D-Val 
L-Thr L-Thr 
Actinomycin D 
NHp 
OMo 0 0^ 6 
Me 
. O H 
'Me 
6 OH 'COCHzR 
Daunomycin R = H 
Adriamycin R = OH 
M e O ^ _ ^ S s ^ N H S 0 2 M o 
OH O NH(CH2)gNH(CH2)20H 
OH 6 NH(CH2)gNH{CH2)20H 
Amsacrine Mitoxantrone 
Figure 4.3 : Some commonly used intercalating drugs for the treatment of cancer 
Actinomycin D is used in the treatment of Wilm's tumour in children, whereas 
the anthracycline antibiotics Daunoraycin and Adriamycin are used in the treatment 
of leukaemia, and as a broad spectrum anti-cancer drug respectively. Acridines were 
one of the first classes of intercalating drugs, and nowadays Amsacrine is used in the 
treatment of acute leukaemias and malignant lymphomas whilst Mitoxantrone, an 
example of the anthraquinone class of intercalators, has been used in the treatment of 
breast cancer. 
One strategy for the control of tumour gene expression involves the use of 
synthetic oligonucleotides which bind to specific regions of DNA or RNA thus 
inhibiting transcription and translation of genetic information. The covalent 
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attachment of intercalating agents to oligonucleotides has been used to increase the 
binding affinity to the oligonucleotide's complementary sequence, and thus enhance 
inhibition of gene replication.^ A similar use of intercalators includes attachment of 
an intercalating agent to a synthetic oligonucleotide attached in turn to a metal 
complex capable of causing DNA cleavage.^'^'^'^ The intercalator anchors die 
oligonucleotide to a specific region of DNA, thus permitting sequence specific 
cleavage of DNA, in effect allowing the metal complex to act as a chemical nuclease 
in a similar manner to resUiction enzymes. 
4.2 T H E TTSE OF TNTFRrAl ATORS TN THIS WORK 
To be at its most effective, radiation produced during the radioimmunotherapy 
of cancer must hit the chromosomal DNA of the tumour stem cells. Although 
antibody fragments are capable of specifically binding an yttrium-90 labelled 
macrocycle to the surface of a cancer cell, the cell's DNA is but a small part of the 
whole cell, and as a result, much of die emitted radiation wil l pass through the cell 
causing unwanted damage of a less severe nature. Ideally, an yttrium-90 labelled 
macrocycle would bind not to the surface of the tumour cell, but to its DNA. 
Obviously this would require the labelled molecule to first pass through die cell wall 
on its way to the nucleus. With the advent of a new breed of antibody fragments 
(specifically one named A33) which are capable of penetrating die cell wall, diis has 
become a distinct possibility. 
It is postulated that, i f a suitable DNA intercalating agent is covalently 
attached to a molecule bearing an yttrium-90 labelled macrocycle and A33 antibody 
fragments, targeting not only of tumour cells, but of their DNA would become 
possible. A molecule of die nature shown in Figure 4.4 is dierefore required. 
As a consequence of being able to bind directiy to a tumour cell's DNA, it 
may be possible to reduce the dose of injected drug needed for effective 
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radioimmunotherapy as there is a significantly increased chance that emitted radiation 
wil l interact with the DNA and cause cell death. 
Figure 4.4 
4.3 r H O T C E OF INTERCALATOR 
There are numerous different classes of intercalating agents available, many of 
which have been found to be potent drugs in the treatment of cancers and other 
diseases. A precise correlation between a drug's structural charactersitics and its 
potency has not been shown, only that potency is in some cases linked to the strength 
of binding. For this work the choice of intercalator was not of crucial importance; it 
was not based on an effectiveness against cancer, but merely on an ability to bind to 
DNA, and as a result, any anti-cancer properties exhibited would be an added bonus. 
The main criteria for the choice of an intercalating agent were ease of 
functionalisation, ease of NMR spectra interpretation, a chemically robust nature, and 
a reasonable amount of relevant background work. With this in mind, there were two 
logical choices, acridines, and to a lesser extent anthraquinones (see Figure 4.1). 
Acridines are probably the most thoroughly studied class of intercalating 
agents and, of those which have found their way into drug use, the majority are 
functionalised at the 9 position with an amino group (e.g. Amsacrine (Fig. 4.3)). The 
simplest acridine of this class is 9-amino acridine (Figure 4.5). 
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Figure 4.5 : 9-amino acridine 
It was decided therefore that initial attempts to conjugate an intercalating 
agent to an yttrium-90 radiolabelled macrocycle would concentrate on the use of the 
ligand (15a) covalenUy attached to an acridine via a 9-amino group. The final goal 
however, was to form a macrocycle-acridine conjugate, leaving a site free for furdier 
maleimide derivatisation to permit subsequent Fab' conjugation. 
4.4 9.AMTNO ACRTDTNE SYNTHESIS 
The starting material for the synthesis of most 9-amino acridines is 9-chloro 
acridine (37). This was formed in a one step cyclisation from N-phenyl anthranilic 
acid using phosphorus oxychloridc^O and was converted to the more reactive 
9-medioxy acridine (38), and 9-phenoxy acridine (39) species (Scheme 4.1). 
OMo 
Na, MeOH 
COoH 
>90% 
93% 
NaOH. PhOH 
Scheme 4.1: Synthesis of 9-chloro, 9-methoxy and 9-phenoxy acridines 
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There are two principal routes to the synthesis of amino acridines: reaction of 
an amine salt with a 9-alkoxy or 9-phenoxy acr id ine ,or reaction of a free amine 
with 9-chloro acridine (37) in phenol proceeding through a 9-phenoxy acridine 
intermediate. 12 Both routes are essentially mechanistically the same; the 9-phenoxy 
acridine (or 9-methoxy acridine) being the reactive species, and the reaction requiring 
a catalysing proton source, the amine salt or phenol respectively (Scheme 4.2). 
X = OPhorOR 
RNH2,-Fr 
X NHR 
Scheme 4.2 : The synthesis of 9-amino acridines 
4.5 AMINO ACRIDINE FUNCTIONALISED LIGANDS 
Initial attempts to form an acridine-ligand conjugate concentrated simply on 
the joining together of the two halves, without incorporation of a site for further 
maleimide derivatisation. The possession of a pendent primary amine made ligand 
(15a) an ideal choice with which to form an amino acridine. Accordingly, (15a) was 
taken, and to it added 9-methoxy acridine (38) in methanol. Unfortunately, no 
reaction was observed. It was suggested that as (15a) possessed phosphinic acid side 
arms, and was used as its hydrobromide salt, 9-methoxy acridine may have been 
acid-hydrolysed to 9-acridanone, or that the reaction's progress may somehow have 
been swamped out by an excess of acid. For this reason, in an attempt to neutralise 
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excess acid, triethylamime was added to (15a), removed under reduced pressure, and 
the resulting ligand added to 9-chloro acridine (37) in phenol. Yet again no reaction 
was observed (Scheme 4.3). 
HOaMeP 
HOaMeP 
NH3+ 
PMe02H 
(15a) 
MeOH 
OR 
(i) EtjN; (ii) PhOH 
HOaMeP 
OMe 
(38) 
H02MeP-
H / \ 
-PMeOaH 
Scheme 4,3 : Failed syntheses of an acridine-ligand conjugate 
The synthesis of an amino acridine in the presence of ligand (15a) had failed 
(Scheme 4.3). It was decided dierefore to start with an amino acridine which could 
then be linked to (15a). 9-Phenoxy acridine (39) was reacted with 3-bromo 
propylamine hydrobromide to give the amino acridine (40) (Scheme 4.4). 
OPh 
(39) 
Br- "NH2 . HBr 
PhOH 40% 
Scheme 4.4 
(40) 
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It was hoped that this could then be reacted with (15a) to yield an 
acridine-ligand conjugate with a free secondary amine site for subsequent maleimide 
derivatisation (Scheme 4.5). 
HOaMeP-' \ / ^PMeOaH 
(15a) 
DMF, K2CO3, 
18-Crown-6 
N N 
HOaMeP ^  ^PMeOzH 
(40) 
Scheme 4,5 : Failed coupling of ligand (15a) and the amino acridine (40) 
The reaction was attempted on a number of occasions at temperatures ranging 
from 45°C to 90°C using either potassium or caesium carbonate as the base, and in 
some instances using 18-crown-6. In all cases, HPLC indicated a large number of 
acridine associated products, none of which were found to be die desired product. 
Failure of the reaction again may have been due to the presence of acidic groups, or 
due in part to decomposition or base hydrolysis of (40), although this does not explain 
the large number of products observed. 
To see i f it was indeed die acidity of (15a) which was die cause of die lack of 
reaction, it was decided to conjugate its parent ester (14a) to the amino acridine (40), 
and then hydrolyse the resulting conjugate to the phosphinic acid using HBr in glacial 
acetic acid (Scheme 4.6). 
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EtOaMeP 
(14a) '^ ^^ 
EtOsMeP 
EtOsMeP 
DMF, K2CO3 
HBr, AcOH, 
PhOH 
H 0 2 M e P ^ A - ^ 
HOgMeP^ V _ y ^PMeOsH 
Scheme 4.6: Failed synthesis of an acridine-ligand conjugate 
Again, HPLC gave none of the desired product, just a variety of unidentifiable 
acridine derivatives. To determine whether the lack of reaction was due to the 
unreactivity of the sulphonamide (14a) or due to the instability of the amino acridine 
(40), the sulphonamide (14a) was converted to its more reactive sodium salt using 
sodium ethoxide, and again added to (40). Once more no reaction was observed. 
It appeared that the use of the pre-formed amino acridine (40) was one cause 
of the problem, and it was accordingly decided to revert back to the idea of forming 
the amino acridine during the main coupling reaction. This time however, instead of 
using the phosphinic acid functionalised ligand (15a) to form an amino acridine 
(as in Scheme 4.3), i t was decided to use a phosphinate ester functionalised with a 
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primary amine site which would then hopefully form an amino acridine when added 
to 9-chloro acridine (37), and be amenable to conversion to the desired phosphinic 
acid functionalised ligand. 
NH2 H^N^-^^PciCHsh ^ 0 S ^ ^ ^ ^ Y 0 C ( C H 3 ) 3 
27% O 93% ^ 0 
(41) (42) 
Scheme 4.7 
The primary amine site to which the acridine was to be attached was 
synthesised separately (Scheme 4.7), and attached in its BOC amine protected form to 
the phosphinate ester (14a) using potassium carbonate in DMF to give (43) 
(Scheme 4.8). 
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EtOgMeP 
EtOaMeP-/ ^PMeOaEt 
(14a) 
EtOzMeP 
EtO^MeP 
DMF, 
K2CO3 
65% 
EtOgMeP 
EtOaMeP-^ V - ^ ^PMe02Et 
TFA 
(43) 
Y°^C(CH3)3 
(42) 
X:(CH3)3 
PMeOgEt 
Scheme 4.8 : The successful synthesis of the primary amine 
functionalised phosphinate ester (44) 
Using trifluoroacetic acid, BOC deprotection of the amine (43) proceeded 
quantitatively, to give the crude amine salt (44), which following HPLC purification 
was extracted as its free amine from a saturated aqueous potassium carbonate 
solution. 
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Reaction of the free amine (44) with 9-chloro acridine (37) in phenol gave 
after preparative HPLC, the amino acridine (45) in 62% yield (Scheme 4.9). It was 
hoped then that subsequent treatment of this amino acridine with HBr, AcOH, PhOH 
would hydrolyse the phosphinate esters to the desired phosphinic acids, and in the 
process remove the p-methoxy-benzenesulphonyl protecting group from the 
secondary amine site leaving it free for maleimide derivatisation. However, HPLC 
indicated complete decomposition of (45) to a large number of products, presumably 
due to the thermal and chemical instability of the amino acridine to acid catalysed 
hydrolysis. 13 
0=S=Oo 
EtOgMeP-
EtOaMeP 
> 4 N-^ 
,NH2 
^ M e O a E t (44) 
PhOH 
0=S=Oo 
EtOoMeP 
^ M e O o E t EtOaMeP 
HBr, AcOH 
PhOH 
PMeOoH 
HOaMeP 
HOaMeP 
H O H 
H 
Scheme 4.9 : Amino acridine synthesis, and unsuccessful deprotection 
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4.6 ACRIDINE A M m E FIJNCTIONALISED LIGANDS 
It became apparent that the use of amino acridines was inherentiy flawed by 
their instability towards acid hydrolysis during exposure to HBr in glacial acetic acid. 
It was therefore decided to look at some other means of conjugating a macrocycle to 
an acridine moiety. The solution appeared to lie not in the use of amino acridines, 
but in acridine amides, whereby linkage to the acridine ring system was achieved via 
an amide functionality. Acridine-9-carboxylic acid was readily available, and 
following prolonged heating in neat thionyl chloride yielded the acid chloride, 
acridine-9-carbonyl chloride (46) as a yellow soUd.^^ Immediate addition of an 
amine resulted in rapid production of an acridine amide (Scheme 4.10). 
H O ^ O 
SOCl, r^'^N^^N^*^ ^ 2 
Scheme 4.10 : Synthesis of acridine amides 
Starting again with the ligand (15a), it was predicted that unlike the formation 
of amino acridines (Scheme 4.3), formation of acridine amides would be unaffected 
by the presence of such an acidic molecule. The acridine acid chloride (46) was duly 
formed, and to it added a solution of (15a) and N-methylmorpholine in DMF 
(Scheme 4.11). Subsequent HPLC purification of the products did indeed give, 
albeit in low yield (14%), the desired acridine labelled ligand (47). 
Building on the successful conjugation of the macrocycle (15a) to acridine 
(Scheme 4.11), it was decided to attach as their amides, acridine and the intercalator 
anthraquinone to (44), which after removal of the p-methoxy benzenesulphonyl 
protecting group should leave a secondary amine site free for maleimide 
derivatisation (Schemes 4.12 & 4.13). As for acridine-9-carboxylic acid, 
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anthraquinone-2-carboxylic acid can also be converted to its acid chloride (48) using 
thionyl chloride. 
(15a) 
N ' 
HOaMeP-/ \ / ^PMeOgH 
14% 
H02MeP 
HOzMeP-^ \ / ^PMe02H 
(47) 
Scheme 4.11: Successful synthesis of the acridine amide (47) 
Conjugation of the acridine and anthraquinone moieties to the amine (44) 
proceeded well to give after HPLC purification, the two amides (49) and (51) in 50% 
and 42% yields respectively. As expected, hydrolysis of the phosphinate ester (49) 
to the phosphinic acid (50) proceeded well with concomitant amine deprotection to 
give after HPLC purification, the desired product (50) in 72% yield. A doubling in 
the overall yield of the phosphinic acid (50) from the amine (44) was achieved when 
(49) was used as its crude without initial HPLC purification. 
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OMe 
0=S=0 o 
H 
EtOgMeP 
^-PMeOgEt EtOaMeP 
0=S=0 o 
Et02MeP 
^ M e O o E t EtOgMeP 
HBr, AcOH 
PhOH 
HOpMeP 
^ M e O o H HOgMeP 
Secondary amine site free 
for maleimide derivatisation 
Scheme 4.12 : Successful synthesis of the acridine amide (50) bearing a free 
secondary amine site for maleimide derivatisation 
Treatment of the anthraquinone amide (51) with HBr, AcOH, PhOH, unlike 
the corresponding acridine derivative, did not appear to give the desired phosphinic 
acid product. Indeed HPLC indicated a number of products, which on isolation of 
the main components did not yield any identifiable compounds. 
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A model reaction was attempted to try to determine the fate of the 
anthraquinone amide (51). A simple anthraquinone butylamide was taken, and as 
before, treated with HBr in glacial acetic acid with phenol to scavenge any bromine. 
After 1 day, analysis of the resulting products showed the presence of approximately 
25% of an insoluble compound, perhaps anthraquinone-2-carboxylic acid, the amide 
hydrolysis product, indicating that (51) may similarly have undergone amide 
hydrolysis. 
EtOoMeP 
PMe02Et EtOgMeP 
EtOjMeP 
PMeOoEt EtOoMeP 
HBr, AcOH 
PhOH 
HOpMeP 
PMeOoH HCbMeP 
Scheme 4.13 : Successful synthesis of the anthraquinone amide (51), but 
unsuccessful deprotection of the amine site 
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4.7 D.N.A. BINDING 
4.7.1 Tests 
The purpose of attaching acridine and anthraquinone intercalating moieties to 
the ligand was to facilitate tumour DNA binding. There are a number of physical 
measurements which can be done to test the strength and degree of this binding, be it 
intercalation, or some other mode of DNA binding. Intercalation results in changes 
in the viscosity, sedimentation coefficient, and electrophoretic mobility of DNA.^^ 
Changes can also be observed in the ^^P NMR of the phosphodiester backbone of 
DNA as well as in the ^H NMR of the aromatic region of the intercalator. 
One of the simplest indications of intercalation is a change in the U.V. 
spectrum of an intercalator on addition of DNA. Many researchers working 
primarily on acridine based intercalating agents, have on addition of DNA, observed 
small shifts to higher wavelength in the U.V. spectra of intercalating agents, as well 
as extinction coefficient reductions. ^ 7 - I t was accordingly decided to test the DNA 
binding ability of the acridine conjugate (49). The phosphinate ester (49) rather than 
the phosphinic acid (50) was chosen for testing for reasons of simplicity and charge. 
The target complex-intercalator conjugate wi l l indeed be a phosphinic acid 
functionalised ligand, but as its yttrium complex. Moreover, the free secondary 
amine site introduced into the backbone of (50) wi l l in the final conjugate be 
maleimide functionalised. The combination of these two facts means that the 
complex-intercalator conjugate wi l l exhibit overall charge neutrality. The 
phosphinate ester (49) is also charge neutral, whereas the phosphinic acid (50) is not. 
The DNA chosen for the intercalation test was Calf Thymus (Type XV) DNA. 
A 10'^ mol dm"3 solution of the intercalator (49) was made up in pH 7.4, 0.05 mol 
dm'3 sodium phosphate buffer, and to it added one equivalent of 50 x 10"^  mol dm'^ 
DNA, also made up in the same buffer. The DNA-phosphate concentration (i.e. the 
concentration of binding sites) was calculated from the extinction coefficient 
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6600 mol'^ dm^ cm"^ at 260 nm. The U.V. spectrum of the solution was recorded, 
and another equivalent of DNA added. This process was repeated until 
approximately 15 equivalents of DNA had been added. The spectra were then 
overlaid to determine the extent of the red shift produced on intercalation. No shift 
was observed for (49), or indeed for the anthraquinone derivative (51). The 
experiment was then repeated using two simple amino acridines (Figure 4.6), and the 
red shifts observed recorded in Table 4.1. On this occasion, shifts although small 
(approx. 2 nm), were observed. 
Figure 4.6 : Amino acridines used in DNA binding study 
Ifttetcaliitor ^ bound 
Red Shift/nro 
I 410 412.9 2.9±0.3 
I I 417.4 418.8 1.4±0.3 
Table 4.1: Red shifts observed on addition of 10-15 equivalents of calf thymus DNA 
tol&II in pH 7.4, 0.05 mol dm'^phosphate buffer at 20°C 
The results obtained for the amino acridines I and n were in accordance with 
other reported amino acridine derivatives which have shown shifts ranging from 
Oto7nm.l8'19 
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4.7.2 DNA Binding Strength 
The question arose as to whether the apparent absence of a U.V. red shift for 
(49), was indicative of a lack of DNA binding, or simply of a much weaker binding. 
It became evident that the reason no DNA binding could be detected lay in the lack of 
charge on the endocyclic nitrogen of acridine. The presence of the amino group in 
9-amino acridines (e.g. I & 11 Figure 4.6) dramatically increases the pKa of the ring 
nitrogen from 5.60 for acridine, to one in the range 9.5 - 10. This essentially 
means that at physiological pH 7.4, amino acridines wi l l exist as mono cations, 
protonated on the ring nitrogen, whilst the acridine amide (49) with a pKa of 
approximately 4.2 21 remains unprotonated. The existence of such a cationic 
acridine species leads to an electrostatic attraction to the polyanionic phosphodiester 
backbone of DNA, producing the largest contribution to DNA binding affinity, and 
hence producing the observed red shifts. Indeed, as far back as 1946, an extensive 
study of the antibacterial activity of over a hundred acridines revealed that 
protonation of the aromatic ring nitrogen was a requisite for bacteriostasis, and most 
likely efficient DNA binding.^l 
o OH o 
OMe O OH 
ObHO 
I I /IS 
r 
OH 
O OH OH OHOHOH 
OH 
Figure 4.7 : Neutral intercalating species 
-128-
Because of their inactivity, there are few reports on the DNA binding 
strengths of neutral intercalators However, two groups working on the kinetics of 
interaction of anthraquinone based intercalators with DNA have shown intercalation, 
albeit weak, to exist for neutral intercalators (Figure 4.7).22-23 
The binding constants for I - IV were found to be 2.7 x 10"*, 1.0 x 10^, 
3.6 X 104, and 3.0 x 10"* M'^ respectively, 10 - 100 times smaller than the 
corresponding derivatives bearing a charged pendent amino group. It therefore 
seems likely that both the acridine amide (49), and the anthraquinone amide (51), do 
in fact bind to DNA, particularly as the anthraquinones (51), I , I I , and IV are all 
substituted in the 2 position. As a consequence of there being no electrostatic 
contribution to the DNA binding of (49) and (51), binding constants will be slighdy 
lower, with no detectable red shift in the U.V. There may however be one distinct 
advantage in a charge neutral intercalator, in that it should lead to reduced membrane 
interactions, and superior in vivo transport properties compared to those of the 
cationic analogue.23 
4.8 rATTONTC ACRTDTNE TNTERCALATQRS 
4.8.1 Charged Chrpmpphprg 
In an attempt to increase DNA binding affinity, it was decided to try once 
again to form a cationic ligand-amino acridine conjugate. Synthesis involved the 
initial formation of the carboxylate functionalised amino acridine (52) from the 
reaction between methoxy acridine (38), and 6-aminohexanoic acid, followed by its 
conversion to the acid chloride (53) (Scheme 4.14). The first step gave (52) in 53% 
yield as a yellow precipitate from a methanol solution, whilst once converted to its 
acid chloride, (53) had to be used immediately owing to it rapidly becoming 
insoluble, presumably due to polymerisation or cyclisation. 
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OMe 
MeOH 53% 
(38) 
CO2H 
(53) 
Scheme 4.14 
Addition of the acid chloride (53) to the amine functionalised ligand (44) was 
carried out in dichloromethane containing an excess of N-methylmorpholine, to give 
after HPLC purification, the amino acridine (54) in 49% yield (Scheme 4.15). 
Subsequent ester hydrolysis and concomitant detosylation of the secondary amine of 
(54) resulted not in the desired product, but in a large number of unidentified 
compounds. Separation of the principal components showed no sign of the desired 
product. It was presumed, that as for HBr, AcOH, PhOH treatment of (45) 
(Scheme 4.9), unwanted hydrolysis of the amino acridine had occurred. 
DNA intercalation studies of (54) did, as predicted for a charged acridine 
moiety, show a U.V. red shift of 1.6 nm from 414.3 nm to 415.9 nm, on addition of 
up to 20 equivalents of calf thymus DNA. The shift became progressively larger, as 
more DNA was added (Figure 4.8). Although a reduction in the extinction 
coefficient of the acridine chromophore does occur on intercalation of DNA, much of 
the reduction in intensity observed in Figure 4.8 was due merely to a reduction in 
concentration, as progressively more DNA solution was added to (54). 
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HOaMeP 
HOaMeP-
OMe 
) 
o 0=^=0 o 
EtOaMeP 
PMeOaEt EtOaMeP 
OMe 49% 
o=s=o O 
EtOgMeP 
PMeOaEt EtOaMeP 
HBr, AcOH 
PhOH 
-PMeOaH 
Scheme 4.15 : Successful synthesis of the ligand-amino acridine conjugate (54) 
but failed ester hydrolysis, and amine deprotection 
4.8.2 Charged Side-chains 
So far, discussion has been limited to intercalating agents which are charge 
neutral, or which possess a cationic charge on their aromatic ring system. The charge 
neutral ligands produced (e.g. (50) Scheme 4.12) may be ideal as their distribution 
properties are predicted to be better than their charged analogues, although it is 
uncertain as to whether their efficacy may be compromised by their weak 
intercalation to DNA. 
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The cationic amino acridines however, although showing strong DNA 
binding, were ruled out because of the difficulties encountered during the final 
detosylation step (Scheme 4.15). 
OMe 
0-S:0 0 
N N 
(54) 
414.3 
No DNA 
415.9 
20 equiv. 
— r ~ 
400 420 nm 440 
Figure 4.8 : U. V. red shift for (54) on addition of 20 equiv. of DNA at pH 7.4 
There is however another class of charged intercalator, which although 
cationic in nature does not possess a charge on the ring system. Incorporation of 
functional groups such as amines into the pendent arms of a potential intercalating 
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agent permits as for amino acridines, electrostatic interaction with the anionic 
phosphodiester backbone of DNA, or more specific hydrogen bonding to DNA bases. 
These effects result in an increase in DNA intercalation strength. 
Ametantrone (I) is an example of an anthraquinone based intercalating agent 
bearing pendent cationic charges which has proven potency in anti-cancer 
chemotherapy,24 and acridine-4-carboxamide (H) is also a pendent-monocation which 
has shown considerable activity against leukaemia25 (Figure 4.9). 
n 
Figure 4.9 : Cationic intercalators Ametantrone (I) and Acridine-4-carboxamide (II) 
Recent preliminary reports on examples of charged pendent arm acridines 
have shown intercalation for di 26 and tri (III)^^ intercalators, and for an 
acridine-oligonucleotide conjugate (IV) (Figure 4.10).27 Compound I I I showed 
strong intercalation of all three chroraophores, and was therefore considered 
interesting as the two acridine units used were in the form of acridine amides 
substituted in die 9-position (cf. (50) Scheme 4.12). The intercalating ability of the 
acridine-oligonucleotide conjugate (IV) also proved interesting as yet again, the 
acridine was in the form of an acridine amide, substituted in the 9-position. 
Acridine-4-carboxamide (II), although not substituted in the 9-position, is also an 
acridine amide which shows intercalation. 
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r ^ 
piigonucleotide 
o' 
•0 - i ! '=0 
H-N' 
IV 
in 
Figure 4.10 : Pendent charged 9-acridine amide intercalators 
With these encouraging results in mind, an acridine amide similar to (49) but 
incorporating a tertiary amine site (will protonate) in the linker between the acridine 
and the ligand was synthesised (Scheme 4.17). In an identical manner to the 
synthesis of the BOC protected amine (42) (Scheme 4.7), the BOC protected amine 
(56) was formed (Scheme 4.16). 
H2N, ,NH2 J ? ^ ^ H 2 N ^ ^ N 0.^(CH3)3 
tOle 58% ° 
(55) 
o 
01 
H H 
C ^ N v ^ N ' 'Sc°"C(CH3)3 
14% 6 >^lo 0 
(56) 
Scheme 4.16 
Subsequent addition of (56) to (14a) was carried out in exactly the same 
manner as for the synthesis of (46) (Scheme 4.8), and the acridine amide (58) formed, 
by the subsequent addition of the acid chloride (46) (as in Scheme 4.12). 
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1 
o=$=o 
:N N : 
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O Me O 
T 
H 
C I ^ , ^ > ^ ^ . C { C H 3 ) 3 
H 
Et02MeP^ ^PMeOgEt 
H 
(56) 
DMF, 
K2CO3 50% 
OMe 
s. 
y 
O 0=$=0 o Me O 
EtO^MeP-. ^ / ^ ^ ^ r ^ ^ A ) - ^ ( ^ H 3 ) 3 
fJ, ^ H 
EtOgMeP-^'^^—/^^PMeOgEt 
(57) 52% 
OMe 
TFA 
O 
EtOaMeP^ /-^ f 
EtOaMeP^ ^PMeOzEt 
0=^=0 o . Me 
H 
"NH2 
(58) 29% 
OMe (46) 
EtOaMeP^ ^ /^Y^^^^^^^T-^ 
c y 
EtOaMeP-^ "^PMeOaEt 
0=S=0 o Me 
H 
(59) 
Scheme 4.17 : Synthesis of the charged pendent arm acridine amide (59) 
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Owing to the small quantity of (59) produced, subsequent phosphinate ester 
hydrolysis and detosylation was not attempted. The DNA binding properties of (59) 
were however tested to determine the extent, if any, of intercalation. 
No red shift was observed for (59) on addition of up to 20 equivalents of 
calf thymus DNA. Although disappointing, the result was the expected one, as the 
intercalation strength was predicted to be one or two orders of magnitude smaller than 
the cationic amino acridines which themselves only gave a red shift of approximately 
2 nm (Table 4.1). The red shift for (59) therefore, would be too small to detected. 
For definitive proof of intercalation, tests such as DNA helix unwinding angle, and 
sedimentation coefficient changes would have to be performed. These were beyond 
the scope of my work, and although interesting were not performed. 
4.9 MALRTMIDE nFRTVATTSATION 
4.9.1 MQnQ-m^Uimi^ ig 
As discussed in Section 4.2, the purpose of the attachment of a DNA 
intercalating agent to a complex-antibody conjugate, was to bind the complex to a 
tumour cell's DNA once the antibody fragment (Fab') had taken the complex inside 
the cell. The ligand-acridine conjugate (50) therefore required maleimide 
derivatisation at the free secondary amine site on the backbone connecting the ligand 
and acridine. The maleimide is able to react selectively in the presence of amines, 
with a free thiol of a Fab', thereby permitting conjugation to the molecule. As for the 
synthesis of the mono-maleimide-ligand conjugate (24) (Chapter 3 Scheme 3.6), 
initial attempts to functionalise (50) with a single maleimide moiety concentrated on 
the use of a maleimide active ester (22) in DMSO. Al l attempts, including the use of 
a model of (50) (Figure 4.11) failed to produce any of the desired maleimide 
derivatised product, and only slow hydrolysis of the active ester (22) was observed. 
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It was suspected that the electron withdrawing effect of the adjacent amide 
functionality of (50) was reducing the nucleophilicity of die amine site, dius halting 
the desired reaction. 
Reaction Site 
Figure 4.11: Model of (50) 
The addition of the more reactive maleimide acid chloride to (50) in a 
DMF / dichloromethane solution did however, cleanly form the mono-maleimide 
derivative (60) (Scheme 4.18), which after HPLC purification gave a yield of 93%. 
Both NMR and electrospray mass spectrometry confirmed the existence of (60). 
HOaMeP 
H02MeP PMeOoH 
93% O 
EtsN, DMF, 
CH2CI2 
H02MeP 
HOaMeP -PMe02H 
(60) 
Scheme 4.18 : Synthesis of the mono maleimide derivative (60) 
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The NMR of (60) was unusual, in that the expected singlet due to the two 
equivalent protons of the maleimide appeared as two distinct resonances in roughly a 
2:1 ratio. Indeed, the singlet and the triplet due to the protons on either side of the 
newly formed amide (see Figure 4.12), also showed in the same 2:1 ratio, chemical 
shift non-equivalence of approximately 65 Hz, giving instead, two singlets and two 
triplets. Even though (60) had eluted from the HPLC column as one clean peak, and 
mass spectrometry had confirmed its existence, it initially appeared that two 
maleimide species were present. Repetition of the reaction using (50) and also its 
model (Figure 4.11), always showed one product by HPLC, yet the unusual 2:1 
non-equivalence of the same three sets of resonances was always observed. The 
answer to the problem was established by a V.T. ^H NMR experiment. As the 
temperature was increased from 5-35°C, careful measurements of the resonance shifts 
showed a slight coalescence of the three sets of anisochronous resonances of 3.2 Hz, 
and 7.6 Hz, for the triplet and the CH2 singlet respectively. This suggested that 
rotation around the newly formed amide C-N bond of (60) was conformationally 
locked due to hydrogen bonding between the amide carbonyl oxygen, and the proton 
of the adjacent amide (Figure 4.12). 
H02MeP-
N H 
HOaMeP-^ ^ ^PMeOaH 
(60) 
H ,=,0 
4 = Site of observed chemical shift non-equivalence 
Figure 4.12 : The locked conformation of (60), showing restricted C-N bond rotation 
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This locked conformation essentially introduced an inequivalency of the 
maleimide protons, and of the protons at other two sites, as well as at other sites 
whose splitting was obscured in the NMR spectrum. 
4.9.2 Tri-m^l^imid^ 
For the same reasons expressed in Chapter 3 (Section 3.6.1), it was desirable 
to functionalise the ligand-acridine conjugate (50) with three antibody fragments, thus 
requiring the addition of three maleimides. 
O 
HOaMeP—' ^PMeOgH 
(50) 
H-N 
=0 DMF, EtjN 
CI 
H-N 
H H 
N 
HOaMeP^ W ^PMeOgH 
(61) 
Scheme 4.19 : Synthesis of the tri-makimide-acridine-ligand conjugate (61) 
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It was suggested that the antibody fragment responsible for cell intemalisation 
(A33), is most effective when surface antigen cross-linking is achieved. Thus, a 
tri-Fab', being capable of cross-linking three antigen sites should be more suitable for 
cell intemalisation than the mono-Fab', Fab'-(60) which is incapable of cross-linking. 
To determine however if a mono-Fab' was capable of cell intemalisation, tests 
were carried out on amongst others, Fab'-(60) to discover their effectiveness 
(see Chapter 5, Section 5.8). 
Synthesis of the tri-maleimide-acridine functionalised ligand (61) was effected 
as for the synthesis of the tri-maleimide (34) (Chapter 3, Scheme 3.12). The 
carboxylic acid functionalised tri-maleimide (35) was converted to its acid chloride 
by the addition of oxalyl chloride, and added immediately to a DMF solution of (50) 
and triethylamine. HPLC purification gave the desired product (61), albeit in very 
low yield (Scheme 4.19). 
4.10 rONCLIJSIONS 
The use of antibody fragments in conjunction with intercalators does in 
principle present a novel and improved technique for accurate radioimmunotherapy of 
cancer. It however waits to be seen i f indeed intercalators wil l show any positive 
improvements over merely Fab' labelled ligands. 
Although DNA intercalation is yet to be proven, the use of uncharged acridine 
amides may in principle allow better conjugate biodistribution. For charged pendent 
arm intercalators, intercalation should also be possible, but has not been proven yet 
in vitro. Along with the tests carried out at Celltech Ltd., (see Chapter 5), more 
accurate biological tests are required to determine the extent, i f any of intercalation. 
This use of intercalators is still in its infancy, and may take time to prove its 
effectiveness. 
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Chapter 5 
Antibody 
Conjugation 
5.1 TNTROmiCTION 
Each year, there are estimated to be over 400,000 new cases of colorectal 
cancer diagnosed world-wide. In its early stages, surgery and chemotherapy can lead 
to greater than 80% five year survival. However, in later stages, when cancer has 
spread, there is only about a 50% five year survival following treatment. For this 
reason, this work is concerned specifically with the radioimmunotherapy of colorectal 
cancer. 
The mono and tri-maleimide functionalised ligands reported in Chapters 3 and 
4 were formed to permit antibody fragment (Fab') conjugation to a metal complex for 
radioimmunotherapy. This chapter is concerned primarily with the techniques of 
Fab' conjugation and purification, as well as subsequent conjugate testing. 
5.2 ANTTBODTES USED 
Chimeric monoclonal antibody fragments (Fab'), rather than whole antibodies 
were used for reasons laid out in Chapter 1 (Section 1.6). Two different antibody 
fragments were available for the targeting of antigens found specifically in colorectal 
cancers. These were B72.3 and A33, both of which have been shown to bind with 
high specificity to antigenic tumour associated glycoproteins (TAG-72 in the case of 
B72.3). The monoclonal antibody A33 has distinct advantages over B72.3, in that 
unlike the antigen TAG-72, which is only present in 80% of colorectal cancers,^  the 
antigen for A33 is homogeneously present in all colorectal cancers. Moreover, in 
clinical studies using ^^^I-radiolabelled whole antibodies, tumour to non-tumour 
ratios for B72.3 were less than ten,2 whereas for A33 the ratios were consistently 
found to be much higher.^ The antibody A33 also has the unusual property of cell 
intemalisation, although one potential limitation of the use of A33 is the expression of 
its antigen in non-cancerous colonic mucosa. 
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5.3 FAB' PREPARATION 
5.3.1 Thiol Reduction 
Antibody fragment conjugation to a maleimide is achieved through a thiol 
group. Both B72.3 and A33 may be modified to contain only one thiol in the form of 
a cysteine residue in the hinge region of the antibody fragment (see Scheme 3.2). 
However, before conjugation to a maleimide is possible, the thiol in the hinge region 
must be reformed immediately prior to use. This was achieved by incubation with 
P-mercaptoethylamine (P-ME), a reducing agent which is able to convert a disulfide 
or SOxH back to a thiol. However, as a Fab' contains five disulfide bridges, a 
selective reduction must be carried out, whilst leaving the disulfide bridges intact. 
Typically, to 0.9 ml of Fab'(B72.3 or A33) at a concentration of 
approximately 5 mg ml"^ in 0.1 M acetate-citrate-EDTA [pH 6.0 buffer], was added 
0.1 ml of 50 mM P-ME in the same buffer. The solution was then incubated in a 
water bath at 37°C, for exactly 30 minutes, at which point, to remove any excess 
P-ME, it was loaded onto a prepacked Sephadex G-25M PD-10 column equilibrated 
in the same buffer. The column was eluted with buffer, and 1 ml fractions collected. 
Beer-Lambert A = e.c.l 
(A = absorbance, c = concentration, e = extinction coefficient, 1 = cell path-length) 
c = A /e . l (1=1 cm) 
c = A /e (e= 1.14cm-^mg-lmlat280nm) 
[Fab'] = A28o/e / mg ml'^ 
Fab'RMM = 50,000 
[Fab'] = A28o/50,000.e / 
Scheme 5.1: Calculation of antibody concentration 
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The antibody concentration in each eluted fraction was then calculated from 
absorbance measurements at 280nm (A280) of diluted samples (approx. 30 fold) of 
each 1 ml fraction (Scheme 5.1). Typically the fourth, and to a lesser extent the fifth 
eluted fractions contained the bulk of the reduced antibody fragment, which was 
stored on ice in an attempt to inhibit aerial oxidation of the thiol group. 
5.3.2 ThiQl A$$3y 
The extent of Fab' reduction (thiol reformation), varies from one incubation to 
another, and affects the degree of maleimide coupling that is possible. Too much 
reduction leads to cleavage of intra disulfide bridges, and can cause aggregation of 
antibodies. Too little reduction on the other hand leads to a wastage of Fab'. 
Ideally, incubation should affect reformation of just one thiol (the cysteine residue) 
per Fab'. The extent of this reduction can be determined using a thiol assay. Values 
in the range 0.9 to 1.1 thiols per Fab' are acceptable for use in conjugation. 
For the assay, three 100 ^il solutions (Test, Blank, and Control) were prepared, 
incubated for exactly 10 minutes, and their U.V. spectra measured at either 324 nm or 
280 nm (Table 5.1). 
w^^m 1 PBS/Hi DTDP/Ml l 
Test 30 60 10 1 324 
Blank 0 90 10 324 
Control 30 70 0 1 280 
(DTDP = 4,4' -Dithiodipyridine 5 mM in ethanol.) 
Table 5.1 
When added to DTDP, a Fab' thiol will liberate an equivalent of thiopyridine 
(Scheme 5.2). Knowing the extinction coefficient e of thiopyridine at 324 nm 
(e = 19800 cm-^ M'^) , its concentration, and hence the concentration of thiol can be 
calculated for the Test and Blank solutions. 
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N . Ji 
^ SH 
Fab'-SH I i^ ab' 
Scheme 5.2 
Measurement of the absorbance of the Control solution at 280 nm then 
permits the overall concentration of Fab' to be calculated (see Scheme 5.1). 
Knowing both the thiol concentration and the concentration of Fab' present, the 
average number of thiols per Fab' can be determined (Scheme 5.3). 
From the Test and Blank at 324 nm. 
[A324 (Test)-A324 (Blank)] x 10^ / \M 
[Fab' Thiol] 
19800 
From the Control at 280 nm. 
[Fab'] = A280 (Control) / 50,000.e / \iM 
Therefore, 
[Fab' Thiol] 
Thiols per Fab' = 
[Fab'] 
Scheme 5.3 : Determination of the average number of free thiols per Fab' 
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5.4 F A R ' rONTIJGATTON TO TRT-MALEIMIDE$ 
5.4,1 Nature of Products 
Initial attempts to conjugate antibody fragments to maleimides concentrated 
on the tri-maleimides (29), (30), and (31) (Figure 5.1). 
NHBOC 
(29) R = CH2-{3- (30) R = (CH2)3 (31) R = (CH2)5 
Figure 5.1: The tri-maleimides used in the coupling reactions 
Contrary to expectations, conversion of a tri-maleimide to its tri-Fab' could 
not be brought about by the simple addition of 3 or more equivalents of reduced Fab'. 
Indeed, addition of too much Fab' appeared to reduce the amount of tri-Fab' formed, 
with both the di-Fab' and the mono-Fab' also being formed. The proportion of each 
of the three products was found to be highly dependent on the ratio of Fab' to 
tri-maleimide used. I f the ratio was too small, then as expected, very little tri-Fab' 
was observed. On the other hand, i f the ratio of Fab' to tri-maleimide was too large, 
then again very little tri-Fab' was formed. 
The reason why complete tri-maleimide conversion to the tri-Fab' could not be 
obtained is unclear. Partial maleiraide hydrolysis, or reaction with trace amines 
could account for the presence of the di and mono-Fab' species. In addition, steric 
inhibition of conjugation may also be involved. Compared to the distance between 
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maleimide moieties of a tri-maleimide, an antibody fragment with a mass of 
50,000 Da is very large. Thus, steric crowding may result when trying to form a 
tri-Fab'. It was for this reason that the three different tri-maleimides (29), (30), and 
(31) were prepared, in an attempt to ascertain i f a difference in the ratio of products 
could be observed on changing the effective distance between the three maleimide 
moieties. 
5.4.2 'One Pot Route' 
Two different routes to the formation of tri-Fab' species were attempted. On 
all occasions, addition of reduced Fab' to a tri-maleimide resulted in a mixture of tri, 
di, and mono Fab' species, as well as unreacted Fab'. Differing ratios of Fab' to 
tri-maleimide were used in an attempt to optimise the amount of tri-Fab' formed. 
Typically, following a '1-pot route', solutions containing reduced Fab' (approx. 
70 | iM) and the tri-maleimide (1 mM in dry DMF), were made up in ratios ranging 
from 1:1 to 8:1, and incubated at 37°C for a minimum of 2 hours. For example, a 3:1 
ratio may contain approximately 2 (il of tri-maleimide (1 mM), and 100 | i l of reduced 
Fab'. The percentage of tri-Fab', di-Fab', and mono-Fab' was then determined by 
analytical HPLC (0.2 M sodium phosphate buffer, pH 7.0,1 ml min. '^ 273 nm) using 
a Dupont Bioseries Zorbax GF250 gel filtration column. Using this technique, the 
three major products could be easily resolved with retention times for the tri, di, and 
mono Fab' species of 8.4 min., 8.9 min., and 9.9 min. respectively. The area under 
each peak could then integrated to give the percentage of each product 
5.4.3 Two Pot Route' 
In addition to the problem of steric inhibition of conjugation, re-oxidation of 
the Fab' thiol group may also occur, effectively reducing the Fab' concentration 
available for conjugation. It was proposed that i f a mono-Fab' of a tri-maleimide was 
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formed, and subsequently reacted with a fresh batch of reduced Fab', then perhaps 
approach of the Fab' to the maleimide moiety may be less sterically hindered, and 
moreover, less Fab' oxidation should occur during the second step, as the reaction 
time should be reduced. It should also be noted that, in related work with 
tetra-maleimides, the formation of a tetra-Fab' species was not possible using the 
1-pot route, but was possible using the 2-pot route. Although more wasteful of the 
tri-maleimide linker, this second alternative technique was tried. 
To a sample of reduced Fab' (approx. 70 p.M) was added a 10 fold excess of 
the tri-maleimide linker (10 mM in dry DMF). This was incubated at 37°C for 
1 hour, followed by a further incubation of 30 minutes with a 3 fold excess 
(over Fab') of N-ethylmaleimide (also in acetate-citrate-EDTA, [pH 6.0 buffer]) to 
cap any unreacted free Fab' thiols. The solution was then desalted using a Sephadex 
PDIO column as before (Section 5.3.1), and the fourth eluted fraction of Fab'-Linker 
(approx. 50 | i M ) retained. Immediately, using a freshly prepared batch of reduced 
Fab', various ratios of Fab': Fab'-Linker from 1:1 to 4:1 were mixed and once again 
incubated for a minimum of 2 hours. The extent of reaction was, as for the 1-pot 
route, determined by analytical HPLC. 
5.4.4 Large Scale Tri-Fab' Synthesis 
Large scale preparation of the B72.3 tri-Fab' of (30) and the A33 tri-Fab' of 
(31) was carried out on approximately 30 mg of Fab' starting material with a view to 
determining in vivo tumour binding ability of the resulting tri-Fab's. However, on all 
occasions, the coupling efficiency was inexplicably reduced by approximately 10% 
compared to that of the small scale tests (Table 5.2 & 5.3). Purification was brought 
about either using preparative HPLC (same type of column as for analytical), or using 
a 2 metre long, gravity fed S200 column, eluting with 0.1 M KG Ac, 0.2 M KCl, 
2 mM EDTA, pH 6.0 buffer over an 18 hour period. After purification, the overall 
yield of tri-Fab' was approximately 20%. 
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5.5 R E S U L T S O F FAR' rON.TUCxATION 
5.5.1 Coupling Efficiency 
The ratio of tri, di, and mono Fab' products observed for each incubation was 
found to be dependent on the ratios of reagents used, and varied from one incubation 
to another. In general however, there appeared to be no observable difference in 
relative ratios of the products on changing from B72.3 to A33 Fab'. The 
tri maleimide bearing cyclohexylmediyl side-chains (29), appeared to be the poorest 
linker, whilst little or no difference in product ratios was observed with the use of the 
C3, and C5 side-chain tri-maleimides (30), and (31) respectively. As predicted, the 
'two-pot route' to Fab' cross-linking did indeed prove itself to be the more successful 
of the two techniques, showing improvements of 5-15% in the amount of tri-Fab' 
produced, although admittedly being more time and reagent consuming. 
Tri^maleimide Fd>* I Linker 
Tri-Fah' Di-Fah' Mot)tO-Fa¥ 
Cyclohexyl 
methyl (29) 
3 1 18.0 45.1 36.9 
4 1 15.4 40.1 44.5 
5 1 16.3 33.4 50.3 
6 1 9.5 34.5 56.0 
C3 (30) 
2 1 5.0 35.0 60.0 
3 1 16.5 48.1 35.4 
4 1 34.5 29.5 36.0 
5 1 35.7 32.9 31.4 
6 1 28.8 28.9 42.3 
C5 (31) 
4 1 24.8 39.9 35.3 
5 1 39.3 36.3 24.4 
6 1 24.4 40.0 35.1 
7 1 22.2 31.8 46.0 
Table 5.2 : Cross-linking results from 1-pot reactions using 572.5 orA33 Fab' 
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It should be noted that, ideally, a large percentage of the tri-Fab' product is 
required, with a small amount of the neighbouring di-Fab', so that purification of the 
desired tri-Fab' is made easier. It appeared that for the diree tri-raaleimides tested, 
and for others run at Celltech, a ratio of 5:1 gave the optimum product distribution. 
Changing from a C 3 (30) to a C 5 (31) tri-maleimide did not appear to affect product 
distribution, although the use of a cyclohexylmethyl tri-maleimide (29) did give very 
poor Fab' conjugation. This could have been as a result of steric crowding, but is 
more likely to be due to an overall loss of activity of the maleimides due to 
competitive base hydrolysis, or amine coupling. 
Using the 2-pot route, results were found to be consistently better. 
Tri-maleimide Fab' 1 Fab'-Linker 
Tri-Fab' Di-Fdb' Mono-Fah' 
C 3 (30) 
2:1 32.4 38.8 28.8 
3:1 39.1 29.0 31.9 
4:1 34.8 24.7 40.5 
5:1 30.1 22.1 47.8 
Table 5.3 : Cross-linking results from 2-pot reactions using B72.3 Fab' 
For both the one and two pot routes, incubation times in excess of 2 hours 
gave negligible improvement in product ratios, whereas a slight improvement was 
seen when initial Fab' concentrations were increased prior to coupling. 
5.5.2 Gel Electrophoresis of Products 
Although HPLC gives an accurate measurement of the percentage of each 
component of Fab' conjugation, as molecular weight increases, HPLC peak separation 
decreases. As a consequence, small amounts of high molecular weight (greater than 
150,000 Da) aggregates may not be revealed. Gel electrophoresis however, is a 
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convenient technique to detect high molecular weight components, and although no 
accurate percentages can be assumed, it is very useful in determining purity. 
Reducing and non-reducing conditions can also be employed on the gel to determine 
the nature of components from their reduced products. 
Gel electrophoresis was performed on the products of Fab' conjugation using 
the 'SDS Page' system on a 4 / 20 Mini Polyacrylamide gradient gel. Samples were 
run under both reducing (P-mercaptoethanol) and non-reducing conditions, and 
compared to both low and high molecular weight standards. 
A sample for electrophoresis was prepared as follows. To 20 }il of approx. 
3 mg ml"^ sample was added 5 p,l of 5 x concentrate reducing or non-reducing sample 
buffer. The solution was then heated in a boiling water bath for 3-4 minutes prior to 
loading 5-10 j i l into a well of the gel. Molecular weight marker proteins were also 
loaded in non-reducing conditions in another well to serve as molecular weight 
standards. The gel was then run in tank buffer at a constant current of 40 mA with a 
varying voltage of approximately 100-200V. Staining of the completed gel was 
brought about using a Coomassie Brilliant Blue R based stain for about 1 hour, 
followed by subsequent destaining of the gel by 7.5 % aqueous acetic acid solution. 
Gel electrophoresis of the products of Fab' conjugation to a tri-maleimide 
clearly showed three distinct well separated bands due to tri, di, and mono Fab' 
species, as well as much smaller slow moving bands corresponding to high molecular 
weight (greater than 150,000 Da) aggregates. 
Hiph Molecular Weight Markers Low Molecular Weight Markers 
212K Myosin 94K Phosphorylase b 
170K a-Macroglobulin 67K Albumin 
116K p-Galactosidase 43K Ovalbumin 
76K Transferrin 30K Carbonic Anhydrase 
53K Glutamic dehydrogenase 20K Trypsin Inhibitor 
14K a-Lactalbumin 
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5.6 TMIVHJNOREArTTVTTY COMPETITION ASSAY 
Since conjugation of antibody fragments involves chemical modification of 
the antibody (at the cysteine thiol), it is feasible that its binding ability and specificity 
(immunoreactivity) to its antigen could be impaired. To test this out, the binding of 
the C 3 (30) B72.3 tri-Fab' was compared to the independently produced B72.3 tri-Fab' 
of CT998 and to the whole antibody B72.3 IgG. To do this, a binding competition 
assay was performed. This entailed competitive binding between a whole antibody-
Horseradish peroxidase conjugate (B72.3-HRPO), and various concentrations of 
either one of the two B72.3 tri-Fab's, or the IgG, to microtitre plates coated with 
bovine submaxillary mucin (which contains the B72.3 antigen). The extent of 
B72.3-HRPO conjugate binding to the mucin, and hence the amount of tri-Fab' or IgG 
bound to the mucin, was determined using a hydrogen peroxide containing 
developing solution (B72.3-HRPO acts on H2O2), the results of which were analysed 
by at 650nm (A^^Q). The less tri-Fab' or IgG bound to the mucin, the more 
B72.3-HRPO conjugate present and hence the greater the observed A^5o. From 
absorbance data at various concentrations of tri-Fab' or IgG, the relative 
immunoreactivity of each conjugate was determined 
Initial sample concentration of the two tri-Fab's was 95 [ig m l ' ^ whilst the 
IgG concentration was 207 ^g m l ' ^ For sample preparation, to 350 )il of each of die 
three samples was added 350 ^i l of 1/2500 B72.3-HRPO. Using a clean non-coated 
ELISA plate (Figure 5.2) 150 ^il of 1/5000 B.72.3-HRPO was placed in all wells, 
except those of column 1. 300 p-l of the prepared samples were then placed in the 
remaining six wells of column 1 (IgG in rows A and B, C 3 (30) tri-Fab' in rows C and 
D, and CT998 tri-Fab' in rows E and F). A 150 ^il sample of solution was then taken 
from each well of column 1, and transferred to its adjacent well in column 2. This 
process was repeated from column 2, so that doubling dilutions were achieved from 
column 1 through to 11 (No transfer was made to wells in column 12). 
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1 2 3 4 5 6 7 8 9 10 11 12 
Figure 5.2 : The wells of an EUSA plate used in an immunoassay 
Next, an identical plate with all wells coated with bovine submaxillary mucin 
was taken, and 100 [LI removed from each of the wells of the original plate, and 
transferred to their corresponding coated wells in the mucin coated plate. The plate 
was then left for 1 hour to permit binding, followed by washing to remove all 
unbound species. To each well was then added 100 \il of substrate reaction mixture, 
and the plate left for 5 minutes to allow development of a blue colour. The plate was 
then placed into an auto-plate reader and the absorbance of each well measured at 
650 nm. The absorbance due to the wells of column 12 containing only 
B72.3-HRPO, gave a 100% maximum mucin binding reference. Absorbance due to 
the other wells gradually increased on going from column 1 to 11, as the amount of 
sample used decreased, and hence the binding due to the B72.3-HRPO conjugate 
increased. 
A graph of the results was then plotted (Figure 5.3). It can be seen, that to 
compete for 50% of available binding sites, an IgG must be much more concentrated 
than a tri-Fab'. From the graph, the relative immunoreactivities of the two tri-Fab's 
were compared to the whole antibody IgG. 
Immunoreactivity (tri-Fab') 
|ig/ml at 50% binding for IgG 
|ig/ml at 50% binding for tri-Fab' 
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However, when 50% binding was observed for the B72.3-HRPO conjugate, 
we assumed 50% binding by a tri-Fab'. What actually occurred was that 50% of the 
binding sites were taken up by the tri-Fab'. As each tri-Fab' wil l in theory bind to 
three independent sites, and B72.3 IgG being divalent will bind to two sites, then 
when 50% of the binding sites are taken up by B72.3-HRPO, there are actually one 
and a half times fewer bound tri-Fab' moieties than B72.3-HRPO. For this reason, 
when comparing the immunoreactivity of a tri-Fab' with that of a whole IgG using 
this method, the lower term of the equation should be replaced by |ig/ml at 60% 
binding for tri-Fab' to take the nature of tri-Fab' binding into consideration. 
0£ 
e "-3 c 
C/3 
CT998 tri-Fab' 
C3 (30) tri-Fab' 
Sample Concentration jig/ml 
Figure 5.3 
Using the equation and die graph, for the C3 (30) tri-Fab' we divide 52 fig/ml 
by 7 |ig/ml, showing the C3 (30) tri-Fab' to be 7.4 times more immunoreactive than 
B72.3 IgG and 1.35 times less immunoreactive than the CT998 tri-Fab'. This cleariy 
showed that not only is immunoreactivity maintained after conjugation, but more 
importantly, the use of a Fab' fragment rather than a whole antibody appeared not to 
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have any detrimental effects on binding. Indeed, as part of the tri-Fab', each Fab' 
became effectively 2.5 times more immureactive than the IgG. In a similar 
immunoassay, the C5 (31) A33 tri-Fab' was formed, and again compared to 
CT998 A33 tri-Fab', and to A33 IgG. Results were very similar to those for the 
C3 (30) B72.3 tri-Fab', in that C5 (31) A33 tri-Fab' was found to be 8.3 times more 
immunoreactive than IgG, and 1.28 times less than the CT998 A33 tri-Fab'. 
In an 'Off-rate' experiment which measured the rate at which antibody species 
were washed off an antigen coated plate, and hence gave their relative binding 
strengths, the half life (i.e. die time taken for half the species to be washed off the 
plate) of the tri-Fab' CT998 was found to be 2-3 times greater than that of the IgG."* 
Thus, in accordance with the results of the immunoassay, the use of the three 
antibody fragments of the tri-Fab' gave an increased avidity for binding sites 
compared to a single antibody. 
5.7 FAB' L A B E L L I N G OF A TRI-MALEIMIDE-LIGAND CON.TUGATE 
The purpose of forming the tri-Fab's discussed in Section 5.4, was to optimise 
conditions for coupling, tri-Fab' purification and analysis, so that the more important 
Fab' conjugation to ligand-tri-maleimide conjugates could be achieved. Accordingly, 
this was attempted on a small scale with (34) (Figure 5.4). 
0 * ^ 0 
r P H O N JN-H 
HOzMeP-- w ^PMeOjH > / 
Figure 5.4 : The ligand-tri-maleimide conjugate (34) 
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Preparation of the tri-Fab' conjugate of (34) was carried out as described for 
the simple tri-Fab's of Section 5.4, and formation was confirmed both by analytical 
HPLC and gel electrophoresis. The optimised percentage of tri-Fab' was however 
very low (5%), with about 25% di-Fab' produced. This was presumably due to a loss 
of maleiraide activity. Indeed, when the ^H NMR of the tri-maleimide (34) was 
re-run after one month storage, the singlet integral for the maleimide double bond was 
vastly reduced, confirming the suspicion that maleimide hydrolysis, or more likely 
reaction with amine had occurred. 
The A33 tri-Fab' of the ^^Y radiolabeled tri-maleimide-ligand conjugate 
CT998 (Figure 5.5), synthesised at Celltech, has enjoyed considerable success in the 
treatment of colorectal tumours implanted in animals. 
^ N - J ^ . ^^  o ) rt o ) QsC^ W ^C02 
H O H O 
Figure 5.5 
Indeed, complete tumour regression has been observed for animals treated 
with this conjugate, whereas animals which remained untreated exhibited rapid 
tumour growth (see Figure 5.6). These results do indeed appear very promising, and 
are being pursued in a clinical trial. 
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Figure 5.6 : Tumour therapy with an ^^Y radiolabelled A33 tri-Fab' 
5.8 TITMOUR BIOmSTRIBUTION RESULTS 
• 3 hours 
24 hours 
• 48 hours 
• 72 hours 
Blood Muscle Bone Lung Uver Spleen Kidney Colon Tumour 
Figure 5.7 : Biodistribution of^^^I radiolabelled C j (31) A33 tri-Fab' 
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The A33 tri-Fab' of (31) was radiolabelled with ^ - ^ ^ I and injected into nude 
mice bearing SW1222 xenografts. It can be seen in Figure 5.7, that at later time 
points the conjugate clears from the blood and other organs much more quickly than 
it does from the tumour, dius showing its selectivity for die tumour. In must be noted 
that the high levels of radiolabel found in the liver, spleen and kidneys are due to 
dehalogenation of the conjugate (when labelled with a stable ^^^In metal complex 
levels in the three organs are much lower). 
5.9 USE OF INTERCALATQRS 
The use of an intercalator to bind an ^^Y radiolabelled Fab' conjugate to 
tumour cell DNA was discussed in Chapter 4. The use of such an intercalating agent 
however, is dependent on the radiolabelled conjugate's ability to penetrate the tumour 
cell wall, and bind to the DNA. 
In an attempt to discover i f the use of an intercalator in conjunction with a 
radiolabelled A33 mono-Fab' would effect more efficient cell death than a purely 
radiolabelled mono-Fab', in vitro tumour cell killing studies were carried out on four 
^^^In radiolabelled conjugates, with and without an intercalator (Figure 5.8). The 
Fab' conjugated compounds Fab'-(24) and Fab'-(60) were formed by adding 
approximately 7 equivalents of the ligands (24) and (60) to Fab' solutions and 
allowing the mixtures to incubate at 37°C. After 1 hour, the solutions were purified 
by gel chromatography, to give Fab' conjugates suitable for testing. ^^^In, rather 
than ^^Y was used because of its short emission range (0.48 mm - 20 nm). For 
efficient cell killing by ^^^In, Auger electrons must be emitted close to the cell 
nucleus as their range is less than a cell diameter.5 Thus, any resulting cell death can 
be attributed to high energy Auger emissions from internalised radiolabelled 
conjugate. It was postulated that in order to effect efficient cell intemalisation, 
surface antigen cross-linking may have to be achieved (see Section 4.9.2).^ This 
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hypothesis means that a tri-Fab' bearing three antigen binding sites should be more 
suitable for this purpose than an IgG bearing two binding sites, which in turn should 
be more suitable than a mono-Fab'. 
Fab' 
n 
PMeOjH c 
Fab'-(60) 
o 
PMeOaH n 
(47) 
PMe02H e 
PM 
Fab'-(24) 
H O g M e P ' ^ ' ^ P e02H 
OMe 
o=s=o 
.1. 
HOzMeP-' pMeOaH 
(16) 
Figure 5.8 
Research at the Sloan-Kettering Cancer Centre in New York showed in vitro 
cell killing by ^^^In radiolabelled A33 IgG.'^ However, researchers at Celltech have 
been unable to reproduce these results. No cell death was observed, perhaps due to a 
lack of cell intemalisation or simply to the short emission range of any internalised 
^^^In. It should be noted then, that even i f cell internalisation does occur for 
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^^^In-A33, little tumour cell killing may be observed without an intercalator to bind 
the radiolabelled conjugate to the DNA. Thus, even though ceU intemalisation may 
be less likely with a mono-Fab', it remains to be seen i f the use of an intercalator in 
conjunction with an A33 Fab' (e.g. ^^^In-Fab'-(60)) will exhibit cell killing properties. 
5.10 CONCLUSIONS 
A simple technique to effect Fab' conjugation and purification was found and 
exploited to form mono and tri-Fab' conjugates. It was however, found not to be 
possible to cleanly form a tri-Fab', without associated production of di, and 
mono-Fab' impurities. The nature of the tri-maleimide used for conjugation appeared 
to have little effect on the nature of products produced, but it did become apparent 
that maleimides should be handled with care, to guard against unwanted maleimide 
base hydrolysis or reaction with amines. 
Compared to a single antibody, the tri-Fab's produced showed a significant 
improvement in immunoreactivity and in antigen binding strength, resulting in a 
greatly increased residence lifetime at the antigen binding site. It would also appear 
that the combination of this improved tumour binding affinity, the better tumour to 
non-tumour ratio and the faster clearance rate observed for tri-Fab' conjugates 
compared to a single antibody, should lead to significant success in 
radioimmunotherapy. Preliminary experiments in animals have shown this to be the 
case (see Sections 5.7 & 5.8). 
The use of intercalators to bind to tumour cell DNA is in the process of being 
tested in vitro, although no results are as yet available for the four ^^^In complexes of 
Figure 5.8. It is most likely that the use of an intercalator in conjunction with an 
A33 tri-Fab' which is capable of antigen cross-linking (e.g. the A33 tri-Fab' of (61)) is 
required for efficient tumour cell killing, although this remains to be established. 
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5.11 BUFFERS AND SOLUTIONS USED 
0.1 M Acetate-Citrate-EDTA pH 6.0 buffer PBS pH 7.4 buffer 
Sodium acetate 
Na4 EDTA 
H4 EDTA 
Citric acid 
Water 
41.02 g 
2.10 g 
1.62 g 
1.50 g 
5 litres 
NaCl 
Na2HP04 
NaH2P04 
EDTA 
Water 
9.00 g 
5.96 g 
1.25 g 
372 mg 
1 litre 
Antibodv conjugate Buffer 
Tris 
NaCl 
Casein 
Tween 20 
HCl 
Water 
6.05 g 
2.92 g 
1.00 g 
0.1 ml 
pH to 7.0 
to 500 ml 
5 X Concentrate Sample Buffer 
Glycerol 25.0 ml 
Upper-Tris 6.25 ml 
SDS 7.5 g 
Bromophenol Blue 4 drops 
Water to 50 ml 
P-Mercaptoethanol 12.5 ml 
for reducing sample buffer 
Tank Buffer 
Tris 
Glycine 
10% SDS 
Water 
7.5 g 
36 g 
25 ml 
to 2.5 litres 
Brilliant Blue R Stain 
Methanol 800 ml 
Acetic acid 140 ml 
Water to 2 litres 
BriUiant Blue R-250 0.5 g 
Upper Tris nH 6.8 
Tris 
10 w/v SDS 
HCl 
Water 
3.0 g 
2 ml 
to pH 6.8 
to 50 ml 
SybStrate Rgagtipn Mixtyre 
Substrate Buffer 30 ml 
0.44% v/v H2O2 300 ^tl 
TMB 0.3 mg 
1/2500 B.72.3-PRPO antihndv conjugate 
5 ^il of B72.3-HRPO -1-12.5 ml of antibody conjugate buffer. 
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Chapter 6 
Experimental 
6.1 S O L V E N T S AND I N S T R U M E N T A T I O N 
6.1.1 Solvents 
A l l reactions, except those employing HBr in glacial acetic acid or water as the 
solvent, were done under dry nitrogen. Most of the solvents used were either distilled 
before use from the appropriate drying agent, or used from Sure-Seal bottles. 
Triethylamine and N-methylmorpholine were distilled from calcium hydride, methanol 
from magnesium methoxide, tetrahydrofuran from sodium benzophenone, and toluene 
from sodium. Water refers to that purified by the 'Puritejjyu^ plus' system. 
6.1.2 Instrumentation 
HPLC analysis was performed using a Varian 9010 / 9065 Polychrom system, 
whilst preparative HPLC was performed on a Varian Vista 5500 / 9050 system using 
unless otherwise stated, Rainin's reverse phase column Dynamax C18 (21.4 x 
250 mm) at 10 ml / min. The solvents employed for HPLC were: 
A = H 2 O / 0.1% trifluoroacetic acid B = C H 3 C N / 0.1% trifluoroacetic acid 
Column chromatography was carried out using neutral alumina Merck Art 1077 
(0.063-0.200 mm) which had previously been treated with ethyl acetate, or using 
gravity silica (Merk Art 7734). Alumina t.l.c was performed using Merck Art 5554 
plates. 
Infra red spectra were run as a thin film on a Perkin Elmer 1600 Series FTIR 
and U.V. spectra were run on a Kontron Instruments Uvikon 930. ^H and ^^C 
spectra were recorded on eidier a Briiker AC250 or on a Varian XL200, 250 or VXR-
400. The Briiker AC250 operating at 62.90 MHz was used for obtaining ^^ P spectra 
whilst ^^Y NMR spectra were run on a Briiker AMX 500 at 24.5 MHz with a 90° 
pulse, and a 30 second delay. 
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Mass spectra were recorded with a VG 7070E mass spectrometer running in 
either DCI or FAB mode with ammonia as the impingent gas for DCI, and glycerol as 
the matrix for FAB analyses. A VG electrospray mass spectrometer was also used. 
Biodistribution studies were performed as previously reported.^ 
6.2 K I N E T I C S O F A S S O C I A T I O N 
Incubations were effected at 310 K and pH 6.5 (0.2 mol dm'^ NH4OAC) with a 
ligand concentration of 5 |imol dm"-^ . Typically, a 1 ^ 1 aliquot (67 |j,Ci) of high 
quality 90Y3+ (Amersham) was added to a solution containing 25 | i l of a 50 |iniol dm"^ 
solution of the ligand, 125 )il of a 0.4 mol dm'-' solution of NH4OAC, and 99 | i l of 
Mil l iQ water, giving an overall volume of 250 j i l . 10 | i l sample was removed at 
various time intervals up to 1 hour, and added to a solution containing 5 |xl of 500 
[imol dm-3 DTPA (500 fold excess) and 85 ^il of 0.15 mol dm'^ NH4OAC (pH 6.8). 
Under these conditions dissociation is stopped, and any dissociated is immediately 
scavenged by the DTPA. (Bound ^ ^ Y has been shown in control experiments to be 
stable for at least 24 hours, with respect to trans-complexation by DTPA, in the pH 
range 5 - 6.5). 
Samples were analysed by anion exchange HPLC (Poros Q/M : eluent 0.15 mol 
dm-3 NH4OAC, pH 6.8 run at 2 cm^ per minute). T R [ ^ O Y . D T P A ] ^ - = ca 2 min., 
whilst the other complexes tested elute with T R = ca 1 min. A Beckman 170 
radioisotope detector was used to detect ^ ^ Y and ^^^Gd in HPLC association and 
dissociation measurements. 
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6 . 3 K T N E T I C S O F D T S S O C T A T I O N 
75 jxl samples of a 40 mmol dm"^ preformed yttrium-90 or gadolinium-153 
complex solution were added to 1.5 cm^ solutions of pH 1.0, 1.5, and 2.0 glycine 
buffers (0.1 mol dm'-^). This gave a final concentration of the complex of 2 mmol 
dm"^. Samples were incubated at 37°C and fractions (20 [LI) removed at regular time 
intervals and added to a fifty fold excess (4 | i l of 500 mmol dm'^) of DTPA to 
scavenge any dissociated cations. These samples were diluted in HPLC running 
buffer (0.15 mol dm'^ NH4OAC, pH 6.8) to 100 ^ i l , and the extent of dissociation 
determined by HPLC using a Poros Q/M column at 2 cm^ min'^. 
6 . 4 S Y N T H E T I C P R O C E D U R E S 
6 . 4 . 1 Chapter 2 
1,3,6,8-tetrakis-(4-tolylsulphonyl)-3,6-azaoctane-l,8-diamine - (1). 
To triethylenetetramine (10.00 g, 68.38 mmol), and mesh potassium carbonate 
(14.58 g, 308.1 mmol) in 400 cm^ of water at 80°C was added tosylchloride (57.49 g, 
301.6 mmol) in small portions over a period of 3 hours. The temperature was 
maintained overnight, followed by a cooling of the solution to effect precipitation. The 
solids were filtered off, washed with methanol, water, and diethylether, followed by 
drying in vacuo to yield the title compound (1), as a white powder (14.72 g, 86%). 
mp 209-211°C. 
1,4,7,10-tetrakis-(toluene-p-sulphonyl}-l,4,7,10-tetra-azacyclododecane - (2). 
To a stirred solution of (1 ) (44.43 g, 58.23 mmol) and mesh potassium carbonate 
(16.72 g, 121.0 mmol) in 700 ml of anhydrous DMF under nitrogen was added 
ethylene glycol ditosylate (21.84 g, 59.28 mmol, in 100 cm^ of dry DMF) dropwise 
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over a period of 3 hours. The solution was left overnight at room temperature, 
followed by 3 hours at 70°C and evaporation of the solvent under vacuum. The 
resulting residue was taken up into 100 cm-^  of water and 100 cm-^  of dichloromethane, 
and the aqueous layer extracted (2 x 50 cm-^ ) with dichloromethane. The organic 
fractions were combined, dried (K2CO3) and the solvent evaporated under vacuum. 
The resulting residues were shaken vigorously in hot toluene (500 cm^), and allowed to 
cool yielding a white precipitate which was filtered off, washed (40 cm^ cold toluene) 
and dried in vacuo to yield the title compound (27.80 g, 61%). 5H(CDC13) 2.40 
(12 H, s, CH3), 3.37 (16 H, s, NCH2), 7.30, 7.64 (16 H, m, ArH). 
1,4,7,10-tetra-azacyclododecane - (3). 
( 2 ) (15.62 g, 19.80 mmol) was refluxed in 25 cm'^  of concentrated sulphuric acid 
under nitrogen at 110°C for approximately 40 hours to give a black solution. To the 
cooled solution was slowly added water (20 cm^), potassium hydroxide pellets 
(to p H > 13) and ethanol (150 cm^). Solids were removed by filtration and the 
solvent removed under vacuum to yield yellow residues which, were acidified to pH < 2 
with 1 mol. dm"^ HCl. To this was added dichloromethane (30 cm^) and the aqueous 
layer extracted (2 x 30 cm^) with dichloromethane. The organic fractions were 
discarded, the pH of the aqueous layer increased to >13 (KOH pellets), and the free 
amine extracted into chloroform (5 x 20 cm^) to yield on drying and evaporation of the 
solvent, the title compound as a white solid (2.71 g, 79%). 5H(CDC13) 2.02 (16 H , 
s, CH2), 1.56 (4 H, s, NH). 5c(CDCl3) 44.8 (8 C, CH2). 
N-(4-Aminobutyl)-4-methoxybenzenesulfonamide - (4). 
4-Methoxy benzenesulphonyl chloride (7.62 g, 36.9 mmol) was added to a stirred 
solufion of 1,4-diaminobutane (22.46 g, 254.8 mmol) in dichloromethane (400 cm^) 
over a period of 45 minutes. The solution was stirred under nitrogen overnight, the 
solvent removed under reduced pressure, and the residues taken up in KOH(aq) to raise 
the pH to 13. The aqueous phase was extracted exhaustively with chloroform, the 
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organic fractions combined, dried (MgS04) and the solvent removed under reduced 
pressure to yield the title compound as a thick pale yellow oil (8.38 g, 88%). I.R. 
(aromatic C=C) 1597 cm'^ 1498 cm'^ (NH2) 1578 cra'^ (S=0) 1320 cm'^ 1154 
c m ' ^ Found: M+, 258.103. CnHigN203S requires M+, 258.104. 5 H ( D M S 0 ) 
1.37 (2 H, p, J 6.8 Hz, C//2CH2NH2 ), 1.39 (2 H, p, J 6.5 Hz, C//2CH2NHSO2 ), 
2.48 (2 H, t, J 6.5 Hz, CH2NH2), 2.72 (2 H, t, J 6.6 Hz, C//2NHSO2), 3.4-4.0 
(3 H, br s, NH2, NH ), 3.84 (3 H, s, CH3O), 7.12 (2 H, d, J 8.8 Hz, CHCSO2), 
7.77 (2 H, d, J 9.1 Hz, C//COCH3), 5c(DMS0) 26.9 (1 C, CH2CH2NH2), 30.7 
(1 C, CH2CH2NHSO2), 41.5 (1 C, CH2NH2), 42.8 (1 C, CH2NHSO2), 55.8 (1 C, 
CH3O), 114.5 (2 C, CHCSO2), 128.9 (2 C, CHCOCH3), 132.6 (1 C, CSO2), 
162.3 (1 C, COCH3). 
N-(4-Bromoacetamidobutyl)-4-methoxybenzenesulfonamide - (5). 
To a solution of the mono-hydrochloride salt of (4) (8.38 g, 28.4 mmol) and sodium 
hydroxide (2.28 g, 57.0 mmol, in 6 cm^ of water) in 1,2-dichloroethane (300 cm-^ ) 
was added bromoacetylbromide (5.71 g, 28.3 mmol in 100 cm^C2H4Cl2) dropwise, 
maintaining a temperature of <-10°C. The solution was stirred at <-10°C for a further 
1 hour, allowed to warm to room temperature, and stirred overnight. The organic 
phase was washed (NaOH 0.1 mol. dm'^ 2 x 25 cm^; HCl 0.1 mol. dm'^, 2 x 25 cm^, 
and water 3 x 25 cm^), dried (MgS04) and the solvent evaporated, to yield on 
standing, the crude yellow solid (approx. 75%). The solid was shaken vigorously in 
hot toluene (100 cm^), the cloudy solvent decanted off, cooled (0°C), and any 
precipitated solids filtered off. These were washed with a small quantity of cold 
toluene, and dried in vacuo. The process was repeated from the addition of hot toluene 
until the solution no longer became cloudy on shaking with the crude solid residue. 
Yield (3.90 g, 36%). m.p. 15-lTC. Found: M+-H1, 379.025. Ci3Hi9N2S04Br 
requires M++1, 379.033. Found: N 7.40%, C 41.3%, H 5.05%. Ci3Hi9N2S04Br 
requires: N 7.39%, C 41.2%, H 5.05%. I.R. ( C O ) 1650 cm'l . 6H(CDC13) 1.48 
(4 H, m, (C//2)2CH2NH) , 2.84 (2 H, q, C//2NHCO), 3.17 (2 H, q, C//2NHSO2), 
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3.69 (2 H, s, CH2Br), 3.80 (3 H, s, OCH3), 5.77 (1 H, t, CONH), 6.92 (2 H, t, 
J 8.4 Hz, CHCSO2), 7.07 (1 H, t, SO2NH), 7.74 (2 H, d, J 8.3 Hz, C//COCH3). 
5c(CDCl3) 26.0 (1 C, CH2CH2NHCO), 26.2 (1 C, CH2CH2NHSO2), 28.8 (1 C, 
CH2Br), 39.2 (1 C, CH2NHCO), 42.4 (1 C, CH2NHSO2), 55.3 (1 C, OCH3), 
113.9 (2 C, CHCSO2), 128.7 (2 C, CHCO), 130.9 (1 C, CSO2), 162.4 (1 C, 
COCH3), 166.2 (1 C, CO). 
2-Bromo-N,N-diisobutylethanamide - (6). 
To a solution of diisobutylamine hydrochloride (33.14 g, 0.20 mol) and sodium 
hydroxide (16 g, 0.4 mol in 20 cm^ of water) in 1,2-dichloroethane (150 cm^) was 
added bromoacetylbromide (40.37 g, 0.20 mol in 25 cra^ of 1,2-dichloroethane) 
dropwise maintaining a temperature of <-10°C. The solution was stirred at <-10°C for 
a further 1 hour, allowed to warm to room temperature and stirred overnight. The 
organic phase was washed (NaOH 0.1 mol. dm'^, 2 x 25 cm^; HCl 0.1 mol. dm'^, 
2 x 25 cm^ and water 3 x 25 cm^), dried (MgS04), and the solvent evaporated to yield 
a colourless viscous oil (36.03 g, 72%). Found: M++1, 250. CioH2oNBrO requires 
M++1, 250. Found: C 47.7%, H 8.2%, N 5.45%. CioH2oNBrO requires C 48.0%, 
H 8.00%, N 5.60%. I.R. (CON) 1655 cm"!. 5H(CDC13) 0.02 (6 H, d, J 6.6 Hz, 
CH3), 0.08 (6 H, d, J 6.4 Hz, CH3), 1.15 (2 H, n, J 7.0 Hz, CH), 2.32 (4 H, d, 
J 7.6 Hz, NCH2), 3.07 (2 H, s, B1CH2). 
Molybdenum tricarbonyl-l,4,7,10-tetraazacyclododecane complex - {!)?• 
1,4,7,10-tetraazacyclododecane (1.64 g, 6.21 mmol), and molybdenum hexacarbonyl 
(1.64 g, 6.21 mmol) were refluxed in dibutylether under argon at 160°C for 2 hours. 
The bright yellow solids were filtered off under argon, and dried in vacuo, to give the 
title compound (2.08 g, 95%). This was used directly in the next step. 
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4-(4-Methoxyphenylsulfonamido)butylcarbomylmethyl-l,4,7,10-tetraazacyclo 
dodecane - (8). 
To the molybdenumtricarbonyl-12N4 complex (7) (3.55 g, 10.1 mmol) in degassed 
DMF (50 cm^) under argon was added (5) (3.83 g, 10.1 mmol), and a slight excess of 
mesh potassium carbonate (1.79 g, 13.0 mmol) and the solution heated for 1-2 hours 
at 80°C. The solvent was removed under reduced pressure (10'^ mmHg), and the black 
residue taken up into 10% v/v HCl and left open to the air overnight. The pH was 
adjusted to 14 (KOH pellets) and the suspension filtered to give a yellow aqueous 
solution which was exhaustively extracted with dichloromethane, the organic fractions 
combined, dried (K2CO3), and the solvent removed to give a pale yellow oil (4.13 g, 
87%). Found: M++1, 471.268. C21N6SO4H38 requires M+-hl, 471.276. 5H(CDC13) 
1.42 (4 H, br, (C//2)2CH2NHS02), 2.10-3.03 (23 H, m, CH2N ring, C//2NHCO, 
N H ring, (CH2)(CH2)NCH2CO), 3.12 (2 H, q, C//2NHSO2), 3.71 (3 H, s, 
OCH3), 6.82 (2 H, d, J 8.8 Hz, CHCSO2), 7.60 (2 H, d, J 8.80 Hz, C//COCH3), 
7.92 (1 H, t, SO2NH). 5c(CDCl3) 26.0 (2 C, (CH2)2CH2NH), 37.8 (1 C, 
CH2NHCO), 42.0 (1 C, CH2NHSO2), 44.4 (2 C, CH2CH2NCH2CO), 46.0 (4 C, 
(CH2)2NHCH2CH2NCH2CO), 52.5 (2 C, CH2NCH2CO), 55.1 (1 C, OCH3), 58.2 
(1 C, NCH2CO), 113.5 (2 C, CHCSO2), 128.3 (2 C, CHCOCH3), 131.8 (1 C, 
CSO2), 161.9 (1 C, COCH3), 171.2 ( I C , CO). 
l-(Diisobutylcarbamoylmethyl)-l,4J,10-tetraazacyclododecane - (9). 
Synthesis was as described for (8) using the molybdenum tricarbonyl-12N4 complex 
(7) (1.75 g, 4.97 mmol), 2-bromo-N,N-diisobutylethanamide (6) (1.24 g, 
4.97 mmol) and fine mesh potassium carbonate (0.96 g, 6.94 mmol) to yield a 
colourless oil (1.43 g, 84%). Found: M++1, 342.317. C18H39N5O requires M+-1-I, 
342.324. 5H(CDC13) 0.73 (6 H, d, J 7.2 Hz, CH3), 0.77 (6 H, d, J 7.0 Hz, CH3), 
1.82 (2 H, m, CH), 2.40-3.10 (23 H, m, NCH2 ring, NH, NC//2CH), 3.40 (2 H, s, 
NCH2CO). 5c(CDCl3) 19.7 (2 C, CH3), 19.8 (2 C, CH3), 26.0(1C,CH), 27.3 
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(1 C, CH), 45.3, 45.4, 46.7, 51.6, 52.4, 54.2, 55.2 (11 C, NCH2 ring, NCHjCO, 
NCH2CH), 170.6 (1 C, CON). 
Triethyl 10-[4-(4-Methoxyphenylsulfonamido)butylcarbamoylmethyl]-l,4,7,10-
tetraazacyclododecane-1,4 J-triyltriacetate - (10). 
To a stirred solution of (8) (0.18 g, 0.38 mmol) in anhydrous ethanol (10 cm^) under 
nitrogen was added mesh potassium carbonate (0.19 g, 1.34 mmol) and 
ethylbromoacetate (0.19 g, 1.14 mmol), and die solution refluxed at 80°C for 18 hours. 
The solvent was evaporated off, the residue taken up in dichloromethane, filtered, and 
the filtrate evaporated to yield a yellow oil . Purified by alumina column 
chromatography (gradient elution 0-5% methanol in dichloromethane) to yield the title 
compound, a pale yellow oil (0.16 g, 57%). Found: M+, 728. C33H56N6O10S 
requires M+, 728. 5H(CDC13) 1.23 (9 H, m, J 7.0 Hz, OCH2C//3), 1.54 (4 H, br, 
(C//2)2CH2NH), 1.80-3.80 (28 H, m, NCH2), 3.84 (3 H, s, OCH3), 4.0-4.3 (6 H, 
m, OCH2), 6.2-6.6 (1 H, br s, NHCO), 6.97 (2 H, d, CHCSO2), 7.84 (2 H, d, 
CHCOCH3), 8.23 (1 H, t, SO2NH). 6c(CDCl3) 14.0 (3 C, OCH2CH3), 25.7, 
26.3 (2 C, (CH2I2CH2NHSO2), 38.5 (1 C, CH2NHCO), 42.6 (1 C, CH2NHSO2), 
46.5-57.5 (12 C, CH2 ring,CH2C02, NCH2CON), 55.4 (1 C, OCH3), 61.0 (3 C, 
OCH2), 113.8 (2 C, CHCSO2), 129.0 (2 C, CHCOCH3), 131.7 (1 C, CSO2), 
162.1 (1 C, COMe), 171.6 (1 C, CON), 172.5 (1 C, CO2), 173.0 (2 C, CO2). 
10-[(4-Aminobutyl)carbamoylmethyl)]-l,4,7,10-tetraazacyclododecane-l,4,7-triyl 
triacetate - (11). 
To the stirred ester (10) (144 mg, 0.20 mmol) was added an equivalent mass of phenol 
and 40% v/w HBr in glacial acetic acid (20 cm^). The solution was refluxed at 100°C 
overnight, and allowed to cool. The product was precipitated out by the addition of 
excess diethyl ether to yield the title compound, an off-white solid as its 
trihydrobromide salt (84 mg, 60%). Compound too hygroscopic for microanalysis, 
m.p. > 210°C. Found: M^^+l, 472.261. C20H38N6O7 requires M++1, 472.265. 
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5 H ( D 2 0 ) 1.40-2.85 (4 H, m, (C;/2)2CH2NH3+), 2.96 (2 H, t, CH2NH3+), 
2.50-4.25 (26 H, m, CH2 ring, CH2CO2, CH2CON, CH2NHCO). 
Triethyl 10-(diisobutylcarbamoylmethyl)-l,4,7,10-tetraazacyclododecane 1,4,7-triyl 
triacetate - (12). 
As for (10) using (9) (0.15 g, 0.43 mraol), mesh potassium carbonate (0.18 g, 
1.33 mmol) and ethylbromoacetate (0.21 g, 1.24 mmol) to yield the title compound, a 
pale yellow oil (0.18 g, 68%). Found: M++1, 600. C30H57N5O7 requires M++1, 
600. 5H (CDC13) 0.82 (6 H, d, J 6.6 Hz, CH3), 0.89 (6 H, d. J 6.5 Hz, CH3), 
1.24 (6 H, t, J 7.1 Hz, CH2C^3), 1.25 (3 H, t, J 7.1 Hz, CH2C//3), 1.91 (2 H, m, 
CH), 2.15-3.90 (28 H, m, NCH2), 4.05-4.30 (6 H, m, OCH2). 5c(CDCl3) 13.9 
(1 C, OCH2CH3), 14.0 (2 C, OCH2CH3), 19.7 (2 C, CH3). 19.9 (2 C, CH3), 26.1 
(1 C, CH), 27.2 (1 C, CH), 46-56 (14 C, NCH2), 60.8 (2 C, OCH2), 61.0 (1 C, 
OCH2), 170.9 (1 C, CON), 173.0 (2 C, CO2), 173.3 (1 C, CO2). 
10-(Diisobutylcarbamoylmethyl)-l,4,7,10-tetraazacyclododecane-1,4,7-triyl triacetic 
acid - (13). 
Hydrolysis of the ester (12) to the carboxylic acid was brought about by dissolving it 
in an excess (> 3 fold) of Iraol dm'^ KOH solution and leaving it for 18 hours. The 
solution was concentrated, and salts removed by gel filtration using an Amberlite 
XAD16 column, to yield the colourless ligand (58%). Alternatively die ligand can be 
obtained as its trihydrobromide salt as for (11) using the ester (12) (120 mg, 
0.20 mmol) to yield an off-white solid (65 mg, 43%). Compound too hygroscopic for 
accurate microanalysis. I.R. (CO2H) 1735 cm"!, (CONH) 1674 cm'l. Found: M++1, 
516.333. C24H45N5O7 requires M++1, 516.340. 5H(D20; pD=2) 0.82 (12 H, 2xd, 
CH3), 1.8-2.1 (2 H, m, CH), 2.7-4.4 (28 H, m, CH2). 5H (D20; pD=8) 0.76 
(12 H, m, CH3), 1.70-1.90 (2 H, m, CH), 2.00-3.23 (26 H, m, NCH2), 3.23-3.48 
(2 H, br, NC//2CH). 
-174-
Triethyl 10-[4-(4-methoxyphenylsulfonamido}butyl carbamoylmethyl]-l ,4,7 
tetraazacyclododecane-l,4,7-triyltrimethylene tri(methylphosphinate) - (14a). 
Diethoxymethylphosphine (1.12 g, 8.23 mraol), followed immediately by 
paraformaldehyde (0.28 g, 9.33 mmol) were added to anhydrous THF (30 cm^) 
containing (8) (0.97 g, 2.06 mmol) at 100°C under nitrogen. The solution was 
refluxed for 18 hours at 100°C with azeotropic removal of water by 4A molecular 
sieves, followed by filtration (to remove excess paraformaldehyde) and evaporation of 
the solvent to yield a pale yellow oil. Purification by alumina column chromatography 
(gradient elution 0-5% methanol in dichloromethane) afforded the title compound as a 
pale yellow gum (1.41 g, 82%). T.l.c. Rf 0.60 (10% MeOH in CH2CI2 on alumina). 
Found M+-hl, 831.377. C33H65N6O10SP3 requires M+-H, 831.377. 5H(CDC13) 
1.2-1.3 (9 H , 2xt, J 6.6 Hz, CH2C//3), 1.47 (13 H, m + 2xd, 2 j 13.O Hz, 
(C / /2 )2CH2NHS02 , PCH3), 2.20-3.30 (26 H, m, NCH2), 3.15 (2 H, q, 
CH2NHSO2), 3.79 (3 H, s, OCH3), 4.00 (6 H, 2xp, J 6.8 Hz, OCH2), 6.78 (1 H, 
t, CONH), 6.88 (2 H, d, J 8.6 Hz, CHCSO2), 7.72 (2 H, d, C^C0CH3), 7.91 
(1 H, t, NHSO2). 8c(CDCl3) 13.1 (3 C, 89 Hz, PCH3), 15.9 (3 C, 5.6 Hz, 
OCH2CH3), 26.1, 25.9 (2 C, (CH2)2CH2NHS02), 37.8 (1 C, CH2NHCO), 41.8 
(1 C, CH2NHSO2), 53.4-55.4 (12 C, CH2 ring, NCH2P, NCH2CO), 54.8 (1 C, 
OCH3), 59.4 (3 C, 2 j 6.7 Hz, OCH2), 113.2 (2 C, CHCSO2), 128.1 (2 C, 
CHCOCH3), 131.7 (1 C, CSO2), 161.6 (1 C, COCH3), 1 C, CO). 5p(CDCl3) 
52.0-52.2 (br m). 
Triethyl 10-[4-(4-methoxyphenylsulfonamido) butylcarbamoylmethyl]-1,4,7,10-
tetraazacyclododecane-1,4,7-triyltrimethylenetributylphosphinate) - (14b). 
As for (14a), using (8) (0.21 g, 0.45 mmol), diethoxybutyl phosphine (0.36 g, 
2.02 mmol) and paraformaldehyde (0.08 g, 2.66 mmol). Yielded a pale yellow gum 
(331 mg, 78%). T.l.c. Rf 0.70 (10% MeOH in CH2Cl2on alumina). Found: M+-(-l, 
958. C42H83N6SO10P3 requires M+-f 1, 958. 6H(CDC13) 0.87 (9 H, t, J 6.6 Hz, 
butyl CH3), 1.26 (9 H, t, OCH2C//3), 1.32-1.68 (16 H, br m, VCUji^filh^ 
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(C / /2)2CH2NHS02), 1.68-1.80, (6 H, m, PCH2CH2). 2.32-3.42 (28 H, m, 
NCH2), 3.81 (3 H, s, OCH3), 4.03 (6 H, m, OCH2), 6.60 (1 H, br s, CONH), 
6.91 (2 H, d, CHCSO2), 7.73 (2 H, d, C / /OCH3), 8.22 (1 H, s, NHSO2). 
6p(CDCl3) 54.1-54.6 (brm). 
Triethyl 10-[4-(4-Methoxyphenylsulfonamido) butylcarbamoylmethyl] -1,4,7,10-
tetraazacyclododecane -1,4,7-triyltrimethylenetri (benzyl phosphinate) - (14c). 
As for (14a), using (8) (0.23 g, 0.49 mmol). diethoxybenzyl phosphine (0.41 g, 
1.93 mmol) and paraformaldehyde (0.08 g, 2.66 mmol). Yielded a pale yellow gum 
(298 mg, 58%). T.l.c. Rf 0.50 (10% MeOH in CH2Cl2on alumina). Found: M+-1-I, 
1059. C51H77N6O10SP3 requires M++1, 1059. 5H(CDC13) 1.00-1.32 (9 H , m, 
OCH2C//3) , 1.32-1.56 (4 H, br m, ( C / / 2 ) 2 C H 2 N H S 0 2 ) , 2.30-3.40 (34 H , m, 
NCH2 ring, NCH2P, NCH2CO, C//2NHCO, PCH2C, C//2NHSO2), 3.76 (3 H, d, 
OCH3), 3.79-4.17 (6 H , m , OCH2), 6.40-6.80 (2 H, br s, CONH, SO2NH), 6.86 
(2 H, d, J 10 Hz, CHCSO2), 7.05-7.40 (15 H, m, ArH), 7.71 (2 H, d, J 10 Hz, 
CHCOMe). 5p(CDCl3) 49.1,49.7 (2:1). 
10-[(4-Aminobutyl)carbamoylmethylJ-l,4,7,10-tetraazacyclododecane -1,4,7-
triyltrimethylenetri(methylphosphinic acid) trihydrobromide salt - (15a). 
Method as for (11) using (14a) (160 mg, 0.19 mmol). Yield (140 mg, 89%). 
Compound too hygroscopic for accurate microanalysis. I.R. (CONH) 1674 cm'^ 
Found: M++1, 577. C20H47N6O7P3 requires M+, 576. 5H(D20; pD=4) 1.47 (9 H, 
d, 2j 14.4 Hz, PCH3), 1.60 (4 H, m, (C//2)2CH2NH3+), 2.98 (2 H,t, C//2NHCO), 
3.05-3.75 (24 H, m, CH2 ring, NCH2P, CH2NH3+), 4.00 (2 H, s, NCH2CO). 
5c(D20) 16.9 (3 C, 89 Hz, PCH3), 26.5. 27.5 (2 C, CH2CH2NH3+, 
CH2CH2NHCO), 41.3, 41.5 (2 C, CH2NH3+, CH2NHCO), 52-56 (11 C, CH2 
ring, NCH2P), 57.6 (1 C, NCH2CO), 167.8 (1 C, NHCO). 
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10-[(4-Aminobutyl)carbamoylmethyl]-l,4,7,10-tetraazacyclododecane -1,4,7-
tr,iyltrimethylenetri(butylphosphinic acid) trihydrobromide salt - (15b). 
Method as for (11), using (14b) (188 mg, 0.20 mmol). Yield (150 mg, 80%). 
Found: M+-H1, 703.423. C29H65N6P3O7 requires M+-f l , 703.421. 5 H ( C D 3 0 D ) 
0.96 (9 H, t, J 6.74 Hz, CH3), 1.30-2.50 (22 H, m, P(CH2)3, (C//2)2CH2NH3+), 
2.90-4.50 (28 H, m, NCH2). 
10-[(4-Aminobutyl)carbamoylmethyl]-l,4,7,10-tetraazacyclododecane-l ,4,7-
triyltrimethylenetri(benzylphosphinic acid) trihydrobromide salt. (15c). 
Method as for (11), using (14c) (166 mg, 0.16 mmol). Yield (138 mg, 84%). 
Compound too hygroscopic for accurate microanalysis. Found: M"^, 804.366. 
C38H59N6P3O7 requires M+, 804.362. 5 H ( C D 3 0 D ) 1.55-1.90 (4 H, br, 
(Ci/2)2CH2NH3+), 2.70-4.10 (34 H, m, NCH2, PCH2C), 7.20-7.55 (15 H, m, 
ArH). 
10-[4-(4-Methoxyphenylsulfonamido)butylcarbamoylmethylJ-l,4,7,10-tetra-aza 
cyclododecane-l,4,7-triyltrimethylenetri(methylphosphinic acid) - (16). 
Base hydrolysis of the ester (14a) as for (13) and purified by reverse phase HPLC 
(t=Omin. 90% A 10% B, t=30min. 25% A 75% B, 254nm T R 16.9 min.). LR. 
(CONH) 1626 cm-\ Found M+-hl, 747.282. C27H53N6O10SP3 requires MUl, 
747.283. 5 H ( D 2 0 ) 0.82-1.09 (9 H, 2xd, PCH3), 1.15 (4 H, br s, 
(CH2)2CH2NHS02), 1.90-2.70 (24 H, br m, CH2N ring, NCH2P, NCH2CO), 2.87 
(4 H, br s, C / /2NHSO2, C//2NHC0), 3.60 (3 H, s, OCH3), 6.80 (2 H, d, 
CHCSO2). 7.43 (2 H, d, C//COCH3). 6c(D20; pD=14) 19.5 (2 C, 89 Hz, 
PCH3), 19.8 (1 C, 89 Hz, PCH3), 28.9 (1 C, CH2CH2NHCO), 31.1 (1 C, 
CH2CH2NHSO2), 41.5 (1 C, CH2NHCO), 47.4 (1 C. CH2NHSO2), 53.4-61.0 
(12 C, NCH2 ring, CH2P, NCH2CO), 58.0 (1 C, OCH3), 116.3 (1 C, CHCSO2), 
130.8 (1 C, CHCOCH3), 137.9 (1 C, CSO2), 163.0 (1 C, COCH3), 175.6 (1 C, 
CONH). 5p(D20;pD=4) 43.0,35.4(1:2). 
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Triethyl 10-(diisobutylcarbamoylmethyl)-l,4,7,10-tetraazacyclododecane-l,4,7-
triyltrimethylenetri(methylphosphinate) - (17). 
Synthesis as for (14a) using diethoxymethyl phosphine (0.81 g, 5.95 mmol), 
paraformaldehyde (0.25 g, 8.32 mmol) and (9) (0.50 g, 1.47 raraol) yielding the title 
compound as a pale yellow gum (0.58 g, 56%). Found: M ' ^ + l , 702.426. 
C30H66N5O7SP3 requires M++1, 702.426. 6H(CDC13) 0.80 (6 H, d, J 6.5 Hz. 
CH3), 0.86 (6 H, d, J 6.5 Hz, CH3), 1.25 (9 H, t, J 7.1 Hz, CH2C//3), 1.49 (9 H, 
d, 2j 13.7 Hz, PCH3), 1.91 (2 H, m, CH), 2.20-3.80 (28 H, m, NCH2 ), 4.01 
(6 H . p, OCH2). 5c(CDCl3) 13.6 (3 C, 90 Hz, PCH3), 16.7 (3 C, J 5.4 Hz, 
OCH2CH3). 20.0 (4 C, CH3), 26.3, 27.6 (2 C, CH), 50-57 (14 C, NCH2), 60.1 
(3 C, 2j 6.1 Hz, OCH2), 170.5 (1 C, CON). 5p(CDCl3) 52 (br m). 
10-(Diisobutylcarbamoylmethyl)-l,4,7,10-tetraazacyclododecane-4,7,10-triyl 
trimethylenetri(methylphosphinic acid) - (18). 
An excess of Imol dm"^ aqueous KOH solution was added to the phosphinate ester 
(17), and the solution shaken to dissolve all of the compound. The solution was left 
overnight, the pH lowered to 5 by addition of acetic acid, and the solution passed down 
a H"*" cation exchange resin column. The solvent was removed to yield the title 
compound, as a clear very pale yellow solid (43%) Found: M' ' '+ l , 618.330. 
C24H54N5O7P3 requires M++1, 618.331. m.p. > 200°C. 5H(D20) 0.55-0.85 
(12 H , m, CH3). 0.92-1.22 (9 H, ra, PCH3), 1.68-1.95 (2 H, m, CH), 2.25-3.50 
(20 H, m. NCH2 ring, ^CHjCH), 2.92-3.17 (6 H, br m, NCH2P), 3.17-3.35 (2H, 
br s, CH2CON). 5p(D20; pD=4) 27.8, 26.6 (2 : 1). 
Yttrium complex - [Y.(13)]'^. 
To (13) (142 mg, 0.28 mmol) in 10 cm^ of water at pH 1.5 (HCl) was added yttrium 
oxide (31 mg, 0.14 mmol). The solution was heated at 110°C for 18 hours after which 
die pH was raised to 6 (aqueous KOH) and the solution heated at reflux for a further 
45 minutes. The solution was concentrated, and salts removed by gel filtration using 
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an Amberlite XAD16 column, to yield the colourless complex (137 mg, 72%). Found: 
M+, 601.215. C24H42N5O7Y requires M+, 601.214. m.p. > 200°C. 5H(D20) 0.78 
(6 H, d, J 6.9 Hz, CH3), 0.82 (6 H, d, J 6.9 Hz, CH3), 1.75-2.04 (2 H, m, CH), 
2.08-4.10 (28 H, m, NCH2). 5c(D20) 22.0, 22.2 (4 C, CH3), 28.9, 29.7 (2 C, 
CH), 48.0, 48.1 (2 C, NCH2CH), 55-60-(8 C, CH2 ring), 64.5-66.5 (1 C, 
NCH2CON), 68.7 (3 C, NCH2CO2), 177.8 (1 C, CON), 183.0 (3 C, CO2). 
5Y (D20) -t-111.3ppm. 
Gadolinium Complex - [Gd.(15a)]'''. 
Synthesis as for [Y.(13)]+ using (15a) (33.3 mg, 0.037 mmol) and Gd203 (8.0 mg, 
0.022 mmol) to yield the colourless complex (27.0 mg, 73%). Sample found to be 
ninhydrin positive. LR. (CONH) 1648 cm'^, (NH3+) 1572 cm'l (cf (CONH free 
ligand) 1674 cm'^). 
Yttrium complex - [Y.{16)]. 
Synthesis as for [Y.(13)]"^ using (16) (289 mg, 0.39 mmol), and yttrium oxide 
(53 mg, 0.23 mmol). Yield (367 mg, 85%). m.p. > 200°C. LR. (CONH) 
1626 cm-1 (cf (CONH) 1679 cm'^ free ligand.). Found (FAB): M+, 832.160. 
C27H50N6O10P3SY requires M+, 832.158. 5H(D20) 1.24-1.60 (13 H, m, PCH3, 
(C / /2)2CH2NHS02), 2.19-2.70 (16 H, br m, CH2 ring), 2.20-2.93 (2 H, m, 
C / f2NHC0), 2.93-3.64 (12 H, br m, C//2NHCO, C / /2NHSO2, NC//2P, 
NC//2CO), 3.77 (3 H, s, OCH3), 7.01 (2 H, d, J 8.6 Hz, CHCSO2), 7.68 (2 H, d, 
J 8.6 Hz, C / /COCH3) . 5c(D20) 18.8 (3 C, 106 Hz, PCH3), 26.1 (1 C, 
CH2CH2NHCO), 28.6 (1 C, CH2CH2NHSO2), 42.4 (1 C, CH2NHCO), 44.9 (1 C, 
CH2NHSO2), 51-62 (12 C, CH2 ring, NCH2P, NCH2CO), 56.2 (1 C, OCH3), 
117.4(2C, CHCSO2), 131.7 (2C ,CHCOCH3), 132.8 (1 C, CSO2), 165.3 (1 C, 
COCH3), 183.9 (1 C, CONH). 5p(D20) 44.63 : 43.13 : 42.91 ratio 1:1:1. 
J Y - P 5 . 1 H Z . 5Y(H20) +151.9 ppm. 
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Indium complex - [InX16)]. 
(16) (46.5 mg, 0.0627 mmol) and indium chloride (13.9 mg, 0.0627 mmol) were 
dissolved in pH 5.5 acetate buffer to form the complex. Purification as for [Y.(13)]'*'. 
Yield (43%). m.p. > 200°C. I.R. (CONH) 1636 cm"^ (cf (CONH) 1654 cm'^ free 
ligand.). Found (FAB): M+, 858. C27H5oN60ioP3SIn requires M+, 858. 5H(D20) 
1.40-1.60 (13 H, m, PCH3, (C//2)2CH2NHS02), 2.60-3.60 (30 H, br m, CH2 ring, 
C//2NHCO, CH2NHSO2, NCH2P, NCH2CO), 3.92 (3 H, s, OCH3), 7.18 (2 H, d, 
CHCSO2), 7.83 (2 H. d, C//COCH3). 
6.4.2 Chapter 3 
N-(5-carboxypentyl) maleamic acid - (19). 
To 300 cm^ of diglyme containing dissolved maleic anhydride (26.84 g. 0.274 mol), 
was added 6-aminohexanoic acid (35.90 g, 0.274 mol). The suspension was stirred at 
room temperature for 3 hours followed by slow heating over 1 hour to 150°C to effect 
complete solvation of all solids. The solution was allowed to cool slowly to room 
temperature, and left overnight at -10°C to afford pale brown solids. The precipitate 
was filtered off, washed (diglyme then water), and dried in vacuo to yield the title 
compound as a pale brown powder (33.6 g, 54% yield). (Can be recrystallised from 
hot acetone to yield a white powder), m.p. 159-160°C. Found: N 5.99%, 
C 52.39%, H 6.59%. C10H15NO5 requires: N 6.11%, C 52.19%, H 6.75% Found: 
M+-1-1, 230. C10H15NO5 requires M+-(-l, 230. 5 H ( D M S 0 ) 1.32 (2 H, p, 
C//2(CH2)2C02H), 1.48 (4 H, m, C//2CH2C//2CH2CO2H), 2.21 (2 H, t, J 7.2 Hz, 
C//2CO2H), 3.19 (2 H, q, J 6.5 Hz, C//2NH), 6.20, 6.27, 6.41. 6.47 (2 H, 4xs, 
CH=CH), 9.21 (1 H, t, NH). 5c(DMS0) 24.4 (1 C, CH2(CH2)2C02H). 26.2 
(2 C, CH2CH2CH2CH2CO2H), 28.3 (1 C, CO2H), 33.8 (1 C, CH2NH). 132.0. 
133.6 (2 C. CH=CH), 165.5, 165.8 (2 C, COCH=CHCO), 174.7 (1 C, CH2CO2H). 
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6-Maleimidohexanoic acid - (20). 
( 1 9 ) (33.57 g, 0.146 mol) and sodium acetate (6.5 g), were heated overnight in 
75 cm^ of acetic anhydride under nitrogen at 50°C. The solution was then poured into 
600 cm^ of water, heated at 75°C for 2-3 hours, concentrated to 150 cm^, and left at 
-10°C overnight to yield a white powder which was filtered off and retained. The 
remaining solution was acidified to pH 1-2 (H2SO4), extracted with EtOAc 
(6 X 50 cm^), and the EtOAc removed to yield a brown crude oil. This was then 
taken up into CHCI3 / 5% AcOH, filtered through a 1" plug of alumina, and the 
solvents removed to give a pale yellow oil. This was then heated / melted in 10 cm^ of 
EtOAc / 5% AcOH, and left at -10°C to yield yet more of the title compound. Yield 
5.2 g, 17%, m.p. 81-84°C (cf. lit. 89-90°C 3), Rf 0.64 (MeOH / CHCI3 1:1 on 
alumina). Found: N 6.20%, H 5.90%, C 56.68%. C10H13NO4 requires N 6.63%, 
H 6.20%, C 56.86%. 5H(CDC13) 1.36 (2 H, m, C//2(CH2)2C02H), 1.63 (4 H, 
m, C//2CH2C//2CH2CO2H), 2.36 (2 H, t, J 7.4 Hz, C//2CO2H), 3.53 (2 H, t, J 7.1 
Hz, CH2N), 6.72 (2 H, s, CH=CH), 11.5 (1 H, br s, CO2H). 5c(CDCl3) 23.9 
(1 C, CH2(CH2)2C02H), 26.0 (1 C, CH2CH2CO2H), 28.0 (1 C, CH2CH2N), 
33.6 (1 C, CH2CO2H), 37.4 (1 C, CH2N), 133.9 (2 C, CH=CH), 170.8 (2 C, 
COCH), 179.5 (1 C, CO2H). 
N-(4-Carboxycyclohexylmethyl)-maleimide - (21).^^ 
A solution of N-(4-carboxycyclohexylmethyl)-maIeamic acid (7.72 g, 30.2 mmol), and 
sodium acetate (1.20 g) was heated for 2 hours at 50°C in acetic anhydride (20 cm^) 
under nitrogen. The solution was then poured into 250 cm^ of water and heated at 
70°C for 2-3 hours until a clear brown solution was obtained (complete decomposition 
of remaining anhydride). The solution was concentrated to 50 cm^ and left overnight to 
yield white crystals which were filtered off, washed with cold water, and dried 
in vacuo (0.8 g, 11%- cf lit. 34%). m.p. 143-145°C. 5H(CDC13) 0.85 - 2.35 
(10 H, m, cyclohexyl H), 3.38 (2 H, d, J 6.84 Hz, NCH2), 6.70 (2 H, s, HC=CH). 
5c(CDCl3) 28.0 (1 C, CH2CH2CHCO2H), 29.6 (2 C, CH2CHCO2H), 36.3 (1 C, 
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CHCH2N), 42.5, 43.6 (2 C, CHCO2H, NCH2). 134.0 (2 C, C=C), 171.0 (2 C, 
COCH=CH), 180.0 (1 C. CO2H). 
Succinimidyl 4-maleimidobutyrate - (22). 
To a solution of 4-maleimidobutyric acid (0.664 g, 3.66 mmol) and N-hydroxy 
succinimide (0.417 g. 3.66 mmol) in DMF (10 cm^) at 0°C was added a solution of 
D C C (0.923 g, 4.48 mmol) in 20 cm^ of DMF also at 0°C. The solution was stirred 
under nitrogen at 0°C for four hours and then at room temperature overnight. The 
solvent was removed and the residues purified by silica chromatography using 70% 
ethyl acetate and 30% hexane as the solvent to yield a white solid. (0.964 g, 95%). 
Silica T.l.c. Rf 0.4 (70% ethyl acetate and 30% hexane). Found: N 9.92%, 
C 51.61%, H 4.64%. C12H12N2O6 requires: N 10.00%. C 51.42%, H 4.31%. 
5H (CDC13) 1.93 (2 H, p, J 7.20 Hz. C//2CH2CO2), 2.57 (2 H. t, J7.50 Hz, 
CH2CO2). 2.76 (4 H. s, CH2CON), 3.54 (2 H, t, J 6.91Hz, CH2N), 6.65 (2 H. s, 
CH). 6c(CDCl3) 23.27 (1 C, CH2CH2CO2), 25.34 (2 C, CH2CON). 28.08 (1 C, 
CH2CO2), 36.37 (1 C. CH2N). 133.96 (2 C, CH), 167.70, 169.09, 170.51 (5 C, 
CO). 
Succinimidyl 6-maleimidohexanoate - (23). 
As ( 2 2 ) using 6-maleimidohexanoic acid (0.504 g, 2.37 mmol), N-hydroxy 
succinimide (0.272 g, 2.37 mmol), and D C C (0.584 g, 2.83 mmol), to yield a white 
solid. (0.420 g. 57%). Silica T.l.c. Rf 0.4 (70% ethyl acetate and 30% hexane). 
5H(CDC13) 1.41 (2 H, m, C//2(CH2)2C02), 1.64 (2 H, m, Ci/2CH2C02), 1.78 
(2 H, p, J 7.9Hz, CH2CH2N), 2.61 (2 H, t, J 7.4 Hz, CH2CO2) 2.84 (4 H, s, 
CH2CON), 3.58 (2 H, t, J 7.1Hz, CH2N), 6.70 (2 H, s, CH). 5c(CDCl3) 23.99 
(1 C, CH2(CH2)2C02), 25.53 (1 C, CH2CH2CO2). 25.75 (1 C. CH2CH2N) 27.97 
(1 C. CH2CO2). 30.70 (2 C, (CH2)2CON), 37.39 (1 C, CH2N), 134.01 (2 C. 
CH), 168.17. 169.16. 170.62 (5 C, CO). 
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Mono-maleimide functionalised ligand - (24) 
HOzMeP-
To (15b) (29.2 mg, 0.030 mmol), in dry DMSO (0.4 cm^), was added N-methyl 
morpholine (18.0 mg, 0.178 mmol) followed by (22). The solution was left under 
nitrogen overnight , and purified by reverse phase HPLC (t=0min. 90% A 10% B, 
t=20min. 25% A 75% B, 300nm), to yield a colourless solid T^ 10.7 min., 13.3 mg, 
38%. Found: (Electrospray) M+-I-1, 742. C28H54N7O10P3 requires M+-f 1, 742. 
6H (D20) 1.29 (6 H, d, 2j 14 Hz, PCH3), 1.33 (3 H, d, 14 Hz, PCH3), 1.38 
(4H, br, (C//2)2CH2NH), 1.75 (2 H, p, 6.8Hz, C//2CH2CO), 2.10 (2 H, t, 
J 6.7 Hz, CH2C//2CO), 2.9-3.5 (26 H, m, CH2N, C//2NH), 3.43 (2 H, t, 
CH2NCO), 3.68 (2 H, br, NCH2CO), 6.70 (2 H, s, CH=CH). 
{2S)-Lysine methylester dihydrochloride - (25).^ 
Acetyl chloride (4 cm^) was carefully added to a solution of (2S)-lysine 
dihydrochloride (19.96 g, 91.10 mmol) in anhydrous methanol (200 cm^) under 
nitrogen and refluxed at 80°C. The volume of the solvent was reduced to 50 cm^ under 
reduced pressure to afford precipitation of a white solid which was filtered off, washed 
with cold methanol, and dried in vacuo (15.93 g, 75%). m.p. 212-213°C. 
(Lit. value: 214-215°C.) 5H(D20) 1.47 (2 H, p, C//2CH2NH3+), 1.67 (2 H, p, 
J 7.7 Hz, C / /2CH2CH), 1.94 (2 H, m, C//2CH), 2.96 (2 H, t, J 7.5 Hz, 
C//2NH3+), 3.79 (3 H, s, OCH3), 4.12 (1 H, t, J 6.5 Hz, CH). 5c(D20) 24.4 
(1 C, CH2CH2CH), 29.1 (1 C, CH2CH2NH3+), 32.1 (1 C, CH2CH), 41.9, 55.5, 
56.5, (3 C, CH2NH3+, CHNH3+, OCH3), 173.4 (1 C, CO2). 
(2S)-N-(2-Aminoethyl)-2,6-diaminohexanamide - (26).^ 
(2S)-Lysine methylester-dihydrochloride (25) (8.35 g, 35.8 mmol) was added in small 
batches to 100 cm^ of ethylenediamine at 90°C. The solution was heated at 120°C for 
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18 hours and the ethylenediamine removed by distillation under reduced pressure 
(10'^ mmHg). The residue was taken up into aqueous sodium hydroxide (4 mol. 
cm^), the solvent evaporated, and the subsequent residue treated with 
dichloromethane (100 cm''), filtered, and the solvent removed under reduced pressure 
to yield a clear viscous pale yellow oil (6.28 g, 93%). Found: M++1, 189. 
C8H20N4O requires M++1, 189. 5H(D20) 1.15-1.75 (6 H, m, (CH2hCU), 2.63 
(2 H, t, CH2NH2), 2.68 (2 H, t, C^2NH2), 3.22 (2 H, t, C//2NH), 3.30 (I H, t, 
CH). 5c(CDCl3) 21.9 (1 C, CH2CH2CH), 31.1 (1 C, CH2CH2NH2), 34.0 (1 C, 
CH2CH), 40.1, 40.3, 40.8, 54.0 (4 C, CH2NH2, CH, CH2NH), 174.9 (1 C, CO). 
(5S)-3-Azanonane-l,5,9-triamine - (27).5 
(2S)-N-(2-Aminoethyl)-2,6-diarainohexanamide (26) (6.20 g, 32.9 ramol) was heated 
to reflux in 1.0 mol. dm'-' borane-THF complex (100 cm-') overnight. Excess borane 
was quenched (100 cm' of methanol) and solvents evaporated to leave residues which 
were refluxed in 6 mol. dm'^ HCl (70 cm') for 3 hours. Evaporation of the solvent, 
entraining in methanol (4 x 25 cm-'), followed by adjustment of the pH to 13 (KOH 
solution) and exhaustive extraction into chloroform gave upon evaporation of the 
chloroform, the free amine as a bright clear viscous yellow oil (4.94 g, 86%). Found: 
M++1, 175. C8H22N4 requires M++1, 175. 5H(D20) 1.00-1.50 (6 H , CH2), 2.10-
2.90 (9 H, CH2N, CH). 5c(D20) 25.6 (1 C, CH2CH2CH), 35.0 (1 C, 
CH2CH2NH2), 37.5 (1 C, CH2CH), 43.0, 43.7 (2 C, (CH2)3CH2NH2, NCH), 
52.6, 54.1, 58.0, (3 C, CH2NHCH2CH2). 
(5S)-N-(5,9-Diamino-7-azanonyl)-t-butyloxycarbonamide - (28). 
To a stirred solution of (5S)-3-Azanonane-l,5,9-triamine (27) (0.92 g, 5.27 mmol) in 
12 ml of water at 50°C was added CuC03.Cu(OH)2 (0.70 g, 3.15 mmol) and the 
solution maintained at 50°C for 30 minutes to give a deep blue solution. To the now 
cooled solution was added triethylamine (8 cm'), 1,4-dioxane (12 cm^) and BCXON 
(1.30 g, 5.27 mmol), and the solution stirred for 4 hours at room temperature. H2S 
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was bubbled through the solution for 15 minutes to give a dark brown precipitate 
(copper sulfide). The solution was then basified (pH 14), and any solids removed by 
filtration. Evaporation of the filtrate yielded a residue which was then taken up into 
water and dichloromethane, the aqueous layer then being exhaustively extracted with 
dichloromethane. The organic fractions were combined, dried (K2CO3), and the 
solvent evaporated to give a thick yellow oil (0.96 g, 66%). 5H(CDC13) 0.7-1.6 
(20 H, m, NH2, NH, iCH2hCH, CH3), 2.0-2.2 (1 H, m, CH), 2.20-2.65 (6 H, m, 
CH2CH2NHCH2). 2.81 (2 H, br, C//2NHCO), 5.18 (1 H, s, CONH). 5c(CDCl3) 
22.8 (1 C, CH2CH2CH), 27.9 (3 C, CH3), 29.6 (1 C, CH2CH2NH), 35.3 (1 C, 
(CH2)3CH2CH), 39.7 (1 C, CH2NHCO), 41.2 (1 C, CH), 50.4, 52.0, 55.9 (3 C, 
CH2NH2, CH2NH), 78.1 (1 C, (CH3)3C), 155.6 (1 C, CO). 
Cyclohexylmethyl tri-maleimide - (29). 
iJHBOC 
Conversion of the maleimido carboxylic acid ( 2 1 ) (314 mg, 1.33 mmol) to the acid 
chloride N-(4-chloroformylcyclohexylmethyl)-maleimide was brought about by the 
addition of a large excess of thionyl chloride and heating for 2 hours in a small quantity 
of anhydrous toluene. The solvent was removed under reduced pressure and the crude 
oil used immediately. I .R. (CO maleimide) 1715 cm"^  , (COCl) 1795 cm"^  . 
8H(CDC13) 0.85-2.70 (10 H. m, cyclohexyl H), 3.31 (2 H, d, J 6.8 Hz, NCH2), 
6.66 (2 H, s, HC=CH). 5c(CDCl3) 28.1 (2 C, CH2CH2CHCOCI), 28.9 (2 C, 
CH2CHCOCI), 35.9 (1 C, CHCH2N), 42.9 (1 C, CH2N), 54.5 (1 C, CHCOCl), 
133.8 (2 C, C=C), 170.7 (2 C, COCH=CH), 173.1 (1 C, COCl). 
To this acid chloride at -10°C in 1 cm^ of CH2CI2 under nitrogen was slowly added a 
mixture of (28) (93 mg, 0.34 mmol) and triethylamine (120 mg, 1.19 mmol) in 1 cm^ 
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of CH2CI2. The solution was allowed to warm to RT, and was left overnight and 
purified by reverse phase HPLC (t=Omin. 90% A 10% B, t=20min. 0% A 100% B, 
302nm) to give the title compound TR 17.7 min. as a colourless solid (21%). I.R. 
( C O N ) 1639 cm-^ (CO maleimide) 1704 cm'^ 5H(CDC13) 0.75-1.15 (6 H, m, 
CH2CHCH2N), 1.15-1.53 (15 H, b r ,CH3 ,C/ /2CHCH2N) , 1.53-1.88 (15 H, m, 
CHCH2l<!, CH2CHCO, (CH2hCH), 1.88-2.13 (6 H, m, CH2CHCO), 2.13-2.37 
(3 H, txt, C H C O ) , 2.96-3.10 (2 H, br, C//2NHCO2), 3.32 (6 H, d, J 6.64 Hz, 
C//2NC0CH=CH), 3.25-3.50 (7 H, br, CH2CH2NCH2CH), 6.70 (4 H, s, 
C H = C H ) , 6.72 (2 H, s, C H = C H ) 5c(CDCl3) 22.6 (1 C, CH2(CH2)2NH), 28.1, 
28.6 (6 C, CH2CHCH2NCH=CH), 28.3 (3 C, CH3), 29.4 (1 C, CH2CH2NHCO2), 
29.5 (6 C, CH2CHCO), 35.4 (1 C, CH2CHNH), 36.2 (3 C, 
CHCH2NHC0CH=CH), 39.1 (CH2NHCO2), 43.5 (3 C, CH2NC0CH=CH), 44.9, 
44.8 (3 C, C H C O N ) , 78.9 (1 C, (CH3)3C), 133.9 (6 C, CH=CH) , 156.5 (1 C, 
O C O N H ) , 170.9 (6 C, COCH=CH), 173.2, 176.6, 177.9 (3 C, C O N , CONH) . 
Cj tri-maleimide - (30). 
NHBOC 
Synthesis and purification as for (29) using the acid chloride 4-maleimido butyryl 
chloride (263 mg, 1.30 mmol) converted from the acid as in (29) , triethylamine 
(120 mg, 1.19 mmol) and (28) (96 mg, 0.35 mmol) to give the title compound as a 
colourless solid (18^°). Alternatively, to (28) (175 mg, 0.638 mmol) in 5 cm^ of dry 
DMF were added dry N-methylmorpholine (290 mg, 2.87 mmol), l-(3-dimethyl 
aminopropyI)-3-ethylcarbodiimide.HCl (E.D.C.) (551 mg, 2.87 mmol), 
l-hydroxybenzatriazole (388 mg, 2.87 mmol), and 4-maleimidobutyric acid (526 mg, 
2.87 mmol). The solution was stirred for 4 days under nitrogen, and purified by 
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reverse phase HPLC (t=Omin. 90% A 10%B, t=25min. 0% A 100% B, 302nm, 
Hypersil 5 ODS, 5 ml min"^), to yield a colourless solid 13.4 min., 45 mg, 9% 
yield. I.R. ( C O N ) 1650 cm'^ (CO maleimide) 1703 cm'^. 5H(400MHZ)(CDC13) 
1.43 (9H, s, (CH3)3), 1.5-1.6 (6 H, m, (C//2)3NHCO), 1.86, 1.92, 1.93 (6 H, 
3xp, C / / 2 C H 2 C O ) , 2.13, 2.22 (6 H, 2xt, CH2CO), 3.55 (6 H, m, 
C / /2NC0CH=CH), 3.10-^ 3.4-3.7 (9 H, br m, CH2NHCO, CH2NCO), 4.70 (1 H, t, 
NHCO2), 6.28 (1 H, d, C H N / / C O ) , 6.700, 6.702, 6.708 (6 H, 3xs, C H = C H ) , 
7.09 (1 H, t, CH2N / /CO). 5c(100MHz)(CDCl3) 23.1, 23.4, 23.6 (3 C, 
(CH2 )3CH2NHC02) , 27.4 (3 C, CH3), 28.6, 28.7 (2 C, NHCOCH2CH2), 29.1 
(1 C. NCOCH2CH2), 31.8, 32.1, 32.4 (3 C, CH2CO), 36.1, 36.2, 26.3, 37.3, 
39.2 (5 C, (CH2)2NCO, CH2CHNHCO, CH2NHCO2), 47.8, 48.8, 49.2 (3 C, 
CH2NC0CH=CH), 133.1 (6 C„ C H = C H ) , 155.0 (1 C, CO2), 169.90, 169.91, 
169.94 (6 C, C O C H = C H ) . 171.8, 171.9 (2 C, C O N H ) , 173.0 (1 C, 
CON(CH2)(CH2)). 
Cj tri-maleimide - (31). 
To (28) (21.6 mg, 0.079 mmol) in dry THE (5 cm^) under nitrogen was added DCC 
(81.2 mg, 0.394 mmol) and (20) (74.8 mg, 0.354 mmol). Reverse phase HPLC 
(t=Omin. 90% A 10% B, t=20min. 25% A 75% B, t=20.1min. 0% A 100% B, 302nm) 
gave the product Tj^ 20.5 min. in approx. 15% yied. Alternatively synthesis as for 
(29) using the acid chloride of 6-maleimidohexanoic acid (20) (298 mg, 1.93 mmol), 
triethylamine (131 mg, 1.30 mmol) and (28) (79 mg, 0.29 mmol). Purified by reverse 
phase HPLC as before to yield a colourless solid 1^ 20.5 min., 38.5 mg, 16%. I.R. 
(COCl) 1795 cm-l. Found: M++1, 854. C43H63N7O11 requires M++1, 854. 
5 H ( 4 0 0 M H Z ) (CDCI3) 1.25-1.55 (12 H, m, (C//2)3C H HC 0 2 , 
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C//2CH2CH2CON), 1.43 (9 H, s, (CH3)3), 1.6 (12 H. m, C//2CH2C//2CH2CO), 
2.05-2.40 (6 H, m, CH2CON), 3.0-3.6 (9 H, m, CH2NU, CffNH, CH2NCOCH2), 
3.49 (6 H, t, C//2NC0CH=CH), 5.45 (1 H, br, CH2N//CO2), 6.10 (1 H, d, 
CHNHCO), 6.692, 6.694, 6.708 (6 H, 3xs, CH=CH), 7.0 (1 H, t, 
CH2N//COCH2). 5c(CDCl3) 134.1 (6 C, C=C), 156.0 (1 C, CO2), 170.8 (6 C, 
COCH), 173.5, 173.9 (2 C, CONH), 175.0 (1 C, CON(CH2)(CH2)). 
Bis para-nitrophenol active ester - (32). 
Succinic acid (0.755 g, 6.39 mmol), para-nitrophenol (2.224 g, 15.98 mmol) and DCC 
(3.957 g, 19.18 mmol) were dissolved in dry THF (60 cm^) containing 4 A molecular 
sieves. The solution was left overnight under nitrogen at room temperature, and any 
solids filtered off Purification required flash silica column chromatography, using 
20% hexane in dichloromethane as the eluant, to give the product as a white solid, 
(1.259 g, 55%). 5H(CDC13) 3.11 (4 H, s, CH2), 7.35 (4 H, d, CHCO), 8.33 
(4 H, d, CHCNO2). 
Active ester functionalised ligand - (33). 
H 
HOjMeP 
N 
H02MeP^ \ / ^PMeCfeH 
To (15b) (118.1 mg, 0.131 mmol) in dry DMSO (0.25 cm^) were added 
N-methylmorpholine (92.9 mg, 0.918 mmol) and the bis paranitrophenol active ester 
(32) (118.2 mg, 0.328 mmol). The solution was heated under nitrogen at 50°C to 
keep all solids in solution, and the progress of the reaction followed by HPLC. This 
indicated a decline in the proportion of title compound after 1 hour. The reaction was 
-188-
then stopped by freezing, and the solution was purified by reverse phase HPLC 
(t=Omin. 90% A 10% B, t=20min. 25% A 75% B, 278nm), to yield a colourless solid 
Tj^ 16.4 min., 49.9 mg, 33% yield. Found: M+-I-1, 798. C30H54N7O12P3 requires 
M+-H1, 798. 5H(D20) 1.36 (6 H, d, 2j 15 Hz, PCH3), 1.40 (3 H, d, h 15 Hz, 
PCH3), 1.47 (4 H, p, (C//2)2CH2NHCO), 2.64 (2 H, t, C//2CONH), 2.93 (2 H, t, 
CH2CO2), 3.0-3.6 (26 H, m, CH2N, C//2NHCO), 3.68 (2 H, br s, NHCOC//2N), 
7.33 (2 H, d, CHCO), 8.30 (2 H, d, CHCNO2). 
Cj tri-maleimide functionalised ligand - (34). 
HCMeP 
N N 
To (31) (6.0 mg, 0.007 mraol) was added 0.03 cm^ of water and 0.27 cm^ of TFA. 
The solution was left at RT for 30 min., and the solvent removed to give the BOC 
deprotected TFA amine salt. To a solution of this in dry DMSO (0.5 cm^) were added 
(33) (5.0 mg, 0.0044 mmol) and N-raethylmorphoIine (2.2 mg, 0.022 mmol), and the 
solution was left overnight at room temperature under nitrogen. Alternatively, oxalyl 
chloride (0.5 cm^) was added to (35) (7.2 mg, 0.0085 mmol) and 1 drop of DMF 
added to the solution. After 45 minutes the solvents were removed and die resulting 
solid acid chloride immediately taken up into dry DMF (0.5 cm^), and added to (15b) 
(8.8 mg, 0.0098 mmol) followed by triethylamine (17.3 mg, 0.171 mmol). The 
solution / suspension was left under nitrogen overnight and the DMF removed. 
In both cases the solutions were purified by reverse phase HPLC (t=Omin. 90% A 10% 
B, t=20min. 25% A 75% B, 302nm. T^ 12.7 min.) to yield 2-3 mg, approximately 
20-25%. 5H(D20) 1.0-1.6 (37 H, br m, PCH3, CH2(C//2)3CH2CO, 
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NHCH2(C//2)2CH2NHCO, CH(C//2)3CH2NHCO), 2.05 (4 H, t, (CH2)2C//2 
CONH), 2.20 (2 H, t, (CH2)2C//2CON(CH2)(CH2)), 2.45, 2.55 (4 H, 2xm, 
CO{CH2)2CO), 2.60-3.60 (43 H, br m, CH2N), 6.69 (6 H, s, CH=CH). 
Carboxylic acid functionalised Cj tri-maleimide - (35). 
0 ^ 0 0 ^ 0 
To ( 3 1 ) (6.3 mg, 0.0074 mmol) was added 0.04 cm^ of water and 0.36 cm^ of TFA. 
After 30 min. the solvent was removed, and the residues taken up into dry DMF 
(0.6 cm^). To this were then added succinic anhydride (0.81 mg, 0.081 mmol) and 
triethylamine (1.49 mg, 0.0148 mmol). The solution was left at room temperature 
under nitrogen overnight and the extent of reaction determined by analytical HPLC 
(t=Omin. 90% A 10% B, t=20min. 25% A 75% B, Hypersil 5 ODS 302 nm). BOC 
deprotected trimaleimide Tj^ 13.2 min., and after reaction with succinic anhydride 
Tf^ 12.7 min.. This showed that a clean and quantitative conversion to the solid 
product had occurred. 5H(400MHZ) (CD3CN) 1.25-1.55 (12 H, m, (CH2hCll2^U, 
CH2iCH2)2CON), 1.6 (12 H, m, C / / 2 C H 2 C / / 2 C H 2 C O ) , 2.08 (4 H, t, 
(CH2)4CH2COmi), 2.23 (2 H, t, (CH2)4C//2CON(CH2)(CH2)) , 2.38. 2.51 (4 H, 
2xm, COCH2CH2CO) , 3.0-3.6 (9 H, m, C/ /2NH, CHNU, C / /2NCOCH2) , 3.49 
(6 H, t, C//2NC0CH=CH), 5.45 (1 H, t, N//CO(CH2)2CO), 6.48 (1 H, d, 
CHN//CO), 6.692, 6.694, 6.708 (6 H, 3xs, CH=CH), 6.90 (1 H, t, 
N//CO(CH2)5). 
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2-Nitroimidazole functionalised ligand - (36). 
^ H O NO, 
HOsMeP -^'^\_v'^^PMe02H 
To (33) (38 mg, 0.033 mmol), in dry DMSO (0.5 cm^), under nitrogen was added 
l-aminopropyl-2-nitroimidazole (29 mg, 0.170 mmol). The solution was left at room 
temperature overnight and was subsequently purified by reverse phase HPLC (t=Omin. 
90% A 10% B, t=20min. 25% A 75% B, 325nm) to yield the title compound as a pale 
yellow solid, T^ 11.6 min., 39 mg, 73%. 5H(D20) 1.21 (3 H, d, 2j 13 Hz, PCH3), 
1.32 (6 H, d, 2j 13 Hz, PCH3), 1.37 (4 H, br, (C//2)2CH2NHCO), 1.94 (2 H, p, 
NCH2C//2CH2NHCO), 2.36 (4 H, s, CO(CH2)2), 2.6-3.6 (30 H, m, CH2N, 
NCH2CO, Ci/2NHC0), 4.35 (2 H, t, J 7.2 Hz, C//2NCH), 7.04 (1 H, s, 
Cm{CYi2h), 7.33 (1 H, s, CHNCNO2). 
6.4.3 Chapter 4 
9-Chloro acridine - (37).6 
To N-phenylanthranilic acid (lOg, 47 mmol) in 60 cm^ of PC)Cl3, were added two 
drops of cone. H2SO4 to stop an explosive start at high temperature (reaction is acid 
catalysed). The solution was heated to 85°C until a vigorous reaction set in, and 
immediately removed from the heat. Once boiling had subsided, the solution was 
heated at 135°C for 2 hours, and excess POCI3 removed by distillation. Once cooled, 
the solution was poured into a well stirred mixture of cone. NH3 (40 cm^), ice (100 g), 
and CHCI3 (40 cm^), and stirred until no solids remained. The chloroform layer was 
separated off, the water layer extracted with chloroform, the organic fractions 
combined, dried (CaCl2), and the solvent removed to yield almost quantitatively a 
greenish-grey powder. Can be crystalised from EtOH by addition of 0.5% ammonia to 
yield yellow crystals, m.p. 119-120°C. 5H(CDC13) 7.52 (2 H, t, J 7.8 Hz, Hg, H3), 
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7.72 (2 H, t, J 7.7 Hz, Hy, H2), 8.15 (2 H, d, J 8.1 Hz, H5, H4), 8.29 (2 H, d, 
J 9.5 Hz, Hg.Hi) . 
9-Methoxy acridine - (38).7 
To 9-chloro acridine (37) (2.0 g, 9.4 mmol) suspended in methanol (30 cm^), was 
added 1.3 equivalents of NaOMe, and the solution heated at 70°C for 2 hours. 
Precipitated sodium chloride was removed by filtration, and the filtrate was treated with 
water to give the title compound as a yellow solid (1.51 g, 77^"). It was possible to 
recrystallise some of the product from 50% aqueous methanol to give pale yellow 
needles, m.p. 103°C. 5H(CD30D) 4.23 (3 H, s, OCH3), 7.54, 7.79 (4 H, 2xt, Hg, 
H3, H7, H2), 8.09, 8.28 (4 H, 2xd, H5, H4, Hg, Hj) . 
9-Phenoxy acridine - (39). 
Sodium hydroxide (0.52 g, 0.013 mmol) was dissolved in phenol (8.74 g, 92.8 mmol) 
at 100°C and 9-chloro acridine (37) (2.0 g, 9.36 mmol) added with stirring. After 
2 hours the product was precipitated out in excess diethyl ether, and recrystallised from 
methanol to give a bright yellow powder, 2.34 g, 93%. 5H(CDC13) 6.77 (2 H, d, 
CHCO), 6.96 (1 H, t, C//(CH)2C0) 7.18 (2 H, t, C//CHCO), 7.36, 7.69 (4 H, 2xt, 
Hg, H3, H7, H2), 8.02, 8.20 (4 H, 2xd, H5, H4, Hg, Hi) . 
9-(y-Bromopropyl) aminoacridine - (40). 
To 9-phenoxy acridine (39) (2.08 g, 7.68 mmol) dissolved in phenol (7 g) at 80°C 
was added 3-bromopropylamine.HBr (1.69 g, 7.72 mmol), and the solution heated at 
120°C for 1 hour. The solution was poured into excess diethyl ether to yield a pale 
yellow precipitate. This was filtered off and recrystallised from hot methanol as a 
yellow powder to yield the product (1.217 g, 40%). 5H(CD30D) 2.55 (2 H, p, 
C//2CH2Br), 3.63 (2 H, t, J 6.3 Hz, CHzBr), 4.35 (2 H, t, J 7.0 Hz, CH2NH), 
7.59, 8.0 (4 H, 2xt, J 7.7 Hz, Hg, H3, H7, H2), 7.84, 8.55 (4 H, 2xd, J 8.5 Hz, H5, 
H4, Hg, Hi) . 
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N-t-butyloxycarbonyl-l,4-diaminobutane - (41). 
To 1,4 diaminobutane (5.57 g, 0.063mol) in 30 ml of 1,4 dioxane under nitrogen was 
slowly added a solution of (B0C)20 in 25 cm^ of 1,4 dioxane. After a further I hour, 
the solution was reduced to 30 cm ,^ and 45 cm^ of water added to precipitate out any 
N,N bis f-butyloxycarbonyl-1,4 diaminobutane. This was filtered off, and the dioxane 
removed under reduced pressure. The remaining aqueous solution was saturated with 
NaCl, extracted with EtOAc (5 x 20 cm'), and the organic solvent removed to yield a 
colourless oil. This oil was taken up into water, acidified to pH 3 (HCl), washed with 
EtOAc, and once more saturated with NaCl. The pH was raised to 14 (KOH) and the 
aqueous layer exhaustively extracted with EtOAc, the fractions combined, dried 
(K2CO3), and the solvent removed to yield a pale yellow oil 1.60 g, 27%. 5H(CDC13) 
1.21 (2 H, s, NH2), 1.39 (9 H, s, (CH3)3), 1.41 (4 H, m, {CH2)2^^^1^1121 2.68 
(2 H, t, C//2NH2), 3.08 (2 H, dt, CH2NH), 4.85 (1 H, br s, NH). 
N-(4-Chloroacetamidobutyl}-t-butyloxycarbonamide - (42). 
To (41) (3.30 g, 17.5 mmol) in 10 cm^ of CH2CI2 was added NaOH (0.710 g, 
17.5 mmol) in 1 cm^ of water. To the cooled solution was added chloroacetylchloride 
(1.98 g, 17.5 mmol) in 10 cm^ of CH2CI2 maintaining a temperature of <-10°C. After 
1 hour the precipitated white product which had formed was filtered off and dried under 
reduced pressure. The organic layer was washed with water, dried (K2CO3) and the 
solvent removed to yield more of the title compound (4.23 g, 91%). 
m.p. 98.5-99.5°C. Found: M+-t-l, 265. C11H21N2O3CI requires M+-1-I 265. 
Found: N 10.27%, C 49.58%, H 7.98%. C11H21N2O3CI requires: N 10.58%, 
C 49.90%, H 7.99%. 6H(CDC13) 1.44 (9 H, s, (CH3)3), 1.56 (4 H, m, 
(CH2)2CH2NHCO), 3.14 (2 H, q, J 6.3 Hz, CH2NHCO2), 3.33 (2 H, q, J 6.1 Hz, 
C^2NHCOCH2), 4.04 (2 H, s, CH2CI), 4.71 (1 H, t, NHCO2), 6.78 (1 H, t, 
N//COCH2). 
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(43). 
OMe 
o-s-o 
°-C(CH3)3 
(14a) (244 mg, 0.294 mmol). (42) (155.5 mg, 0.587 mmol), and fine mesh 
potassium carbonate (162.3 mg. 1.175 mmol) were heated overnight at 80°C under 
nitrogen in dry DMF (2 cm^). The solvent was removed under reduced pressure, the 
residues taken up into CH2CI2 (2 cm^), washed (5 x 1 cm^ of water), dried (K2CO3), 
and the solvent removed to yield the crude product. This was used directly in the next 
step without further purification. 6H(CDC13) 1.24 (9 H, t. J 7.0 Hz, OCH2C//3), 
1.37 (9 H, s, (CH3)3), 1.45 (9 H, 2xd, PCH3), 1.2-1.7 (8 H, m, (C//2)2CH2NH), 
2.3-3.4 (32 H, br m, CH2N, C//2NH), 3.58 (2 H, s, COCH2NSO2). 3.81 (3 H, s, 
OCH3), 3.99 (6 H, p, J 7.1 Hz. OCH2), 6.42 (1 H, t, NHCO2), 6.91, 8.01 (2 H, 
2xt, NHCOCH2), 6.93 (2 H, d, J 9.0 Hz, CHCOMe). 7.68 (2 H, d, J 9.0 Hz, 
CHCSO2). 
(44). 
OMe 
EtOjMeP 
ElOsMeP 
o.$-oo 
.NHj 
To (43) was added 0.9 cm^ of TFA, and 0.1 cm^ of water, and the solution left at 
room temperature for 30 min. to afford amine deprotection. The solvent was removed, 
and the residues purified by reverse phase HPLC (t=Omin. 90% A 10% B, t=30min. 
25% A 75% B, 254nm) to give the TFA salt as a colourless solid, 15.2 min. This 
was then taken up into water, the pH raised to 11 (saturated with K2CO3), the solution 
exhaustively extracted with CH2CI2, and dried (K2CO3) to yield on removal of the 
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solvent, the free amine as a colourless gum 86 mg, 31%. Found: M'*'+l, 959. 
CsgHyvNgOnPsS requires M++1, 959. 5H(CDC13) 1.24 (9 H, 2xt, J 7.1 Hz, 
OCH2C//3), 1.3-1.6 (6 H, br, (Ci/2)2CH2NS02, NH2), 1.46, 1.47 (9 H, 2xd, 
2j 13.5 Hz, PCH3), 1.78 (4 H, br, (C//2)2CH2NH2), 2.2-3.3 (32 H, br m, CH2N, 
C//2NH, C//2NH2), 3.58 (2 H, br s, COCH2NSO2), 3.81 (3 H, s, OCH3), 3.99 
(6 H, p, J 7.1 Hz, OCH2), 6.93 (2 H, d, J 8.8 Hz, CHCOMe), 7.21, 8.02 (2 H, 
2xt, NHCO), 7.70 (2 H, d, J 8.8 Hz, CHCCSO2). 
(45). 
o 0 - ^ 0 0 
E t O j M e P ^ W ^ M e O j E I 
A solution of (44) (13.2 mg, 0.0138 mmol), and 9-chloro acridine (37) (7.4 mg, 
0.036 mmol) was heated in 1 g of phenol at 70°C overnight followed by heating at 
120°C for 2 hours. The phenol was removed by warming under vacuum,and the 
residues purified by reverse phase HPLC (t=Omin. 90% A 10% B, t=30min. 25% 
A 75% B, 353nm) to yield the title compound as a yellow gum 19.6 min., 
13.6 mg, 62%. 5H(D20) 1.23, 1.24, 1.32 (9 H, 3xt, J 7.1 Hz, OCH2C//3), 
1.4-1.9 (8 H, br, (C//2)2CH2NHCO), 1.58, 1.78 (9 H, 2xd, 2j 14.0Hz, PCH3), 
2.7-3.9 (34 H, br m, CH2N, C//2NH), 3.69 (3 H, s, OCH3), 3.9-4.3 (6 H, m, 
OCH2), 6.83 (2 H, d, CHCOMe), 7.47 (2 H, d, CHCSO2), 7.30 (4 H, 2xd, H5, 
H4, Hg, Hi) , 7.73, 7.95 (4 H, 2xt, Hg, H3, H7, H2). 
Acridine-9-carbonyl chloride - (46). 
Acridine-9-carboxylic acid was heated at 80°C under nitrogen for 2 hours in thionyl 
chloride. The solvent was removed, and the residues azeatroped with dichloromethane 
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to give the product as a bright yellow solid. This was used immediately in the next 
step. 
(47). 
HOjMef C ^ M e P y ^ ^ ^ 
H 
HOjMeP^  ^MeQH 
To (15a) (8.0 mg, 0.009 mmol) in 0.5 cm^ of dry D M F under niu-ogen was added a 
5 fold excess of (46) in 0.5 cm^ of dry D M F followed immediately by an excess of 
N-methyl morpholine (18.0 mg, 0.178 mmol). After 18 hours the solution was 
purified by reverse phase HPLC (t=Omin. 90% A 10% B , t=30min. 25% A 75% B , 
353nm) to yield a yellow solid TR 13.5 min., 1.5 mg, 14%. 5H(CD30D) 1.41 (6 H , 
d, 2j 14.0 Hz, PCH3). 1.43 (3 H , d, 14.0 Hz, PCH3), 1.6-1.9 (4 H , br m, 
(C//2)2CH2NH), 2.8-4.2 (28 H , br m, CH2N, C^2NH), 7.80 (2 H , t, H5), 
8.0-8.4 (6 H , m, Hg, H7, Hg). 5p(CD30D) 40.3, 44.4 (1:2). 
Anthraquinone-2-carbonyl chloride - (48). 
Anthraquinone-2-carboxylic acid (6.1 mg, 0.024 ramol) was heated for 1 hour at 80°C 
in thionyl chloride. The solvent was removed, and the resulting bright yellow solid 
acid chloride (I.R. (COCl) 1743 cm'^ (CO) 1672 cm'^ (C=C) 1590 cm'^) used 
immediately in the next step without purification. 
(49). 
ElOjMeP 
EtOjMeP^  "w'^ MeOaEI 
To (46) (10.8 mg. 0.039 mmol) in 0.5 cm^ of CH2CI2 at -10°C under nitrogen was 
slowly added a solution of the amine (44) (12.4 mg. 0.013 mmol) and triethylamine 
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(13.1 mg, 0.129 mmol). The solution was then left at room temperature overnight 
under nitrogen, and purified by reverse phase HPLC (t=0min. 90% A 10% B, 
t=30min. 25% A 75% B, 353nm) to give the product as a yellow gum Tj^ 19.6 min 
10.5 mg, 50%. LR. (C=C, C=N) 1635 cm"!' (COCl) 1777 cm'^ 5 H ( C D 3 0 D ) 
1.33, 1.36 (9 H, 2xt, OCH2C//3), 1.2-2.0 (8 H, br, (C//2)2CH2NH), 1.64 (6 H, d, 
2j 14.0 Hz, PCH3), 1.68 (3 H, d, 2j 14.0 Hz, PCH3), 2.7-3.8 (30 H, br m, CH2N, 
C//2NH), 3.72 (2 H, t, C//2NHC0acridine), 3.76 (2 H, s, COCH2NSO2), 3.88 
(3 H, s, OCH3), 4.12 (6 H, p, OCH2), 7.09 (2 H, d, J 9.0 Hz, CHCOMc), 7.78 
(2 H, d, J 9.0 Hz, CHCSO2), 7.96 (2 H, t, CH acridine), 8.36 (6 H, m, CH 
acridine). 5p(CD30D) 56.0,55.7(1:2). 
(50) 
o 
H O s M e P - v r ^ . / ^ ' 
—v / \ f rt 
HOsMeP-^ W N-PMeQiH 
(49) (94.0 mg, 0.081 mmol) was heated at 100°C overnight in 2 cm^ of 44*^ " v/w HBr 
in glacial acetic acid containing 8 mg of phenol to stop bromination of the product The 
solvent and phenol were removed by warming under vacuum, and the residue purified 
by reverse phase HPLC (t=0min. 90 "^ A 10^ " B, t=30min. 25^° A IS"^" B, 353nm) to 
yield a yellow solid Tj^ 12.5 min, 45.3 mg, 38 "^. When (49) was not initially purified 
by HPLC but instead used as its crude, the overall yield for the conversion of (44) to 
(50) was doubled from 19% to 38%. 5H(CD30D) 1.47 (6 H, d, 2j 14.6 Hz, PCH3), 
1.49 (3 H, d, 2j 14.6 Hz, PCH3), 1.5-2.0 (8 H, br, (C//2)2CH2NH), 3.05 (2 H, t, 
(C//2NHCOCH2N(CH2)(CH2)), 2.9-3.7 (28 H, br m, CH2N ring, CH2P, 
CH2NC//2CO, C/f2NHCH2CO, C//2NHCOCH2NH), 3.72 (2 H, t, J 6.7 Hz, 
C//2NHC0acridine), 3.82 (2 H, s, (CH2)(CH2)NC//2CO), 3.98 (2 H, s 
NHC//2CO), 7.96 (2 H, t, J 7.7Hz, Hg, H3), 8.20-8.45 (6 H, 2xd + t, H5, H4, Hg, 
H j , H7, H2). 6C(CD30D) 15.9 (2 C, 97 Hz, PCH3), 16.1 (1 C, 97 Hz, 
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PCH3), 24.3 (1 C. CH2CH2NHCOCH2NH). 27.1 (1 C, CH2CH2NHCOacridine), 
27.7, 27.9 (2 C, (CH2)2CH2NHCH2), 39.4, 40.1, 40.9 (3 C, CH2NHCO), 161.5, 
162.2 (2 C. COCH2), 166.5 (1 C, COacridine). 
(51). 
OMe 
O O i - O n if 
EtOjMeP-^ ^/^^fir^^'<^\r'--^^^ 
EtOaMeP^ K—Z^-PMeOzEl 
To anthraquinone-2-carbonyl chloride (48) (6.5 mg, 0.024 mmol) in 0.3 cm^ of 
CH2CI2, was added a solution of (44) (7.7 mg, 0.008 mmol) and Et3N (16.2 mg, 
0.161 mmol) in CH2CI2 (0.2 cm )^ at a temperature of-10°C. This was then allowed to 
warm to room temperature, and left for a further hour. The solution was then purified 
by reverse phase HPLC (t=Omin. 90% A 10% B, t=20min. 25% A 75% B, 278nm) to 
yield a pale yellow soUd TR 19.0 min.. 5.2 mg. 42%. I.R. (CO) 1677 cm" .^ (CONH) 
1642 cm-1, (C=C) 1590 cm'^ 5H(CDC13) 1.35 (9 H. 2xt, OCH2CH2), 1.50-1.80 
(8 H, br. (C^2)2CH2NHCO), 1.62 (9 H, 2xd, PCH3), 2.20-3.80 (32 H, br m, 
CH2N, CH2NH), 3.72 (2 H, s, COCH2NSO2). 3.86 (3 H. s. OCH3). 4.18 (6 H. p. 
OCH2), 6.98 (2 H, d. CHCOMe), 7.75 (2 H, d, CHCSO2), 7.83 (3 H, m. CH 
andiraquinone). 8.35 (4 H, m, CH anthraquinone). 
9-(e-Carboxypentyl)-aminoacridine - (52) 
To 9-methoxy acridine (38) (289 mg, 1.38 mmol) in 4 cm^ of methanol at 60°C was 
added 6-aminocaproic acid in 0.5 cm^ of water. The solution was left at 60°C for 
2 hours, and the precipitate formed filtered off washed (water, methanol, ether), and 
dried under vacuum to yield a yellow powder (226 mg, 53%). m.p. 186-189°C. I.R. 
(C02-, aromatic) 1500-1610 cm'^. Found: N 8.19%, C 70.00%, H 6.81%. 
C19H20N2O2 requires: N 9.09%, C 74.00%, H 6.54%. Found: M++1, 309. 
C19H20N2O3 requires 309. 5H(CD30D) 1.52 (2 H , m, HN(CH2)2C//2). 1.68 (2 H , 
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p, C//2CH2CO2H), 1.98 (2 H, p, HNCH2C//2), 2.21 (2 H, t, C//2CO2H), 4.12 
(2 H, t, C^2NH), 7.52 (2 H, t, Hg, H3), 7.78 (2 H, d, H5, H4). 7.91 (2 H, t, H7, 
H2), 8.48 (2 H, d, Hg, Hi) . 
9-(£-Chloroformylpentyl)-aminoacridine - (53). 
(52) (13.4 mg, 0.044 mmol) was heated at 80°C for 1 hour in thionyl chloride 
(1.5 cm^). The solvent was removed, and the acid chloride (I.R. (COCl) 1790 cm"^ ) 
used immediately without purification in the next step. 
(54). 
EtCMeP 
EtOjMeP 
ceo 
^-PMeOoEt 
The acid chloride (53) (14.2 mg, 0.044 mmol) was taken up into CH2CI2 (1 cm^) and 
added immediately to a solution of (44) (8.7 mg, 0.009 mmol) and 
N-methylmorpholine (13.3 mg, 0.136 mraol) in CH2CI2 (1 cm^). The solution was 
left at room temperature under nitrogen overnight, and purified by reverse phase HPLC 
(t=Omin. 90% A 10% B, t=30min. 25% A 75% B, 353nm) to yield a pale yellow gum 
TR 19.9 min., 7.5 mg, 49%. 5H(CD30D) 1.33 (9 H, m, OCH2C//3), 1.52 (2 H, 
m, C//2(CH2)2CONH), 1.62 (9 H, d, PCH3), 1.4-1.8 (8 H, m, (C//2)2CH2NHCO), 
1.70 (2 H, m, C//2(CH2)3CONH), 1.95 (2 H, p, C//2CH2CONH), 2.33 (2 H, t, 
CH2CH2CONH), 2.6-3.6 (32 H, br m, CH2ring, CH2P, CH2NECO, 
NC//2CONH(CH2)4, CH2C/y2NS02), 3.71 (2 H, s, COC//2NSO2), 4.07 (2 H, m, 
C//2NHAcridine), 4.10 (6 H, p, OCH2), 7.03 (2 H, d, Cf/COMe), 7.72 (2 H, d, 
CHCSO2), 7.58 (2 H, t, Hg), 7.80 (2 H, d, H5), 7.95 (2 H, m, H7), 8.47 (2 H, m, 
Hg). 
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N^-t-butyloxycarbonyl-N^-methyl-diethylenetriamine - (55). 
To N^-raethyldiethylenetriamine (8.900 g, 0.0759 mol) in 1,4-dioxane (15 cm^) at 
room temperature was slowly added (B0C)20 (3.315 g, 0.0152 mol) in 1,4-dioxane 
(15 cm^) over a period of 2 hours. All solvents and excess amine were removed by 
strongly heating at 120°C under vacuum, and the resulting residues taken up into water 
whereupon any diprotected amine precipitated out and was removed by filu-ation. The 
aqueous solution was saturated with NaCI, exhaustively extracted with ethyl acetate, 
and the organic solvent removed to yield an oily residue. This residue was taken up 
into water, the pH raised to 14 (KOH), and the solution extracted with ethyl acetate. 
The organic solvent was dried (K2CO3), and removed to yield a yellow oil. 1.929 g, 
58%. 5H(CDC13) 1.28 (2 H, s, NH2), 1.39 (9 H, s, (CH3)3C), 2.18 (3 H, s, 
NCH3), 2.39, 2.42 (4 H, 2xt, {CH2)2^Cl{^), 2.72 (2 H, t, C//2NH2), 3.18 (2 H, 
q, C//2NH), 5.08 (1 H, br, CH2N//) . 
N^-t-butyloxycarbonyl-N^-methyl-N^<hhromethanecarbonyl-diethylenetriam -
(56). 
To (55) (1.929 g, 8.875 mmol) in 10 cm^ of CH2CI2 and 1 cm^ of NaOH (0.3905 g, 
9.763 mmol) at <-10°C was slowly added chloroacetyl chloride (1.103 g, 9.763 mmol) 
(in 10 cm^ of CH2CI2) over a period of 1-2 hours maintaining a temperature of <-10°C. 
The organic layer was separated off, washed once with water (0.5 cm^), dried 
(K2CO3), and the solvent removed to yield the title compound as a pale yellow solid. 
Yield 357 mg, 14%. I.R. (CO) 1682 cm"!. Found: M++1, 294. C12H24N3O3CI 
requires M++1, 294. 5H(CDC13) 1.42 (9 H, s, C(CH3)3), 2.23 (3 H, s, NCH3), 
2.50, 2.53 (4 H, 2xt, {CH2)2^CH^), 3.18 (2 H, t, C / /2NHBOC), 3.34 (2 H, t, 
Cf / 2NHCOCH2) , 4.04 (2 H, s, CICH2), 4.95 (1 H, br, NHCOBOC), 7.17 (1 H, 
br, NHCOCH2). 5c(CDCl3) 28.4 (3 C, ( ^ 3 ) 3 ) , 36.8, 37.8 (2 C, CH2CI, NMe), 
41.3 (1 C, CH2NHCO), 42.7 (1 C, CH2NHCOCH2), 55.7 (1 C, CH2CH2NHCO2), 
56.6 (1 C, CH2CH2NHCOCH2) , 79.6 (1 C, C(CH3)3), 156.2 (1 C, CO2), 166.0 
(1 C, C O C H 2 C I ) . 
-200-
(57). 
OMe 
Ma O 
H 
EtOsMeP-^ V_V v^PMeOsEt 
(14a) (45.7 mg, 0.0055 mmol), (56) (32.3 mg, 0.110 mmol) and fine mesh 
potassium carbonate (30.4 mg, 0.220 mmol) were heated overnight at 80°C in dry 
DMF under nitrogen. The solvent was removed under reduced pressure and the 
residues taken up into dichloromethane (2 cm-^ ). The solution was washed twice 
( 5 x 1 cm^ of water), dried (K2CO3) and the solvent removed to yield the crude 
product (NB More products can be re-extracted from the water washings.). The 
product can be purified by reverse phase HPLC (t=0min. 90% A 10% B, t=30min. 
60% A 40% B, 254nm Tj^ 25.8 min.), although it was used in the next step without 
further purification. 5H(CDC13) 1.33 (9 H, t, OCH2C//3), 1.42 (9 H, s, C(CH3)3), 
1.4-1.7 (4 H, br, (C//2)2CH2NS02), 1.5-1.7 (9 H, 2xd, PCH3), 2.5-4.0 (38 H, br 
m, CH2N, C//2NH), 2.67 (3 H, s, NCH3), 3.88 (3 H, s, OCH3), 4.07 (6 H, p, 
OCH2), 6.99 (2 H, d, CHCOMe), 7.70 (2 H, d CHCSO2). 5p(CDCl3) 50.3,51.5 
(2:1). 
(58). 
OMe 
O O-s-O o Me 
EI02MeP^VJV^Me02Et 
To crude (57) was added 0.1 cm-^  of water and 0.9 cm^ of TFA, and the solution left 
at room temperature for 30 min.. The solvent was removed, and the residues purified 
by reverse phase HPLC (t=Omin. 90% A 10% B, t=30min. 60% A 40% B, 254nm) to 
yield the TFA salt Tj^ 25.8 min. as a colourless oil. Overall yield from (14a) 26%. 
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5H(CDC13) 1.22-1.42 (9 H, 2xt, OCH2C^3), 1.56 (9 H, 2xd, PCH3), 1.2-2.1 
(2 H, br, NH2), 1.7-2.1 (4 H. br, (C//2)2CH2NS02), 2.1-3.7 (35 H, br m, CH2N, 
C//2NH), 2.68 (3 H, s, NCH3), 3.89 (3 H, s, OCH3), 4.10 (6 H, p, OCH2), 6.95, 
7.80 (2 H, 2xt, CONH), 7.01 (2 H, d, J 8.8 Hz, CHCOMe), 7.71 (2 H, d, J 8.8 Hz, 
CHCSO2). 
(59). 
OMe 
E t O ^ M e P - y ^ - J ^ 
E t O z M e P - ^ W ^ M e O a E I 
Acridine-9-carbonyl chloride (46) (5.6 mg, 0.020 mmol) in 0.5 cm^ of CH2CI2 was 
added to a solution of the free amine of (58) (5.0 mg, 0.005 mmol) and triethylamine 
(7.7 mg, 0.076 mmol) in 1 cm^ of CH2CI2. The solution was left under nitrogen 
overnight and purified by reverse phase HPLC (t=Omin. 90% A 10% B, t=30min. 25% 
A 75% B, 353nm) to yield the title compound as a yellow solid Tj^ 20.7 min., 2.6 mg, 
29%. 5 H ( C D 3 0 D ) 1.2-1.5 (9 H, m, OCH2C//3), 1.5-2.0 (13 H, m, PCH3, 
(C//2)2CH2NS02). 2.5-3.7 (38 H, br m, CH2N), 2.68 (3 H, s, NCH3), 3.78 (3 H, 
s, OCH3), 4.15 (6 H, m, OCH2), 7.11 (2 H, d, C/ZCOMe), 7.70-8.40 (10 H, m, 
CH Acridine, CHCSO2). 
Maleimide-acridine functionalised ligand - (60). 
o °< 
ft ^ ^ J 
HOaMeP-
HOzMeP-^ W "M'MeOzH 
To 4-maleimidobutyric acid (4.9 mg, 0.027 mmol) in toluene (1 cm^) was added 
thionyl chloride (0.1 cm^), and the solution heated at 80°C for 2 hours. The solvents 
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were removed, and the resulting 4-maleimidobutyryl chloride taken up into 
dichloromethane (0.05 cm^) and added to a solution of (50) (9.9 mg, 0.007 mmol) 
and Et3N (11.5 mg, 0.114 mmol) in 0.5 cm-^  of DMF. The solution was left at room 
temperature overnight, and a drop of water then added to hydrolyse any remaining acid 
chloride. The solution was then purified by reverse phase HPLC (t=Omin. 90% A 10% 
B, t=30min. 25% A 75% B, 353nm) to yield a yellow solid T^ 17.3 min., 9.5 mg, 
93%. Found: M++1, 1075. C48H73N10O12P3 inquires M+-hl, 1075. 5H(400MHZ) 
(D2O) 1.42 (6 H, d, PCH3), 1.48 (3 H, d, PCH3), 1.32-1.65 (4 H, br, 
(C//2)2CH2NCO), 1.65-1.78 (4 H, m, (C//2)2CH2NHCOacridine), 1.82 (2 H, p, 
NCH2C//2CH2CO), 2.28, 2.45 (2 H, 2xt (1:2), N(CH2)2C//2CO), 3.05-3.60 
(30 H, NCH2 ring, NCH2P, NC//2(CH2)2CO, NHC//2(CH2)2C//2NCO, 
C / / 2 N H C O C H 2 N C O ) , 3.72 (2 H, t, C//2NHC0acridine), 3.78 (2 H, 
(CH2)(CH2)NC//2CO), 3.98, 4.13 (2 H, 2xs {2:1), CONCH2CO), 6.76, 6.78 (2 H, 
2xs (1:2), CH=CH), 7.99 (2 H, t, Hg, H3), 8.25-8.40 (6 H, d+t+d, H5, H4, H7, 
H2,H8 ,Hi). 5p(D20; pD=4) 29.1,24.8 (1:2) 
Tri-maleimide-acridinefiinctionalised ligand - (61). 
HOzMeP-^ ^PMeQzH 
Oxalyl chloride (0.5 cm^) was added to (35) (6.2 mg, 0.0074 mmol) and 1 drop of 
DMF added to the solution. After 45 minutes the solvents were removed and the 
resulting acid chloride immediately taken up into dry DMF (0.3 cm^), and added to 
(50) (10.0 mg, 0.0068 mmol) followed by triethylamine (11.2 mg, 0.111 mmol). The 
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solution / suspension was left under nitrogen overnight, the DMF removed, and the 
solids taken up into water to be purified by reverse phase HPLC (t=Omin. 90% A 10% 
B, t=30min. 25% A 75% B, 353nm) to yield the product T^ approx. 17 min. 1.2 mg, 
8%. 5 H ( C D 3 0 D ) 1.1-1.9 (41 H, br m, PCH3, (C / /2)2CH2NHCOacridine, 
( C H 2 ) 2 C H 2 N ( C O ) C H 2 , C H ( C / / 2 ) 3 C H 2 N H C O , CH2(C / /2)3CH2), 2.1-2.6 (10 H, br 
m, CO(CH2)2CO, (CH2)4C//2CO), 2.60-4.0 (49 H, br m, CH2N, CH2NH, C H N H ) , 
6.80 (6 H, s, C H = C H ) , 7.75 (2 H, t, Hg, H3), 7.97.(2 H, t, H7, H2), 8.13 (2 H, d, 
H5, H4), 8.23 (2 H, d, Hg, Hi). 
6.4.2 Chapter 5 
(29) and (30) B72.3 Tri-Fab's, & (29), (30), and (31) A33 Tri-Fab's. 
To 0.9 cm^ of Fab' (B72.3 or A33) at approximately 20 mg ml"^ in 0.1 M acetate-
citrate-EDTA, pH 6.0 buffer was added 0.1 cm^ of 50 mM P-ME in the same buffer. 
The solution was mixed and incubated at 37°C for exactly 30 min. and then desalted on 
a prepacked Sephadex G-25M PD-10 column equilibrated in the same buffer. The 
concentration of antibody in each eluted fraction was determined by measuring its 
absorbence at 280nm (A2go)- A five fold excess of this reduced Fab' was added to the 
appropriate tri-maleimide, and the solution incubated at 37°C for 2-3 hours. The 
percentage of tri-Fab' formed was then determined by analytical gel filtration HPLC 
using a Bioseiies Zorbax GF-250 column with 0.2 M sodium phosphate buffer as the 
eluanL Generally about 30% tri-Fab' was formed which was purified by HPLC using 
a preparative size gel column, or by gravity gel filtration overnight to give roughly 20% 
(3-4 mg) of pure product. The prepared triFab's were shown by gel electrophoresis 
(4 / 20 gradient polyacrylamide gel) to be pure, and to have a molecular mass of 
approximately 150,000 Da as determined using molecular weight markers whilst 
running the gel. An immunoassay also showed the tri-Fab's to have greater antigen 
binding ability than a whole antibody. 
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(34)-A33 tri-Fab: 
Reduced A33 Fab' was prepared as for the tri-Fab's of (29), (30) and (31) except 
used 0.9 cm^ of A33 Fab' (5 mg ml'^) and 0.1 cm^ of 50 mM p-ME to give after Fab' 
purification, a 1 cm-' fraction of 3.79 mg ml'^ Fab'. This was added to the 
tri-maleimide (34) in ratios varying from 7:1 to 1:1 Fab' : (34) and incubated 
overnight at 37°C. The resultant solutions were analysed by gel HPLC showing the 
presence, albeit small, of the tri-Fab'. This observation was confirmed by gel 
electrophoresis. No purification was attempted. 
Fab'-(24) and Fab'-(60). 
To 1.35 ml of 5.0 mg ml'^ A33 Fab' was added 0.15 ml of 50 mM P-ME, the solution 
incubated for 30 minutes, and purified as for the synthesis of the tri-Fab's, to give 2 ml 
of reduced Fab' (3.29 mg ml-^ 65.8 ^iM). To (24) (0.50 mg, 0.461 ^imol) in DMF 
(30 jil) was added 1 ml of reduced Fab' to give a final ratio of 7:1 for (24): Fab'. The 
solution was then incubated for 1 hour at 37°C and any unreacted linker (24) removed 
using a prepacked PD-10 Sephadex column to give 1 ml of 2.89 mg ml"^ Fab'-(24). 
Similarly, to (60) (0.70 mg, 0.494 ^imol) in 30 ^il of DMF was added 1 cm^ of the 
same reduced Fab', and the solution incubated and purified as before, to give 1 cm^ of 
3.10 mg ml-i Fab'-(60). 
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APPENDIX 1 
RESEARCH CQLLOQUIA. SEMINARS AND LECTURES 
Organised by the Department of Chemistry (Aug. 1991 - July 1994) 
1221 
October 17^ Dr. J. A. Salthouse,* University of Manchester. 
Son et Lumi^re - A demonstration Lecture. 
October 31^' Dr. R. Keeley, Metropolitan Police Forensic Science. 
Modem Forensic Science. 
November 6^ Prof. B. F. G. Johnson.t University of Edinburgh. 
Cluster - Surface Analogues. 
November 7*^  Dr. A. R. Butler, University of St. Andrews. 
Traditional Chinese Herbal drugs - a different way of treating 
disease. 
November 13^ ^ Prof. D. Gani,t* University of St. Andrews. 
The chemistry of PLP-dependent Enzymes. 
November 20* Dr. M. More 0' Ferrall.t* University College, Dublin. 
Some Acid-Catalysed Rearrangements in Organic Chemistry. 
November 28* Prof. L M. Ward, IRC in Polymer Science, University of Leeds. 
The SCI Lecture - The Science and Technology of Orientated 
Polymers. 
December 4* Prof. R. Grigg.t* University of Leeds. 
Palladium-Catalysed Cyclisation and Ion-Capture Process. 
December 5* Dr. A. L. Smith, ex Unilever. 
Soap, Detergents and Black Puddings. 
December 11* Dr. W. D. Cooper, Shell Research. 
Colloid Science - Theory and Practice. 
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January 22"^ ^ Dr. K. D. M. Harris, t University of St. Andrews. 
Understanding the Properties of Solid Inclusion Compounds. 
January 29* Dr. A. Holmes, t* University of Cambridge. 
Cycloaddition Reactions in the Service of the Synthesis of Piperidine 
and Indolizidine Natural Products. 
January 30* Dr. M. Anderson, Shell Research, Sittingbome. 
Recent Advances in the Safe and Selective Control of Insect Pests. 
February 12* Dr. D. E. Fenton,t* University of Sheffield. 
Polynuclear Complexes of Molecular Clefts as Models for Copper 
Biosites. 
February 13* Dr. J. Saunders, Glaxo Group Research Limited. 
Molecular Modelling in Drug Discovery. 
February 19* Prof. E. J. Thomas,t* University of Manchester. 
Applications of Organostannanes to Organic Synthesis. 
February 20* Prof. E. Vogel,* University of Cologne. 
The Musgrave Lecture - Porphyrins - Molecules of Interdisciplinary 
Interest. 
February 25* Prof. J. F. Nixon, University of Sussex. 
The Tilden Lecture - Phosphaalkynes - New Building Blocks in 
Inorganic and Organometallic Chemistry. 
February 26* Prof. M. L. Hitchmann.t University of Strathclyde. 
Chemical Vapour Deposition. 
March 5* Dr. N. C. Billinghara, University of Sussex. 
Degradable Plastics - Myth or Magic ? 
March 5* Dr. S. E. Thomas,t* Imperial College. 
Recent Advances in Organo-Iron Chemistry. 
March 12* Dr. R. A. Hann, ICI Imagedata. 
Electronic Photography - An Image of the Future. 
March 18* Dr. H. Maskell,t* University of Newcastle. 
Concerted or Stepwise Fragmentation in a Diamination Type 
Reaction. 
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April 7* Prof D. M. Knight, Philosophy Department, University of Durham. 
Interpreting Experiments - The Beginning of Electrochemistry. 
May 13* Dr. J-C. Gehret, Ciba Geigy, Basel. 
Some Aspects of Industrial Agrochemical Research. 
October 15^ Dr. M. Glazer, Dr. S. Tarling, Oxford University & Birbeck College. 
It Pays to be British ! - The Chemist's Role as an Expert Witness in 
Patent Litigation. 
October 20^ *^  Dr. H. E. Bryndza,* Du Pont Central Research. 
Synthesis, Reactions and Thermochemistry of Metal (Alkyl) Cyanide 
Complexes and Their Impact on Olefin Hydrocyanation Catalysis. 
October 22"^ Prof. A. Davies,* University College London. 
The Ingold-Albert Lecture - The Behaviour of Hydrogen as a 
Pseudometal. 
October 28* Dr. J. K. Cockcroft,* University of Durham. 
Recent Developments in Powder Diffraction. 
October 29* Dr. J. Emsley, Imperial College, London. 
The Shocking History of Phosphorus. 
November 4 * Dr. T. P. Kee, University of Leeds. 
Synthesis and Co-ordination Chemistry of Silylated Phosphites. 
November 5* Dr. C. J. Ludman,* University of Durham. 
Explosions - A Demonstration Lecture. 
November 1 1 * Prof. D. Robins,t* Glasgow University. 
Pyrrolizidine Alkaloids - Biological Activity, Biosynthesis and 
Benefits. 
November 12* Prof. M. R. Truter, University College, London. 
Luck and Logic in Host - Guest Chemistry. 
November 18* Dr. R. Nix,t Queen Mary College, London. 
Characterisation of Heterogeneous Catalysts. 
November 25* Prof. Y. Vallee. University of Caen. 
Reactive Thiocarbonyl Compounds. 
November 25* Prof. L. D. Quin,t University of Massachusetts, Amherst. 
Fragmentation of Phosphorous Heterocycles as a Route to 
Phosphoryl Species with Uncommon Bonding. 
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November 26^^ ^ Humber, Glaxo, Greenford. 
AIDS - The Development of a Novel Series of Inhibitors of HIV. 
December 2"^ ^ Prof. A. F. Hegarty, University College, Dublin. 
Highly Reactive Enols Stabilised by Steric Protection. 
December 2"^ ^ Dr. R. A. Aitken,t* University of St. Andrews. 
The Versatile Cycloaddition Chemistry of BU3P.CS2. 
December 3'"'^  Prof. P. Edwards, Birmingham University. 
The SCI Lecture - What is Metal ? 
December 9^ ^ Dr. A. N. Burgess, t* ICI Runcorn. 
The Structure of Perfluorinated lonomer Membranes. 
1222 
January 20^ Dr. D. C. Clary,t* University of Cambridge. 
Energy Flow in Chemical Reactions. 
January 21^^ Prof. L. Hall, Cambridge. 
NMR - Window to the Human Body. 
January 27^ Dr. W. Kerr,* University of Strathclyde. 
Development of the Pauson-Khand Annulation Reaction : 
Organocobalt Mediated Synthesis of Natural and Unnatural 
Products. 
January 28^ Prof. J. Mann,* University of Reading. 
Murder, Magic and Medicine. 
February 3^"^^ Prof. S. M. Roberts, University of Exeter. 
Enzymes in Organic Synthesis. 
February 10* Dr. D. Gillies,t University of Surrey. 
NMR and Molecular Motion in Solution. 
February 11* Prof. S. Knox,* Bristol University. 
The Tilden Lecture - Organic Chemistry at Polynuclear Metal 
Centres. 
February 17* Dr. R. W. Kemmitt,t University of Leicester. 
Oxatrimethylenemethane Metal Complexes. 
February 18* Dr. I . Eraser, ICI Wilton. 
Reactive Processing of Composite Materials. 
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February 22"^ Prof. D. M. Grant, University of Utah. 
Single Crystals, Molecular Structure, and Chemical-Shift 
Anisotropy. 
February 24* Prof. C. J. M. Stirling.t University of Sheffield. 
Chemistry on the Flat-Reactivity of Ordered Systems. 
March 10* Dr. P. K. Baker, University College of North Wales, Bangor. 
Chemistry of Highly Versatile 7-Coordinate Complexes. 
March 11* Dr. R. A. Y. Jones, University of East Anglia. 
The Chemistry of Wine Making. 
March 17 th Dr. R. J. K. Taylor,t* University of East Anglia. 
Adventures in Natural Product Synthesis. 
March 24* Prof. I 0. Sutherland.t* University of Liverpool. 
Chromogenic Reagents for Cations. 
May 13* Prof. J. A. Pople, Carnegie-Mellon University, Pittsburgh, USA. 
The Boys-Rahman Lecture - Applications of Molecular Orbital 
Theory. 
May 21 Prof. L. Weber, University of Bielefeld. 
Metallo-phospha Alkenes as Synthons in Organoraetallic Chemistry. 
June l^ ' - Prof. J. P. Konopelski, University of California, Santa Cruz. 
Synthetic Adventures with Enantiomerically Pure Acetals. 
June 2"^ ^ Prof. F. Ciardelli, University of Pisa. 
Chiral Discrimination in the Stereospecific Polymerisation of Alpha 
Olefins. 
June 7* Prof. R. S. Stein, University of Massachusetts. 
Scattering Studies of Crystalline and Liquid Crystalline Polymers. 
June 16* Prof. A. K. Covington, University of Newcastle. 
Use of Ion Selective Electrodes as Detectors in Ion Chromatography. 
June 17* Prof. 0. F. Nielsen, H. C. 0rsted Institute, Copenhagen University. 
Low-Frequency IR and Raman Studies of Hydrogen Bonded 
Liquids. 
September 13* Prof. Dr. A. D. Schluter, Freie Universitat Berlin. 
Synthesis and Characterisation of Molecular Rods and Ribbons. 
-212-
September 13* Dr. K. J. Wynne, Office of Naval Research, Washington. 
Polymer Surface Design for Minimal Adhesion. 
September 14* Prof. J. M. DeSimone, University of North Carolina, Chapel Hill. 
Homogeneous and Heterogeneous Polymerisations in 
Environmentally Responsible Carbon Dioxide. 
September 28* Prof. H. Ila, North Eastern Hill University, India. 
Synthetic Strategies for Cyclopentanoids via Oxoketene 
Dithioacetals. 
October 4* Prof. F. J. Feher,t University of California, Irvine. 
Bridging the Gap Between Surfaces and Solution with 
SessUquioxanes. 
October 14* Dr. P. Hubberstey, Nottingham University. 
Alkali Metals - Alchemist's Nightmare, Biochemist's Puzzle and 
Technologist's Dream. 
October 20* Dr. P. Quayle,t University of Manchester. 
Aspects of Aqueous ROMP Chemistry. 
October 21^ ^^  Prof. R. Adams,t* University of South Carolina. 
Chemistry of Metal Carbonyl Cluster Complexes - Development of 
Cluster Based Alkyne Hydrogenation Catalysts. 
October 27* Dr. R. A. L. Jones,t* Cavendish Laboratory. 
Perambulating Polymers. 
November 10* Prof. M. N. R. AshfoId,t University of Bristol. 
High Resolution Photofragment Translational Spectroscopy : A New 
Way to Watch Photodissociation. 
November 17* Dr. A. Parker,t*Laser Support Facility, RAL. 
Applications of Time Resolved Resonance Raman Spectroscopy to 
Chemical and Biochemical Problems. 
November 24* Dr. P. G. Bruce,t* University of St Andrews. 
Structure and Properties of Inorganic Solids and Polymers. 
November 25* Dr. R. P. Wayne, Oxford University. 
The Origin and Evolution of the Atmosphere. 
December 1^ ^ Prof. M. A. McKervey,t* Queen's University, Belfast. 
Synthesis and Applications of Chemically Modified Calixarenes. 
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December 8* Prof. O. Meth-Cohan,t University of Sunderland. 
Friedel's Folly Revisited - A Super Way to Fused Pyridines. 
December 16* Prof. R. F. Hudson, University of Kent 
Close Encounters of the Second Kind. 
1224 
January 26* Prof. J. Evans, t University of Southampton. 
Shining Light on Catalysts. 
February 2"^ ^ Dr. A. Masters,t University of Manchester. 
Modelling Water Without Using Pair Potentials. 
February 9* Prof. D. Young.t* University of Sussex. 
Chemical and Biological Studies on the Coenzyme Tetrahydrofolic 
Acid. 
February 16* Prof. K. H. Theopold, University of Delaware, USA. 
Paramagnetic Chromium Alkyls - Synthesis and Reactivity. 
Febniary 23^^ Prof. P. M. MaiUis,t University of Sheffield. 
Across the Border: From Homogeneous to Heterogeneous Catalysis. 
March 2"^ Dr. C. Hunter,t* University of Sheffield. 
Non Covalent Interactions Between Aromatic Molecules. 
March 9* Prof. F. Wilkinson, Loughborough University of Technology. 
Nanosecond and Picosecond Laser Flash Photolysis. 
March 10* Prof. S. V. Ley,* University of Cambridge. 
New Methods for Organic Synthesis. 
March 25* Dr. J. Dilworth,* University of Essex. 
Technetium and Rhenium Compounds with Applications as Imaging 
Agents. 
Apil 28* Prof. R. J. Gillespie, McMaster University, Canada. 
The Molecular Structure of some Metal Fluorides and Oxofluorides -
Apparent Exceptions to the VSEPR Model. 
May 12* Prof. D. A. Humphreys, McMaster University, Canada. 
Bringing Knowledge to Life. 
t Invited specially for the graduate training programme. ^Author's attendance. 
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APPENDIX 2 
rONFERENCFS ATTENDED 
1. Stereochemistry at Sheffield, 
University of Sheffield. 
2. North East Graduate Symposium, 
University of Durham. 
3. XVIII International Symposium of 
Macrocyclic Chemistry, 
University of Twente, Enschede, Netherlands. 
4. R.S.C. U.K. Macrocycles Group, 
University of Warwick. 
December 18* 1991 
April 3^ *^ 1992 
June 27* - July 2"'* 1993 
January 5* - 6* 1994 
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